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Abstract
The rapid pace of scientific advances is enabling a greater understanding
of diseases at the molecular level. In turn, the process for researching and
developing new medicines is growing in difficulty, costs, and length as a
result of the scientific, technical, and regulatory challenges related to the
development process.
In light of these challenges, drug repositioning, the utilization of known
drugs for a new medical indication, has emerged as an increasingly important
strategy for the new drug discovery. Availability of prior knowledge regard-
ing safety, efficacy and the appropriate administration route significantly
reduces the development costs and cuts down the development time resulting
in less effort to successfully bring a repositioned drug to market.
In another aspect, a protein’s shape is closely linked with its function;
thereby, the ability to predict this structure unlocks a greater understanding
of what it does and how it works. Nowadays, more than 10,000 biologically
relevant protein structures are yearly released and available to the scientific
community. A number suspected to triple over the following years due to
the recent breakthroughs in structure prediction techniques.
This work introduces a novel structure-based drug repositioning approach,
exploiting the similarities of drugs’ binding mode via identification and
virtual screening of interaction patterns. Such patterns are uncovered with
the use of PLIP, an automated tool for the in silico detection of non-covalent
interactions defining the binding mode between drugs and their protein
targets. Besides, the approach has been applied to a series of case studies
with tangible results: the uncovering of an antimalarial drug as potential
chemoresistance treatment, the explained binding mode of ibrutinib to the
target VEGR2 as potential B-cells deactivator in autoimmune diseases, and
three over the counter drugs with a proved anti-trypanocidal activity as
treatments for Chagas disease.
Overall the structure-based approach with interaction patterns proved to
be a suitable framework for identifying novel repositioning candidates. The
uncovered candidates were structurally unrelated to the currently available
treatments, and experimental assays successfully demonstrated their in-
hibitory activity on the protein targets of interest. Furthermore, the approach
represents a promising option for the "in high demand" diseases and all rare
and neglected diseases for which no reliable treatment has yet been found
and for which the pharmaceutical industry makes only a little investment.
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Overview
In Part I of this thesis, the basic concepts and technologies will be
introduced as the preliminaries that have ultimately led to the chal-
lenges addressed in this thesis. Starting with the impact of drug
discovery in society and the current challenges in the field, followed
by a chapter on drug repositioning as an alternative to drug discov-
ery, with the underlying concepts and potentials of this approach, to
finalize with an overview chapter to the existing computational drug
repositioning strategies, with an emphasis on current structure-based
techniques.
The following Part II will introduce the concept of drug reposi-
tioning via interaction patterns, together with the tool PLIP for the
characterization of non-covalent interactions and the in silico screening
of interaction patterns, which is the enabling technology for the three
case studies described in Part III.
Finally, Part IV will discuss the remaining challenges of the pre-
sented approach with a suggested novel perspective to overcome the







The development of a new drug encompasses many complex pro-
cesses and scientific disciplines that are focused on the identification,
chemical and pharmaceutical optimization, and development of novel
compounds to treat human disease states.
1.1 The Pharmaceutical industry today
Over the past century, the pharmaceutical industry has produced
a vast amount of drugs that have increased life expectancy and the
quality of life for many people in the developed world and are begin-
ning to reflect progress in improving Third World health care. Several
bacterial infections, tuberculosis, polio, smallpox, among many other
diseases that were often fatal in the past, are nowadays minor public
health issues concerns[19].
For individuals infected with AIDS1, access to drug treatment has 1 Acquired immunodeficiency syndrome
(AIDS) is a chronic condition caused
by the human immunodeficiency virus
(HIV)
transformed a disease with a once-fatal prognosis into a chronic con-
dition. Similarly, cancer is becoming viewed as a potentially chronic
rather than a fatal disease. Nevertheless, there remains a need for
novel, innovative therapeutic agents, not only for the many diseases
associated with the ageing process for which there are generally
no effective medications (e.g. Alzheimer’s disease, mild cognitive
impairment, stroke), but also in areas where it is required the genera-
tion of therapeutic agents with novel mechanisms of action, e.g. the
development of bacterial resistance.
Furthermore, there is a recent increased concern for the so-called
Rare or Orphan diseases and the Neglected Tropical Diseases (NTD).
Rare diseases are usually defined as those affecting a meagre number
of individuals, but which can be associated with chronic debilitation
and adverse health outcome, up to death[60]. On the other hand,
NTDs are a group of bacterial, parasitic, viral, and fungal infections
that prevalent in many tropical and sub-tropical developing countries,
where poverty is flagrant[81]. Since currently available drugs are
inadequate for both NTD and rare diseases, there is an urgent need
for new treatments. Such diseases have not only a health impact but
also a socio-economic impact, which has become a huge challenge to
both the pharmaceutical industry and society.
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1.2 The steady production trend in drug discovery
As science and novel technologies progress, a raised efficiency in com-
mercial drug research and development (R&D) is expected. However,
the pharmaceutical industry remains under enormous pressure to
address the high attrition rates in drug development.
New molecular entities (NMEs) are designed to bind a particular
target2 of interest and cause a desired effect or indication. Although2 A drug target is a macromolecule, usu-
ally a protein, that is intrinsically associ-
ated with a specific disease process and
that could be addressed by a drug to
produce a desired therapeutic effect.
the pharmaceutical industry brings on to the market NMEs every
year, they are produced at almost the same rate today as they were
about 70 years ago (Figure 1.1). According to the FDA3 archive, of
3 US Food and Drug Administration
the 1,538 NMEs that have been approved since 1950, about a 90% are
small molecules under the NDA licence4, and the remaining 10% are
4 New Drug Application to permit the
sale and marketing of a new drug
biological compounds under the BLA licence5.
5 Biologic Licence Application to allow
sale and marketing of a biological com-
pound
Figure 1.1: Timeline of FDA approvals
between 1950 and 2018 for new molecu-
lar entities (NMEs) in blue and new bi-
ologics Licence Applications (BLAs) in
orange[200, 85]. The dotted lines reflect
the timeline production trend.
Figure 1.1 shows that for the first 30 years until 1980, the trend
line remained almost flat. Then, for the following 15 years, the curve
slopes gently upwards, culminating in 1997 with the highest number
of approvals (53) in the history of drug discovery. However, after that
year, approvals have returned to their historical range. In the case
of biological compounds, the first research and development records
were dated in 1982. Since then, the BLAs growth has been steady
but relatively slow, with a trend line as flat as for NDAs. The whole
picture reflects that drug discovery is not taking off as expected from
the new technologies and scientific resources.
Moreover, pharmaceutical companies’ production rate of new
drugs has been constant since they began producing drugs. Sur-
prisingly, nothing that companies have done in the past 60 years
has affected their rates of new-drug production, usually well below
one per year[200]. Such poor tendency raises questions about the
sustainability of the industry’s R&D model, as the costs per NME
have escalated into billions of dollars.
1.3 Drug development is a complex and time consum-
ing process
There is a formal process by which new drugs are approved for mar-
keting. The standards of evidence for new drug approval are similar
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across countries, although the specific process can differ. However,
the three largest prescription drug markets globally (the United States,
the European Union and Japan) have taken steps to harmonize their
procedures to ensure the timely introduction of new drugs and re-
duce the cost of development. An overview of the drug approval
process, shown in Figure 1.2, demonstrates both the complexity and
the time-consuming characteristics of the process.
The approval process of an NME begins with a preclinical stage
in which the toxic and pharmacological effects of a new compound
are tested in vitro and then in vivo in at least two laboratory animals
species. If the compound is considered safe and promising, the devel-
oper will file an Investigational New Drug Application (IND) to the
FDA describing the compound’s pharmacological profile and present-
ing results of short-term toxicity testing. If during the following 30
days, the FDA approves such an application, the sponsor can begin
Phase I clinical trials in humans.
Figure 1.2: Drug development and ap-
proval process. The timeline consist of
three main stages: preclinical R&D, clin-
ical R&D, and NDA/BLA review by the
FDA. The time range are shown in years,
whereas the average estimated time in
months. The sub processes differ in time
and it might be directly determined by
the industry (blue) or be dependant of
the FDA (orange). [66, 70]
Phase I clinical trials are conducted in a small number of regular,
healthy volunteers to determine the compound’s safe dosing range
and toxicity. If the compound proves to be safe and non-toxic, it
will move to Phase II testing. There, it is tested in a larger sample
of volunteers diagnosed with the medical condition of interest. If
the compound shows promising results, it will progress to Phase III
testing, which uses a larger sample of subjects diagnosed with the dis-
ease to test different dosing quantities or schedules than those used in
Phase II trials. The main purpose of a Phase III trial is to demonstrate
the efficacy of the drug. However, due to the increased number of
subject in Phase III trials, it is likely to observe more adverse events
than in Phase II. If the compound still seems promising at the end
of Phase III, the manufacturer will submit a New Drug Application
(NDA) to the FDA[85, 66] to be revised and finally accepted for the
drug’s marketing.
Development times increased substantially from the 1960s through
the 1980s but overall remained relatively stable during the 1990s.
DiMasi et al. revealed that the time between the start of clinical
testing and the submission of an NDA/BLA licence with the FDA was
estimated to be 80.8 months and 96.8 months until the FDA marketing
approval[70]. If the preclinical research time is also considered, for
one single drug, it takes on average 9.5 years (114 months) from its
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first synthesis until it is finally out on the market.
Development times have not directly contributed much to the rapid
increase in pharmaceutical R&D costs[69]. Nonetheless, if the clinical
trials become larger and more complex, the associated costs with the
investment of resources in new drug development will increase in
absolute terms, even if the development times remain the same.
1.4 The low success rates in drug discovery
Because health care is viewed differently from consumer products,
drug development activities of the pharmaceutical industry are ex-
amined closely and subjected to a higher standard of performance
than other private sector businesses. The clinical trial process has
become more extensive and complex in the past few decades, espe-
cially in terms of what is done to patients and the record-keeping
procedures[71, 131]. Such complexity goes hand to hand with the
stricter safety and efficacy regulations imposed by the FDA to approve
drugs, which are observed in the long periods of clinical trials. In that
sense, the risk of a drug’s failure is associated with efficacy, safety, or
commercial concerns.
The historical literature focusing specifically on quantifying drug
development risks is fairly robust[253, 28, 267, 67, 68, 153, 71, 69, 70].
Early research on development risks suggested that clinical approval
rates for self-originated drugs in the 1960s were about one in eight.
Subsequent studies indicated that development risks fell in the 1970s,
with approval rates averaging approximately one in five; the risk levels
pertaining to the 1970s remained reasonably stable to the mid-1990s.
In 2010, updated studies indicated that about one in six drugs that
enter the clinical testing pipeline would eventually obtain approval
for marketing in the United States.
According to Wang et al., a drug faces its lower success rate during
the Phase I and Phase II of the clinical trials (Figure 1.3), where the
drug is evaluated for a safe dosing range, low toxicity, and promising
effectiveness[295]. However, once it reaches Phase III, there are about
a 59% chance that it will move forward and over 80% prospects to
be approved if the NDA/BLA licence request has been submitted to
the FDA. The overall probability of clinical success6 was estimated at6 The likelihood that a drug that enters
clinical testing will eventually be ap-
proved
13.8%. This success rate is substantially lower than the widely cited
rate of 21.50% estimated in previous studies[71], but consistent with
several recent ones[221, 110, 70].
Nonetheless, it is still challenging to identify all the possible factors
influencing the high attrition rates. Many hypotheses have been for-
mulated to explain such negative trend, like the research shift towards
more difficult targets, the necessity to meet the standard of quality
set by previously marketed drugs, and the tendency to overestimate
the ability of advances in basic research[217, 244]. Pammolli et al.
examined the decline of R&D productivity in pharmaceuticals and
its possible determinants[217]. Their work showed that the decline
described above is highly associated with an increasing concentration
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Figure 1.3: Estimated phase transition
probability to the approval state for new
molecular entities (NMEs) from 1995 to
2007. The blue bar represent the prob-
ability rate of the FDA approval for a
drug in a current Phase in clinical trials.
of R&D investments in areas in which the risk of failure is high (i.e.,
unmet therapeutic needs and unexploited biological mechanisms).
For instance, the R&D projects in the ATC7 class of antineoplastic 7 Anatomical Therapeutic Chemical. In
this classification system, the active sub-
stances are divided into different groups
according to the organ or system they
act on and their therapeutic, pharmaco-
logical and chemical properties.
and immunomodulating agents grew from 21.27% to 29.77% (+8.50%)
between 1990 and 2007, despite the fact that the probability of success
was only 1.8%.
1.5 Drug development costs
As discussed in the previous section, the discovery and development
of new drugs is a very lengthy and rigorous process. Thereby, the
costs associated with it are highly driven by the expenses of long
development times and failure.
In 2016, DiMasi et al. reported a sharp increase in the mean cost
of developing a single new therapeutic agent from $1.1 billion in
2003[71] to $2.8 billion in 2013 (in 2018 US dollars)[70].
More recently, Wouters et al. confirmed with similar parameter
what has been published in the past, although this time it rebuts
the nearly $3 billion previously suggested. Their analysis, which
accounts for projects that failed in clinical development, reported that
between 2009 and 2018, the median cost of developing a new drug
was $985 million, while the mean totalled $1.3 billion[296]. Moreover,
according to the ATC classification, expenditures were also calculated
by therapeutic area (Table 1.1).
Therapeutic area Expenditure in US$ Million
(ATC classification) (Median)
Oncology and Immunology 2772
Sensory organs 1303
Antiinfectives for systemic use 1260
Alimentary tract and metabolism 1218
Musculoskeletal system 1053





Table 1.1: Median expenditure of the
new therapeutic agents approved by the
FDA (2009-2018) grouped by their thera-
peutic indication.[296]
Among all the therapeutic categories evaluated, oncology and
immuno-modulatory drugs were the most expensive to develop, com-
ing in at a median of about $2.8 billion and a mean of $4.5 billion.
An example is the drug Dupixent (immuno-modulating agent ap-
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proved to treat moderate-to-severe atopic dermatitis), which with an
estimated cost of more than $6 billion, is one of the drugs with the
highest expenditures during the development process.
CONCLUSIONS
Taking all together, despite the substantial efforts to understand
and improve the management of the commercial drug development
process[244], it seems indisputable that the current R&D model effi-
ciency has remained the same as in the past decades. Moreover, taking
into account the increasing technologies and scientific resources, it is
fair to say that the R&D efficiency has steadily declined, putting in
doubt whether the high costs of the marketed drugs are justifiable
and whether better solutions can be expected for the increasing public
health concern issues that still strikes society.
Chapter 2
Drug Repositioning
As discussed in the previous chapter, the conventional drug devel-
opment technique is a rigorous, uncertain, and expensive process.
Consequently, there is a growing urge to discover new strategies that
support drug discovery and help to reduce the development time
frame.
2.1 An alternative route to drug discovery
In light of these challenges, drug repositioning has emerged as an
increasingly important strategy for discovering new drugs. Interest-
ingly, this approach has accounted for 30% of all newly approved
drugs by the FDA in recent years[227].
Drug repositioning sometimes referred to as drug repurposing, is
the utilization of known drugs for a new medical indication[219, 175].
Such drugs have been either already approved by regulatory agencies
such as the FDA or are in current experimental studies for specific
indications. For a new investigational molecule, safety and efficacy
data are not yet available, resulting in higher attrition during the
drug discovery process leading to the most failures regarding safety
or effectiveness. By contrast, all safety, preclinical and efficacy data
are readily available for a repurposed molecule, thus enabling the
investigator to make an informed decision at each stage of drug
development.
Figure 2.1: Drug repositioning as a short-
cut to drug discovery. The timeline
starts with the preclinical testing of the
novel proposed indication. If there is
evidence enough about the new indi-
cation, the FDA process skip the pre-
clinical R&D and Phase I of clinical tri-
als (gray boxes), and it starts directly
at Phase II to prove the new indication.
After that, it continues as regular until
approval by the FDA. [18, 219]
Availability of prior knowledge regarding safety, efficacy and the
appropriate administration route significantly reduces the develop-
ment costs and cuts down the development time (Figure 2.1), resulting
in less effort required for successfully bringing a repositioned drug
to market[18, 175]. Baker et al. reported that about 60% of all drugs,
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both approved and experimental, have been tested for more than one
disease, which directly translates into shorter routes to the clinical
trials and posterior approval[21].
In addition, repurposing also provides an excellent opportunity for
NTD and rare disease therapy by reducing the risk and development
costs.
2.2 Renamed and novel repositioning case studies
Over the past years, many studies have reported new indications for
already-approved drugs using repurposing approaches (Table 2.1).
Some of them obtained approval for the novel indication and have
been widely used with positive effects. Such is the case of tamoxifen,
rapamycin, minoxidil, raloxifene, thalidomide, and sildenafil. The
latter, well known for its repositioning from heart disease to erectile
dysfunction, targets the phosphodiesterase PDE5. Some other drugs
entered the FDA process but still face the required clinical trial to
obtain the corresponding approval or denial.
Table 2.1: Approved and under-studied
repurposed drugs over the past years
with their original indication, novel indi-
cation, and the current completed status
in clinical trials. [219]
Drug Original Novel Status
indication indication completed
Sildenafil Angina pectoris Erectile dysfunction Approved
Raloxifene Osteoporosis Breast cancer Approved
Thalidomide Morning sickness Multiple myeloma Approved
Tamoxifen Metastatic breast cancer Bipolar disorder Approved
Rapamycin Avoid transplant rejection ALPS Approved
Minoxidil Antihypertensive Hair regrowth Approved
Dapsone Leprosy Malaria Phase III
Amphotericin Antifungal Leishmaniasis Phase III
Eflornithine Cancer A. trypanosomiasis Phase III
Metformin Type II diabetes Prostate cancer Phase II
Aspirin Fever and Pains Melanoma Phase II
MSDC-0160 Type II diabetes Parkinson’s diseases Phase II
Fosmidomycin UTI Malaria Phase II
Rilusole Sclerosis Melanoma Phase I
Itraconazole Antifungal Prostate cancer Phase I
Digoxin Heart failure Cancer Phase I
Apart from the already approved or in clinical testing drugs, more
recent studies are joining the race of drug repositioning. Wu et al.
reported in a recent study that acetazolamide, originally used to treat
altitude sickness, can also be used in combination with temozolomide
(TMZ) to treat glioblastoma[297]. In addition, Cruz et al. reported the
antimicrobial properties of the anti-cancer drug mitomycin-C, which
due to its cytotoxic effects it can be repurposed to treat persistent
bacterial infections from Acinetobacter baumannii[56]. Gerits et al.
reported the effects of Toremifene, an anti-cancer drug, in oral bac-
teria infections via membrane-damaging activity[92] and Costabile
et al. proved the antivirulence properties of the anthelmintic drug
niclosamide and demonstrated its potential therapeutic value against
Pseudomonas aeuruginosa lung infections[54].
drug repositioning 27
2.3 Drug promiscuity is the key
The reason why repositioning can be successfully applied lies in the
binding behaviour of small molecules. While early studies on protein
ligand binding were shaped under the concept of "lock and key":
one unique drug to one unique target, nowadays it is widely known
that the binding of a molecule to two or more different targets, also
regarded as promiscuous binding, is closer to reality[115, 117]. In
drug development, compound promiscuity is often regarded as an
unfavourable property because drugs binding multiple targets are
expected to cause undesirable side effects. However, promiscuity
can also positively affect the efficacy of a drug by introducing a
polypharmacology effect, i.e., a drug binding several targets linked
to the same disease will have an increased impact compared to a
single-target modulator[17].
Understanding drug promiscuity is essential for discovering new
off-targets for existing drugs and leading to new therapeutic indi-
cations. According to literature, there is a significant correlation
between compound promiscuity and binding site similarity[108] and
the number of ways a drug can interact with its target is limited. In
terms of protein-protein interactions, Aloy et al. estimated 10,000
interfaces [11] and Gao et al. reduced this number to 1,000 distinct
interface types [89]. While the exact number of protein-ligand interac-
tions has yet not been calculated and it may be debatable, a limit itself
has important consequences, i.e. there is redundancy and re-use in
drug-target interaction, making it difficult to design a target-specific
or one target-only drug. Therefore, the promiscuous binding of the
hit drugs to several targets is not an exception but rather a frequent
observation that can be exploited to dig out novel repurposing stories.
2.4 The potential of drug repositioning
Identifying a drug and developing it further requires significant in-
vestment, primarily due to the various physicochemical properties
of the chemical entities and the complexity of scaling up the produc-
tion. This limitation further empowers pharmaceutical companies or
academic centres to quickly and efficiently utilize already-approved
medications for a new indication not yet available to the patients with
that disease.
Investigational molecules that fail to show efficacy for a predeter-
mined indication typically provide a good start for their revival by
repurposing. They can be further rediscovered for a new indication(s),
ultimately being developed as viable therapies, particularly useful
in rare diseases, which present significant challenges in diagnosis,
treatment and lack of resources. For instance, some autoimmune
disorders, bacterial infections and rare cancers are not inherited, thus
making it more challenging to treat because they are idiopathic in
nature.
Drug repurposing, being a less expensive and shorter approach,
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brings effective therapies to patients compared with cumbersome
traditional discovery and development processes. Moreover, this ap-
proach helps overcome the inflating costs for drug development, thus
lowering the out-of-pocket cost for patients and ultimately reducing
the actual cost of therapy.
Drug repositioning also offers a great deal of potential for out-
licensing because these drugs possess characteristics attractive to
potential buyers. Although tempting, it is also essential that identify-
ing a new disease target should not cripple the marketing potential of
the drug for its initial indication. Furthermore, drug repositioning of-
fers opportunities for rare diseases, where lack of pathophysiological
characterizations and difficult commercial conditions are the causes
for the absence of an FDA approved drug for 95% of indications and
for personalized medicine where the small size of cohorts makes the
discovery process hard and highly expensive.
Chapter 3
Computational Drug Repositioning
This chapter is partially based on the publications Structure-
based drug repositioning: Potential and limits[5] published in 2020
in Seminars in Cancer Biology and Drug repositioning or target
repositioning: A structural perspective of drug-target-indication re-
lationship for available repurposed drugs[218] published in 2020
in Computational Structural Biotechnology. For detailed infor-
mation on author contributions see the chapter Publications
and Contributions.
With the advent of new technologies as well as the availability
of computational tools, drug discovery is a much more affordable
approach when starting with an already-approved drug.
3.1 Strategies towards computational drug reposition-
ing
There are many reasons why a drug could be a cure for two diseases.
The diseases might be closely related, the drug’s target may play a
role in two different diseases, or the drug has two targets, each linked
to a different disease[5, 218] (Figure 3.1).
Disease-centric repositioning.
A focus on disease is the most direct approach since the hypothesis
drives that a drug’s use can be expanded from the original to a closely
related indication. For example, consider nilotinib, a tyrosine kinase
inhibitor, approved for the treatment of imatinib-resistant chronic
myelogenous leukaemia. A few years later, the Novartis company
proposed the reposition of nilotinib to gastrointestinal stromal tu-
mours. The underlying assumption for disease-centric repositioning
is that diseases of the same type have shared guiding principles, e.
g. summarized in the hallmarks of cancer. However, despite such
commonalities, indications differ and hence repositioning may fail.
Actually, Novartis’ efforts to expand nilotinib to gastrointestinal stro-
mal tumours were abandoned after a phase III trial concluded that it
could not be recommended.
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Target-centric repositioning.
Complementary to a disease-centric approach, target-centric repo-
sitioning builds on a novel link between a new indication and an
established target (Figure 3.1). As an example, the protein tyrosine
kinase ABL was recently suggested as a novel player in Parkinson’s
disease, and therefore its inhibitors, such as the anti-cancer drug
nilotinib, may also be effective against this syndrome.
Figure 3.1: Repositioning strategies. A
drug (D) has a target (T), which is linked
to an indication (I) and possibly side ef-
fects (S). There are three ways how the
drug can be repurposed. The indica-
tions are closely related (disease-centric),
the target is linked to two indications
(target-centric), and the drug has two
targets each linked to a different disease
(drug-centric).
Drug-centric repositioning.
Besides an established route from a drug via target to an indication,
as shown in Figure 3.1, sometimes a novel target is predicted for
the drug which is associated with a new indication. For example,
valproic acid is used in bipolar disorder and seizures because of
its ability to hit the mitochondrial enzymes Succinate-semialdehyde
dehydrogenase (ALDH5A1) and 4-aminobutyrate aminotransferase
(ABAT). However, due to its off-target interaction with the Histone
deacetylase 2 (HDAC2), and the role of this protein in many types of
cancers, it has been hypothesized to induce differentiation, growth
arrest, and apoptosis in cancer cells. These lead to the repositioning
of valproic acid for the treatment of neoplastic conditions such as
familial adenomatous polyposis.Figure 3.2: Drug repositioning cases ac-
cording to the strategy applied. The bar
chart shows the percentage of known
repositioning cases classified by strat-
egy. More than half of the cases (59%)
are disease-centric repositioning cases,
a third of the drugs (36%) are target-
centric repositioning, while only a small
group (6%) of cases are classified as
drug-centric. [218]
After comparing the different strategies, disease-centric reposition-
ing is the most covered strategy for drug repositioning (Figure 3.2),
since it is direct and guided by a good understanding of the molec-
ular mechanisms behind the indications and patents that are broad
enough to capture both indications. On the contrary, the target-centric
approach is less obvious and, therefore, less frequent. The same
target can have very different functions, which can be fine-tuned and
regulated by the cell. A key is the link of a target to an indication.
Often exact causal relationships are unknown, but high throughput
techniques such as deep sequencing, microarrays, and RNAi provide
many correlations. The most indirect of the three approaches is the
drug-centric one. Like the target-centric one, this approach requires
target-indication links, but it relies additionally on drug-target re-
lations, which have to be derived from the limited data available
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today.
In summary, disease-centric repositioning is more prominent than
target-centric, which is more apparent than drug-centric. This order-
ing reflects the need for external, novel data, and hence risk. Once
disease-centric repositioning is saturated, it becomes vital to obtain
the high-quality data needed for target-centric and drug-centric repo-
sitioning to take off.
3.2 Computational drug repositioning approaches
Compared to experimental biological approaches, computational ap-
proaches have much lower costs and much fewer barriers. With the
fast development of biology techniques, various drug, disease, ge-
nomic, and proteomics databases such as DrugBank[292], KEGG[133],
ChEMBL[192], PubChem[148], PDB[25], Uniprot[52], and GenBank[23],
have been built. This knowledge and data contribute and further pro-
mote the rapid development of novel computational approaches.
Figure 3.3: Example network of the drug
aspirin. The pill shaped orange nodes
represent the related drugs and the blue
nodes, the related targets. The network
was generated using STICH v.5.0 which
integrates knowledge from 5 main data
sources[160].
Network-based approaches
Network-based approaches are widely used in drug repositioning
given their ability to integrate multiple data sources (Figure 3.3). Base
on the idea that biologic entities, i.e., disease, drug, protein, side
effects, etc., share similar characteristics, several recent studies have
proposed network-based approaches to discover novel drug-disease
relationships or drug-target relationships.
Cheng et al. uncovered the potential repurposing of hydroxychloro-
quine as a coronary artery disease treatment by the generations of
a protein-protein interaction network proximity, complemented by
mechanistic in vitro studies[45]. Lu et al. introduced a novel k-means-
based network cluster algorithm and studied the drug repositioning
of small-cell lung cancer[183]. Chemical-chemical interactions and
chemical-protein interactions were utilized to select candidate drug
compounds with close associations with approved lung cancer drugs
and lung cancer-related genes. Nepusz et al. proposed a greedy net-
work cluster approach named ClusterONE[208], which can accurately
predict not only disease-drug relationships in disease-drug networks
but also protein interactions in protein-protein networks. Kohler et
al. developed a network propagation approach based on the global
information of a network to find novel disease-gene interactions[152].
The positive aspect of network-based approaches is their general
applicability. For instance, some cluster algorithms in the social
network analysis field can be employed for detecting modules in bio-
logical networks. In addition, network-based propagation approaches
use not only information from the selected components but also in-
formation from expanding components[301]. Nonetheless, the lack
of a gold standard to evaluate cluster associations among biological
entities remains one of the major challenges of this topic.
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Text mining-based approaches
Over the past decades, a tremendous amount of medical and biologi-
cal literature has been published. Text mining techniques deal with
the challenge of extracting valuable biological entity relationships
from such literature. The main goal is to mine knowledge from scien-
tific literature and identify connections between biological concepts
or biological entities.
There is a standard pipeline for biological text mining, which
includes four phases: information retrieval, biological name entity
recognition, biological information extraction, and biological knowl-
edge discovery[301]. With the development of natural language pro-
cessing techniques 1, increasing numbers of text mining tools, such1 Field concerned with the human-
computer interaction to understand and
make sense of the human languages in
a valuable manner
as Biovista[172], BioWisdom[158], FACTA+[275], and TextFlow[223]
among others, have been developed and used to discover reposition-
ing cases. In a recent study, Li et al. built a disease-specific drug-
protein connectivity map combining network mining and text mining.
As a result, diltiazem and quinidine used to treat hypertension and
arrhythmia, respectively, were predicted as potential treatments for
Alzheimer’s disease and later confirmed by clinical evidence[176].
Text mining tools reduce the time complexity of drug repositioning
and assist researchers in verifying their experimental results by return-
ing massive amounts of biological entity relationships. Nonetheless,
they still deal with the limited coverage of biomedical entities and the
inconsistency in biological nomenclature.
Semantics-based approaches
Semantics-based is widely used in information retrieval, image re-
trieval and other unrelated fields. In more recent terms, semantic
search has also been applied to drug repositioning via the prediction
of novel entity relationships. Semantic search is based on the existing
ontology networks and entity relationships obtained from massive
medical and biological databases.
Since the concept is relatively new in drug repositioning, only a
few approaches have been reported to the date. For instance, Palma
et al. proposed an unsupervised algorithm leading to the successful
prediction of novel drug-target relationships[216]. Mullen et al. used
a Bayesian statistics approach to rank drug-disease relationships ac-
cording to prior knowledge[198]. The study resulted in more than
200 novel drug-disease associations. Chen et al. built a semantic
linked network with multi-source data including drugs, targets, pro-
teins, and disease pathways and applied a statistical model to predict
drug-target relationships[43].
Semantics-based approaches take full advantage of semantic in-
formation included in massive amounts of biological data. However,
there is an unmet challenge of constructing semantic networks by
integrating real medical records’ multi-source data.
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3.3 Structure-based approaches
While all the previous mentioned computational methods can give
useful hints at commonalities between drugs and targets, only com-
putational structural approaches can provide definite insights into
molecular recognition and predict binding with high confidence.
The Protein Data Bank (PDB)[25], as the primary public data source
for protein structures, currently holds more than 174,000 protein
structures2 and more than 30,000 distinct compounds, making it an 2 A PDB structure refers to a 3D model
from X-ray crystallography, NMR stud-
ies or in silico modelling deposited in
the PDB. They usually describe the struc-
ture of a protein, often in complex with
ligands, i.e. one or multiple organic
or inorganic small molecules, ions, nu-
cleotides, peptides or other polymers.
One structure can contain multiple such
complexes.
excellent resource for large-scale approaches. In fact, about 75% of
structures are complexed with a compound, which enables compar-
ative approaches of interactions between proteins and their bound
ligands. Moreover, according to the BioLiP database[303], data on
more than 600 biologically relevant protein-ligand complexes are
added each week, which for comparative approaches, translates into
tens of millions of new pairings to be analyzed weekly.
Most of the known structural approaches utilize structural infor-
mation of the active or drug-binding site of the target to infer novel
connections between drugs and targets. They directly exploit the
shared binding sites among targets and the one drug multiple targets
concept to uncover novel repurposing stories.
Binding site similarity methods
Approaches in this category do not put much attention to the com-
pound ligands but rather focus on the target properties. More pre-
cisely, they exploit the assumption that similar protein cavities might
present a similar pharmacological profile and hence, accommodate
the same ligands. Figure 3.4 reflects the underlying assumption of
this methods: Drug dA is known to bind protein A, and drug dB is
known to bind protein B. If the proteins A and B share a binding site,
it can be assumed that drug dA will bind to protein B (and vice versa
for drug dB to protein A). Thus, the so-called target hopping can
be achieved by identifying shared binding sites between structurally
unrelated targets. On the other hand, scaffold hopping describes
the discovery of such a relationship between two compounds from
different chemical classes.
Figure 3.4: Binding hypothesis of repo-
sitioning drugs to another unrelated tar-
get sharing similar binding site. Based
on the know binding of drugs to protein
targets, if the binding site similarity be-
tween proteins is sufficiently high, one
can assume that the drug dA (originally
binding target A) may also bind target
B and dB (originally binding target B)
may bind target A.
Several approaches for binding site alignment and comparison have
been reported in the recent years, using either geometrical criteria or
chemical descriptors, e.g., Sitemap[102], FindSite[260], LigASite[64],
and PDBeMotif[279]. However, the computational expenses of pair-
34
wise alignments and associated scoring methods have given rise to
so-called alignment-free methods. Prominent approaches use geomet-
ric hashing to represent geometries and chemical features of binding
sites in a feature vector (e.g. in PocketMatch [304]). Results from
alignment-free methods, however, have the severe disadvantage of
being hard to interpret. Consequently, they are often used in com-
bination with alignment-based methods. Furthermore, binding site
similarity approaches have to deal with the possibility of the ligand to
change conformation upon binding different targets, as well as, with
the noise produced by the flexible chains present in the protein cavity.
Figure 3.5: Example of a pharma-
cophore model. The colored circu-
lar grids describe different properties
and molecular features, e. g. hydropho-
bic centroids, aromatic rings, hydrogen
bond acceptors or donors, cations, and
anions. These pharmacophoric points
may be located on the ligand itself or
may be projected points presumed to be
located in the receptor.
Figure 3.6: Docking predicts multiple
potential binding conformations of a lig-
and into a cavity of a protein target.[8]
Docking
In the field of molecular modelling, docking is a technique to predict
the orientation of a ligand into a cavity of a target protein (Figure
3.6), including estimation of the binding affinity[162]. Docking can
be applied in computational drug repositioning pipelines in differ-
ent ways. For example, by screening a single compound against a
library of protein structures, it is possible to identify new drug-target
interactions. It can also be coupled with other techniques and placed
either at the end of the computational pipeline to evaluate candidates
previously selected with different in silico approaches or at the be-
ginning to generate hypotheses which might be subsequently filtered
with other data- and knowledge sources. Several docking algorithms
have been developed (e.g. Glide[87], AutoDock[86], Flare[42], Induce
fit[255], MolDoc[272], and Gold[127], among others), each one with
its own strong and weak points, which make each tool diverse and
suitable for different cases. Although the technique is very well-
defined and widely used, molecular docking results are prone to a
high false-positive rate, which makes the approach unreliable and of
low confidence among the scientific community.
CONCLUSIONS
The discovery of remote similarities between structurally or function-
ally unrelated proteins is of particular interest for drug repositioning
since they are not reflected by the chemical similarity of ligands or
global structures of proteins. However, all the methods described
above tend to be focused either on the protein pocket or on the molec-
ular properties of the ligands. Consequently, as a dependant of such
properties, there is a tendency to stay within a limited scope of struc-
turally or functionally related proteins and drugs with high similarity








As described in Chapter 3, the current computational drug reposition-
ing approaches are usually not able to uncover remote similarities
in structural data. On the contrary, they offer a limited scope of
possibilities and novelty.
Integration of protein-ligand interaction profiles has recently come
into research and may offer a solution to this problem. They can
grasp the essence of binding sites, ignore amino acids not involved
in binding, and take a more uncoupled viewpoint from the chemical
structures of proteins and ligands. Although it might seem that the
analysis of interactions is somehow related to the concept of phar-
macophores, it is essential to note that they are different approaches.
Whereas the interaction analysis describes the observable contacts,
pharmacophores capture only the potential for contacts. This is piv-
otal as the interactions in a complex depend on many additional
factors, such as the environment and flexibility of protein and ligand.
Figure 4.1: Non-covalent interaction
types between proteins (blue) and
ligands (orange) after analysis with
PLIP[241]. Interactions are visualized
with colored lines.
4.1 Non-covalent interactions
Molecular recognition is mainly governed by a specific 3D arrange-
ment of reversible, so-called non-covalent interactions. Reversibility
is a significant trait of most biologically relevant contacts, allowing
ligands to unbind from the receptor. However, some well-known
exceptions act via covalent bonds, i.e. non-reversible interactions,
such as the suicide inhibitors penicillin and aspirin[235].
Proteins can recognize and bind their ligands via specific arrange-
ments of reversible (non-covalent), weak contacts:
Hydrophobic contacts
Hydrophobic interactions are formed by the tendency of water to
displace the non-polar molecules (Figure 4.1). Aggregation of hy-
drophobic molecules or chemical groups in an aqueous solution
reduces their water-accessible surface area and leads to a release of
water molecules into the bulk, accompanied by an entropic gain[199].
In protein-ligand binding, pairings of hydrophobic amino acids and
corresponding ligand groups are governed by this effect.
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Hydrogen bonds
Hydrogen bonds are formed between a donor group (D-H), providing
a positive end in the form of a hydrogen atom due to a polar covalent
bond and an acceptor group (A) of high electron density (Figure
4.1). Hydrogen bonding is considered the most important of all
directed non-covalent interactions between biomolecules, supposedly
increasing the binding affinity of a ligand one order of magnitude
with each additional hydrogen bond[300, 264, 119]. Nonetheless,
regardless of their strength and selectivity, H-Bonds are not essential
for high-affinity binding.
Figure 4.2: Non-covalent interaction
types between proteins (blue) and
ligands (orange) after analysis with
PLIP[241]. Interactions are visualized
with colored lines.
Water bridges
Water enhances the adaptability in binding as it can serve as both
hydrogen bond donor and acceptor and induces only minimal steric
hindrance (Figure 4.1). The energetic gain from additional hydrogen
bonds involving a buried water molecule can exceed the entropic loss
from keeping the water molecule isolated from bulk liquid[165].
Salt bridges
Salt bridges, also known as ionic interactions, are formed with charged
amino acids not more than 4 Å away from a ligand atom of oppo-
site charge (Figure 4.1). Salt bridges play a key role in molecular
recognition and are crucial for conferring specificity[300].
π-stacking
Interactions between aromatic rings (p-stacking) are governed by an
interplay of electrostatic, van-der-Waals and hydrophobic interactions
(Figure 4.2). Stable arrangements of aromatic rings are either in
parallel (sandwich) or a perpendicular (T-shaped) orientation [286].
π-cation
Interactions formed between a positive charge and an aromatic ring
due to its negative charged layer of delocalized π electrons (Figure
4.2)[286, 306]. They have been increasingly acknowledged as an
essential non-covalent bond for molecular recognition, playing a
decisive role in the recognition of ligands by GPCRs[199].
Halogen bonds
The halogen bond resembles hydrogen bonding in some aspects, with
the main difference that a halogen atom is shared between an acceptor
and donor instead of hydrogen (Figure 4.2). Many drugs have donor
groups for this interaction type, and halogenated ligands are present
in over 1000 PDB structures[259, 184]. The preferred orientation is
linear with interaction energy depending on the halogenated atom
type(I > Br > Cl > F).
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Metal complexes
Metal interactions are often encountered in binding sites of enzymes.
They serve as catalysts for biological reactions, e.g. in metalloproteases
or carbonic anhydrases. Metals can also maintain protein structure.
Usually, the protein takes the role of a so-called multidentate ligand in
the complex, represented by the partaking aminoacids or conserved
water molecules[106]. This arrangement forms a cage around the
ligand ion with a specific coordination geometry[105] (Figure 4.2).
4.2 The energetic contribution of non-covalent interac-
tions
Covalent and non-covalent interactions comprise the direct forces
involved in protein ligand binding, being in the focus of theoretical
and experimental characterization.
Figure 4.3: Non-covalent interaction
types, their typical distances and
approximate energy contributions to
protein-ligand binding. The abscissa
shows the energy contribution in a rel-
ative order, beginning with the low-
est on the bottom. Openings of the
boxes indicate more permissive dis-
tance constraints for upper or lower
boundaries[240].
Although contributions of single non-covalent interactions (Figure
4.3) are small in comparison to covalent bonds (100 kJ/mol), additive
and synergistic effects of non-covalent interactions result in average
energies of 10-80 kJ/mol for a protein-ligand complex[240]. Moreover,
indirect forces such as water-mediated interactions or solvent effects
can fundamentally influence the binding behaviour.
Kasahara et al. reported that the majority of interactions is universal
for all protein families. About two-thirds of all ligand atoms take part
in physically favourable interactions, whereas the rest is supposedly
used for scaffolding and tuning of binding properties[136]. Therefore,
the complex ligand recognition is described based on combinations
of the atomic contacts between amino acids and ligands. However, it
has to be noted that the general interaction profiles and preferences
for interaction types vary among different types of ligands.
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4.3 Interaction patterns defining drug’s binding mode
The binding mode of a drug is of high relevance to understanding
drug promiscuity. It is still unclear to which degree the actual binding
behaviour is coupled to physicochemical properties. Korkuć and
Walther already pointed out that no monotonic relationship between
any compound properties and promiscuity can be observed, but
rather one or more so-called sweet spot regions (e.g. both very low
and very high hydrogen bond acceptor counts)[155].
Figure 4.4: Effect of adding a hydro-
gen bond in a thrombin inhibitor: (a)
chemical structure of a pair of throm-
bin inhibitors. (b) crystal structure of 4
(cyan carbons) in complex with throm-
bin (PDB:2ZC9). Hydrogen bonds are
displayed in dotted green lines.[61]
As previously discussed, the additive and synergistic effects of non-
covalent interactions result in a significant contribution to the binding.
Such synergistic effect is defined by the so-called interaction patterns,
where the geometrical features such as position, distances, and angles
between two or more interactions, directly contribute to the energy
and stability of the binding. One example pattern is the cooperative
attribute of hydrogen bonds, which refers to the enhanced stability
of a system containing two or more hydrogen bonds(Figure 4.4). De
Freitas et al. modified a series of potent thrombin inhibitors and
showed that they have a remarkable increase in binding affinity (>500-
fold) through the simple addition of hydrogen-donating ammonium
group[61].
Molecular compounds can display different binding modes, i.e.
different set of non-covalent interactions when binding to different
proteins. The latter results from functional groups in the ligand which
can recognize different parts in the protein, e.g. a ligand aromatic ring
binding to another ring via π-stacking or to a charged amino acid
via a π-cation interactions. Moreover, water molecules or the protein
backbone can take the role of hydrogen bond acceptors or donors and
thus enable recognition in different binding environments.
Conversely, it has been observed that certain compounds tend
to have conserved binding modes, primarily when binding to the
same protein targets, but also when binding unrelated proteins, e.g.
the antiviral drug brivudine displays a set of specific non-covalent
interactions to its known target thymidine kinase and the unrelated
cancer target the protein HSP27[112].
Figure 4.5: Brivudine’s conserved bind-
ing mode to thymidine kinase and
Hsp27. In both cases the drug displays
the same set of interactions: π-stacking
(green), hydrogen bonds(blue), and hy-
drophobic contacts (gray) with different
protein residues.[5, 112]
It has been theorized that promiscuous compounds could belong to
clusters of compound hubs which are metabolically most important,
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ancient, or frequent and therefore need to be recognized by many
different protein groups[268]. Further studies have indicated that
promiscuity goes hand to hand with the ability of proteins to share
binding sites, which may play a more prominent role[108]. Moreover,
the existence of similar structures (binding sites features, compound
subgroups, interactions) in different functional context may serve as
a driver for evolution and help organisms to adapt to environmental
changes while keeping an overall robust system[289].
CONCLUSIONS
The analysis of non-covalent interactions is of high interest and value
to drug discovery. Indeed, given the significant energetic contribution
of non-covalent interactions to protein-ligand binding, it seems im-
perative to study the role of certain key interaction patterns presence
in the modulation of protein function and exploit the interactions
profiles to uncover novel repositioning stories.

Chapter 5
In silico detection of Non-covalent Interactions
This chapter is based on the publications PLIP: fully automated
protein–ligand interaction profiler[241] published in 2015 in Nu-
cleic Acids Reasearch and PLIP 2021: Expanding the scope of the
protein-ligand interaction profiler to DNA and RNA[4] published
in 2021 in Nucleic Acids Reasearch. For detailed informa-
tion on author contributions see the chapter Publications and
Contributions.
5.1 Currently available tools
As discussed in the previous chapter, the binding of a ligand to
its host protein requires a specific arrangement of attractive non-
covalent contacts. Thereby, a detailed characterization of interaction
patterns is crucial to understand molecular recognition. However,
the scientific community lacks freely available tools that provide
comprehensive detection and facilitate the study of non-covalent
protein-ligand interactions.
Table 5.1 summarize the current tools and the supported features
for the characterization of non-covalent interactions. Generic tools
for structural analysis, such as MOE[123] and Proasis4[263], offer a
wide and detailed detection of non-covalent interactions. However,
due to their commercial character, they are not freely available to
the scientific community. On the contrary, non-commercial tools
such as RasMol[270], Chimera[225], and Pymol[180], offer a few
integrated functionalities for the non-covalent interactions detection
and visualization.
Interactions detected Features






ol RasMol[270] X 3D X X
Chimera[225] X 3D X X
PyMol[180] X X 3D X X
Proasis4[263] X X X X X X X 3D X X






HBPLUS X X X X X
LigPlot+[168] X X X 2D X X
PoseView[265] X X X X X 2D X X X
LeView[33] X X X X 2D X X
PROLIX[288] X X X X X X 2D X
BINANA[76] X X X X X 3D X X
Arpeggio[130] X X X X X X X X 3D X X X
D
B CREDO[248] X X X X X X X X X X
Table 5.1: Current tools for the in silico
detection of non-covalent interactions ac-
cording to the three categories: generic
tools, specialized tools, and data bases.
The table shows the interactions types
detected by the tool: hydrophobic con-
tact (HY), hydrogen bond (HB), water
bridge (WB), salt bridge (SB), π-stacking
(πS), π-cation (πC), halogen bond (HA),
and metal complex (MC). Extra features
include: possible 2D/3D visualization
of results (VI), fully automated process-
ing (AU), customized outputs (CU), and
availability under a non-commercial li-
cence (NC).
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Over the last years, many specialized softwares have become avail-
able to the community. Some of them, such as HBPLUS[190], cover
a limited set of interactions types, with special emphasis on hydro-
gen bonds. Other tools consider more interaction types in their
analysis, but they are designed for visualization purpose only, e.g.
PoseView[265], LigPlot+[168], and LeView[33] are specialized in gen-
erating 2D interaction diagrams and do not provide parseable files
for further analysis.
To enable a comprehensive detection of non-covalent interactions,
it is necessary to explore the 3-dimensional space of the protein-
ligand complexes. Durrant and McCammon developed the BINding
ANAlyzer (BINANA)[76], which can detect five of the eight previ-
ously discussed interaction types. However, it requires an extensive
structure preparation for input processing. In addition to BINANA,
the recent tool Arpeggio[130] has been made available for the 3D
inspection of a wide set of interactions. Although it offers automated
and easy processing of inputs, the 3D visualization of the complex is
unnecessarily overcrowded. Consequently, the results are difficult to
inspect, hard to customize, and not optimal for proper visualization.
Moreover, although Arpeggio allows the analysis of customized input
files, there is no option for customized thresholds.
5.2 PLIP for the characterization of interactions profiles
Figure 5.1: PLIP detects non-covalent
interactions (colored lines) between
residues of mocromolecule receptors
(blue) and small molecules ligands (or-
ange).
The Protein-Ligand Interaction Profiler (PLIP) addresses the limi-
tations of currently available tools and offers rich functionality for
detection of interactions (Figure 5.1). PLIP is available online at
https://plip-tool.biotec.tu-dresden.de and as open source code
on https://github.com/pharmai/plip under the GNU GPLv2 li-
cence.
PLIP uses a rule-based system to detect non-covalent interactions:
knowledge on chemical groups able to participate in a specific inter-
action (e.g. hydrogen bond donors) and interaction geometries (e.g.
distance and angle thresholds) from literature are used to characterize
non-covalent interactions between receptor and ligand. PLIP can ana-
lyze the interactions between protein and small molecules complexes,
nucleic acids and small molecules complexes, and protein and nucleic
acids complexes. Overall, the detection algorithm can be divided into
four sequential steps:
A. Preparation step
In this step, the input structure is hydrogenated and ligands ex-
tracted along with their binding sites. To this end, PLIP makes use
of the OpenBabel[211] tool1 for internal representation of molecules1 Open Babel is a chemoinformatics tool
designed for the analysis of chemical
data in molecular modelling, chemistry,
solid-state materials, biochemistry, or re-
lated areas.
and most chemoinformatic calculations (Figure 5.2.A). To retain only
specifically binding small molecules, PLIP uses a blacklist to exclude
preparation artefacts, modified residues, ions and solvent compounds
as ligands. The complete blacklist is available for download on the
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PLIP website.
Figure 5.2: Example illustrating the four
steps of PLIP in interaction detection for
palmitic acid in Bacillus subtilis DegV
protein (PDB ID 3FYS).[241]
B. Functional characterization
To find interacting groups, the binding partners need to be function-
ally characterized first (Figure 5.2.B). This includes the detection of
hydrophobic atoms as well as acceptors/donors for hydrogen and
halogen bonds. Furthermore, PLIP searches for aromatic rings and
charge centers in protein and ligand. The latter functionalities are a
precondition for the formation of π-stacking, π-cation interactions or
salt bridges.
C. Rule-based matching
Following, putative interacting groups are matched by applying
mostly geometric criteria. Depending on the interaction type, this
can include distance or angle constraints between the arrangement of
atoms (Figure 5.2.C). The applied thresholds are taken from literature
and are thus knowledge-based (Table 5.2). Most of them originate
from the analysis of large sets of high-quality protein structures in
other studies. To account for low-quality structures and structural
errors, some thresholds have been modified to be more permissive.
Furthermore, PLIP allows customized thresholds for special applica-
tions.
D. Interactions filtering
In the last step, redundant or overlapping interactions are removed.
This is especially important for hydrophobic contacts, which can
be formed between any close apolar parts of ligand and protein
(Figure 5.2.D). PLIP automatically searches for the most relevant
contacts (shortest interatomic distance within the neighbourhood) to
be reported. Some interaction types (e.g. salt bridges and hydrogen
bonds) are very similar in their characteristics. In the case of detection
of both interaction types for the same pairing of atoms, only one of
them (e.g. a salt bridge) is reported.
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Table 5.2: PLIP angle and distance
thresholds for the detection of non-
covalent interactions.
Threshold description Value
Max. distance to define binding site residues 7.5Å
Min. distance for interaction detection 0.5Å
Max. planarity deviation in aromatic rings 5°
Max. distance of carbon atoms for a hydrophobic contacts 4Å
Max. distance between acceptor and donor in hydrogen bonds 4.1Å
Min. angle at the hydrogen bond donor (D-H...A) 100°
Max. distance between ring centers for stacking 5.5Å
Max. deviation from optimum angle for stacking 30°
Max. offset between aromatic ring centers for stacking 2.0Å
Max. distance between charge and aromatic ring centers 6.0Å
Distance between two centers of charges in saltbridges 5.5Å
Max. distance between oxygen and halogen 4.0Å
Optimal halogen bond acceptor angle 120°
Optimal halogen bond donor angle 165°
Max. deviation from optimal halogen bond angle 30°
Optimal distance between water oxygen and polar atom 2.5Å-4.1Å
Optimal angle between acceptor, water oxygen and donor hydrogen 71°− 140°
Min. angle between water oxygen, donor atom and hydrogen 100°
Max. distance between metal ion and interacting atom 3.0Å
5.3 PLIP performance
Validation set
Thirty literature-validated examples were collected as a validation set
for PLIP. They comprise diverse cases of protein–ligand complexes
from PDB, covering all interaction types detectable by PLIP at resolu-
tions of 1.2− 3.3. During the testing, the initial thresholds obtained
from the literature (Table 5.2) have been slightly modified (distance
thresholds max. ±1.5 and angles max. ±20°) to account for a broad
range of interaction geometries while keeping the values as restrictive
as possible. For each case, a test was implemented to check whether
PLIP successfully detects all interactions reported in the correspond-
ing literature or not. Thus, the set of interacting residues for a specific
interaction type was compared against the set PLIP detects for the
given complex. Contacts reported in the literature and detected with
PLIP are listed as true positives. Additional contacts detected by PLIP
but not listed in the publication are labelled as false positives, and on
the other way around, as false negatives. A number of 245 specifically
interacting residues together with the interaction types were reported
in the selected publications. With 193 correct detections, 45 false
positives and seven false negatives reports, PLIP reaches a recall (true
positive rate) of ≈ 79% at a precision of ≈ 81%.
However, it should be noted that after careful inspection, most of
the false-negative contacts were the result of errors in the publica-
tion, different interpretation of contact, or unreasonable thresholds.
This means that generic rules as used in PLIP might always miss
out in some specific cases. Moreover, there might be a bias in litera-
ture towards the relevant interactions for the authors’ study, directly
increasing the number of PLIP false positives.
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Computational complexity
PLIP uses OpenBabel[211] for internal representation of molecular
structures. After reading the input structure, the complete molecule is
loaded into memory for the subsequent analyses, resulting in constant
memory usage. Since classes are instantiated for each atom and its
associated information, the space complexity for the data space grows
linear with O(a), where a is the total number of atoms in an input
structure.
In terms of computation time, PLIP reaches its maximum by calcu-
lating pairwise distances between ligand and protein atoms. First, a
preselection of binding site residues is made by approximate distance
calculations between the ligand centroid and residue centroids. In the
worst case, all protein residues for each of the n ligands are selected
for the following pairwise distance calculation. This makes it neces-
sary to consider all combinations of al ligand and ap protein atoms
and yields a cubic time complexity with O(n× al × ap). However,
the preselection step usually reduces the search space to an average
of 19 out of 800 residues from a typical protein, resulting in a linear
complexity of O(n) for the average case.
5.4 PLIP applications
PLIP can be used for both––structures from the PDB archive and
structure files from other tools. It is, therefore, possible to integrate
PLIP into pipelines for analyses related to protein-ligand binding.
The study of complex biological systems
Transcription, the synthesis of RNA from a DNA template, is one of
the most important steps in controlling cell growth and differentiation
[305, 171]. During transcription, the information in a strand of DNA is
copied into a new mRNA molecule, mainly carried out by the enzyme
RNA polymerase II and several accessory proteins called transcrip-
tion factors [101]. The RNA polymerase begins mRNA synthesis by
unwinding the DNA helix and adding complementary bases to the
RNA strand (elongation). Wang et al. obtained the X-ray structure
revealing the transcribing complex in the “post-translocation” state
with the nucleotide added to the RNA transcript [283] (Figure 5.3).
The substrates for RNA synthesis are the four nucleoside triphos-
phates ATP, GTP, CTP, and UTP. Figure 5.3 shows how PLIP analyses
the transcription complex and characterises the binding of GTP (or-
ange) to the RNA polymerase (purple-grey), RNA strand (green), and
DNA strand (blue), all at the same time.
The guanine group in GTP binds to the DNA strand with three
hydrogen bonds and the RNA strand via parallel π-stacking and one
hydrogen bond. Moreover, the phosphate groups in GTP binding to
the RNA polymerase residues via a salt bridge and a metal complex.
The characterisation of the GTP binding mode in the elongation
complex provides a structural understanding of the transcription
48
Figure 5.3: PLIP analysis for the tran-
scription complex. GTP binds RNA
polymerase II and DNA/RNA of the
elongation complex (PDB ID 2E2H). Lig-
ands are shown in orange and recep-
tors in blue, green or purple grey. Pro-
tein residues are labeled in black and
DNA/RNA bases in red.
mechanism.
Novel inhibitors design
In the initial stages of inhibitor design or before library screening,
comparative analyses of known binding patterns with the target pro-
tein help identifying key residues. Here, PLIP is used to analyse
interactions in three complexes of different inhibitors (PDB IDs 1IEI,
1Z89, 3P2V) with human aldose reductase (Figure 5.4). Aldose reduc-
tase binds ligands via induced fit, leading to drastic conformational
changes around the binding pocket.
Figure 5.4: PLIP analysis for human al-
dose reductase with different inhibitors.
(A) Zenarestat (1IEI), (B) a sulfonyl-
pyridazone inhibitor (1Z89) and (C) a
benzothiazepine inhibitor (3P2V).
The three considered inhibitors show common interaction patterns
but also individual subpatterns. All three inhibitors form the hy-
drogen bond to Tyrosine 48 and a hydrophobic contact to Leucine
300. Notably, while both zenarastat (Figure 5.4.A) and the benzoth-
iazepine inhibitor (Figure 5.4.C) form a salt bridge to Histidine 110,
sulfonyl-pyridazone inhibitor (Figure 5.4.B) lacks this interaction due
to the missing carboxyl group, and it has a hydrogen bond instead.
Although all inhibitors have aromatic rings, only two forms π-tacking
interactions with Tryptophan 111. One of the most unique interaction
patterns can be seen in the complex with zenarestat, where halogen
bonds to the protein backbone are formed from both ends of the
inhibitor.
Indeed, having such a perspective on the binding mode of the
known inhibitors will help to elucidate which chemical fragments of
scaffolds are the key players in the binding and might be ignored or
replaced.
Docking post processing
The elimination of false-positive results from docking results can be
performed using post-processing pipelines. One approach is to use
existing knowledge on key interactions with the protein of interest
to filter from high-scoring poses. Cathepsin K in complex with a
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small molecule inhibitor (PDB ID 1VSN) was used for a redocking
experiment. While the top prediction corresponds to the pose found
in the crystal structure, the first alternative pose shows a different
ligand conformation (Figure 5.5).
Figure 5.5: PLIP analysis for the eval-
uation of docking results. Natural (A)
and alternative pose from redocking (B)
of Cathepsin K with a small molecule
inhibitor (PDB ID 1VSN). Shared inter-
acting residues are labeled. The second
pose lacks characteristic halogen bonds.
PLIP was used to analyze the interaction patterns in the complex
from the crystal structure (Figure 5.5.A) and the complex with the
alternative pose from docking (Figure 5.5.B). In the alternative pose,
the ligand part containing the aromatic rings is flipped to the opposite
direction. A rich network of hydrogen bonds and water bridges can
only be observed for the correct pose. However, most strikingly, the
characteristic halogen bonds are entirely missing in the alternative
pose, leaving the trifluoride group exposed. With the detailed inter-
action patterns at hand, it is thus possible to identify wrong poses
based on previous knowledge.
CONCLUSIONS
The PLIP algorithm enables fast and reliable characterization of the
complex three-dimensional binding patterns arising from protein-
ligand binding. With its universal availability and unique combination
of comprehensive detection, visualization, and atomic-level reports
on contacts and their geometries, PLIP is the current state-of-the-art
tool for detecting non-covalent interactions. With access to largely
untouched data on almost 4 million contacts from the structural
proteome, PLIP can enable the improvement of docking and ligand
design routines and the perfect means to exploit virtual screening
techniques for repositioning candidates.

Chapter 6
Drug Repositioning via PLIP Interaction Patterns
This chapter is based on the publications From malaria to cancer:
Computational drug repositioning of amodiaquine using PLIP inter-
action patterns[239] published in 2017 in Scientific Reports and
Structure-based drug repositioning explains ibrutinib as VEGFR2
inhibitor[6] published in 2020 in PLoS ONE. For detailed infor-
mation on author contributions see the chapter Publications
and Contributions.
Besides the mentioned applications of PLIP (Chapter 5), there are
many others possible. This chapter will particularly focus on describ-
ing a novel technique for drug repositioning using PLIP interaction
patterns similarity.
6.1 Hypothesis underlying the approach
Chapter 4 discussed the influence and energetic contribution of non-
covalent interactions in the binding mode of drugs. Therefore, this
approach uses non-covalent interaction patterns comparison to exploit
binding mode similarities of drugs and identify potential reposition-
ing candidates.
In contrast to the computational approaches based on binding site
similarities, the hypothesis underlying the interaction patterns simi-
larity approach is illustrated in Figure 6.1. Knowing that drug dA and
drug dB are known to bind protein A and protein B, respectively, if
proteins A and B share similar interaction patterns, it can be assumed
that drug dA will bind to protein B and vice versa for drug dB to
protein A.
The approach relies on the idea that interaction patterns can grasp
the essence of binding sites, completely ignoring the amino acids
in the binding site and rather focusing on non-covalent interactions
that allow binding. Thus, a drug having similar interaction patterns
should bind the same protein targets. Under this novel perspective,
the technique offers a more uncoupled viewpoint from the chemical
structures of proteins and ligands. Hence, it expands the search scope
for drug repurposing cases to discover novel links between completely
unrelated proteins and drugs.
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Figure 6.1: Assessing protein’s remote
similarity using interaction patterns fin-
gerprints. (A)The two proteins are glob-
ally dissimilar in sequence and structure.
(B)The local similarity at the binding
site is also low, with distinct residues
involved in the binding. (C)On the
contrary, the interaction patterns of the
drugs turn to be highly similar after
comparison via encoded interaction fin-
gerprints. Given the shared binding
mode between the drugs, there is a pro-
posed binding of them to both proteins
(dashed gray arrows).
6.2 Virtual screening with interactions fingerprints
Large-scale interaction data from protein-ligand complexes allows
screening for similar interaction patterns. The main idea behind the
comparison of protein-ligand complexes with interaction pattern fin-
gerprints was shown in Figure 6.1 and the virtual screening approach
will be further described in this section.
The general steps in the approach are:
1. For a given protein-ligand complex of interest, the interactions
profile is obtained with PLIP tool, and special key interaction
patterns are detected.
2. Identified relevant pattern are encoded into PLIP fusion finger-
print.
3. The generated fingerprint is screened against the full PDB screen-
ing set to identify other complexes with a similar fingerprint, thus
a similar binding mode. The similarity is achieved by standard
distance and similarity measures.
4. To avoid redundancy, the results are aggregated by ligands and
ranked by p-value. If there are multiple complexes of the same
drug with different proteins, they are all grouped and regarded
as one hit, with the lowest p-value being chosen to represent the
group.
5. The resulting predictions are further analyzed and filtered accord-
ing to the case study requirements.
drug repositioning via plip interaction patterns 53
Definition of the key Interaction Patterns
To exploit the binding mode of drugs under a structural basis, it is
first necessary to identify the drug or target of interest. As for any
other structural approach, the availability of 3D structural data is a
must. Therefore the approach is applicable to the case study only if
there are 3D structures of the targets or the drugs in question.
When structural data is available, it is crucial to identify the key
non-covalent interactions in charge of the significant energetic con-
tribution to the binding. As discussed in Chapter 4, the energetic
contribution of single non-covalent interactions is small compared to
the covalent bonds. Nonetheless, additive and synergistic effects of
non-covalent interactions result in a significant contribution to the
binding. Such synergistic effect is defined by the so-called interaction
patterns, where the geometrical features such as position, distances,
and angles between one or more interactions, directly contribute to
the energy and stability of the binding (Figure 6.2).
Figure 6.2: Example of an interactions
pattern defined with geometrical fea-
tures of distances and angles. The dis-
tances are calculated between the center
of the interactions and the angles are
calculated to the meeting point between
the projections of the interactions pair.
Some interaction patterns are easily detectable and can be manually
defined. As briefly discussed in Chapter 4, brivudine is an excellent
example of such a case with a highly conserved binding mode. After
PLIP analysis of the 3D structures containing brivudine as a small
molecule ligand, a set of recurrent non-covalent interaction is exposed
by PLIP and effortlessly identified as interaction patterns (further
details on this case study will be discussed in Chapter 7).
On the other hand, the interactions profile of some drugs might be
too complex for a manual inspection, and therefore, they require ad-
vanced techniques for their automated detection. Moreover, the large
amount of data in the PDB with several 100,000 single interactions
makes it impossible to perform exhaustive comparisons visually.
Automated encoding of interaction patterns
To generate simplified representations (profiles), data has to be re-
duced in complexity, often accompanied by dimensional reduction.
In previous approaches, 3D interaction data has been encoded in
graphs[63], matrices[63], and one-dimensional feature vectors, so-
called fingerprints[47, 50, 222, 269, 280]. These structures have gained
the most attention in the last years due to their fast processing and
comparison and low memory consumption.
Fingerprinting has explored many different concepts for encod-
ing and comparing the complex patterns from biological complexes.
Protein-ligand fingerprints have proven helpful for ligand and target
prediction (Rognan, 2010) but are usually limited to homologous
targets. To obtain more flexible and universal interaction profiles, ap-
proaches have been developed to encode interaction patterns without
mapping them onto atoms or residues in the ligand or protein.
The Atom-pairs-based Interaction Fingerprint (APIF) by Pérez-
Nueno et al. is the first introduced interaction patterns fingerprint[222].
This descriptor labels atoms according to their affiliation (protein or
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ligand) and their type (hydrophobic, hydrogen-bond acceptor or
donor). Not single, but pairs of interactions in a complex are then
fingerprinted together with the distances between them. The resulting
fingerprint length is fixed to 6× 72 = 294 bits according to the seven
binned distances and six interaction types considered.
Triplets of Interaction Pseudo atoms (TIFP) approach by Desaphy et
al. uses pseudo atoms for the representation of interactions and their
relative positions encoded[63]. In this approach, for each detected
interaction, a pseudo atom, named Interaction Pseudo atom (IPA), is
created in the mid-distance of the participating atoms or groups of
atoms and an integer fingerprint of 210 bins is generated by encoding
the count of IPA triplets. Although TIFP has been successfully ap-
plied to re-scoring of docking poses and binding site alignments, the
fingerprint has a fixed size, limited to only 5 types of non-covalent
interactions (e.g. waters excluded). Additionally, the TIFP design
requires a recalculation for each data set to remove weakly populated
triplets and reduce the fingerprint size to a reasonable size from an
original length of > 12, 000 bins due to the ample feature space of
pseudo atom triplets.
PLIP Fusion Fingerprint
In 2017 Sebastian Salentin introduced the PLIP Fusion fingerprint[238].
The structure-invariant design of PLIP fusion fingerprint is based on
PLIP tool detection and profiling of non-covalent interactions to screen
interactions in the structural proteome and unravel hidden similarities
between unrelated targets and ligands. Each bin in the PLIP Fusion
fingerprint corresponds to an observed combination of features in the
3-dimensional interaction patterns from the complex. The smallest
elements being encoded are pairs of interactions represented as two
vectors in 3D space (Figure 6.3). Each pair is characterized by the
combination of interaction types and the binned distance and angle
between the vectors. Within the fingerprint, each bin corresponds to
such a unique combination and counts the occurrence of the pattern
in the original complex. For a complex with n observed interactions,
n×(n−1)
2 pairings need to be encoded.
The new design improves upon the previous ones APIF[222] and
TIFP[63] by incorporating far more interaction types and considering
water molecules in complexes. Regarding the interactions encoding,
while TIFP uses pseudo atoms to represent interactions, the new
PLIP design operates directly on the interacting atoms or the vector
between them. Similarly, as APIF, PLIP fusion uses duplets of interac-
tions and not triplets as the TIFP fingerprint. Although encoding of
triplets gives a more intuitive representation of spatial patterns, TIFP
design requires a recalculation for each data set to remove weakly
populated triplets and reduce the fingerprint size to a reasonable size.
In contrast, the PLIP Fusion Fingerprint yields the final fingerprint
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Figure 6.3: PLIP Fusion Fingerprint de-
sign. (A)Raw interaction data from PLIP
is calculated for a complex. (B)For each
pair of interaction vectors, their dis-
tances and angles are calculated. (C)The
geometric measures are binned and com-
bined with the types of the pairing into a
string representation. Each such combi-
nation corresponds to a bin in the finger-
print, which is incremented for each ob-
servation of the encoded pairing. The re-
sulting fingerprint is structure-invariant
since it only considers the interaction
vectors.
in just one step. Furthermore, PLIP fusion incorporates the angle
between interaction vectors, which allows encoding relative spatial
orientations (as achieved with triplets in the TIFP fingerprint) while
being able to stick to duplets for a smaller feature space. While the
new fingerprint is the largest among all design, it still has a suitable
size for fast processing and has a small storage footprint.
PDB screening set for 3D interaction profiling
The PDB structural data was downloaded from the PDB FTP Archive
on the 8th of April, 2015. The data set contains 107, 663 structure
files which were later analyzed with PLIP to detect the relevant non-
covalent interactions. The interaction profiles were obtained using
PLIP v1.1.1 with default settings, and the results were deposited in
XML format for further analysis. Processing with PLIP was successful
for 106,577 structures covering about 99% of the PDB data set. The
remaining structures failed the PLIP analysis due to truncated or
obsolete structures, no binding ligand detected in the structure, or no
interactions detected in the binding sites. In the subsequent steps of
the analysis, only biologically relevant complexes were considered.
To achieve this, the set of binding sites was filtered with BioLiP, yield-
ing 170, 219 complexes in 55, 597 PDB structures (52% of processed
structures). This final screening set contains complexes from 16, 460
unique targets (Uniprot IDs) and 13, 704 unique ligands (PubChem
IDs).
Standard distance and similarity measurements
Interaction fingerprint as binary or integer features vectors can be
compared using standard distance and similarity measures such as
the Jaccard-Tanimoto coefficient[49], Euclidean distance [154], or sim-
ple matching[197]. However, the choice of a measure can heavily
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influence score distributions and thus interpretation of datasets. For
instance, the Euclidean distance measures the distance between points
defined by two vectors, whereas the cosine similarity measures the
angle of feature vectors with respect to the origin. Therefore, Cosine
similarity tends to cluster vectors by direction, while Euclidean dis-
tance by magnitude. Nevertheless, when ranking the most similar
items, the order is fixed no matter if Euclidean or cosine similarity is
used since the transformation from one to the other is monotonic[154].
Features in interaction fingerprints are high-dimensional repre-
sentations of data and often sparse. Thus, distance and similarity
measures can often show counter-intuitive behaviours when moving
to higher dimensions[7]. Nonetheless, in the chemoinformatics do-
main, cosine similarity and Tanimoto coefficient are established as
equally reliable measures[20]. Thereby, the PLIP Fusion Fingerprint
was benchmarked with cosine similarity, Jaccard-Needham dissimi-
larity, and Rogers-Tanimoto dissimilarity[238].
PLIP fusion distribution
After fingerprint similarity is calculated, it is necessary to assess the
significance of the retrieved hits to achieve an optimized ranking. To
provide an estimation on score frequencies with p-values, similarities
were calculated for the complete screening set. Each item from this
set was compared against all other items of the set, and the resulting
distribution discretized with bin sizes of 0.001. For each score thresh-
old S, it was recorded how often a score > S was observed in the
dataset, generating a cumulative distribution. Division by the total
number of comparisons yields a p− value distribution: it indicates
how probable it is by random to yield a hit with or above a similarity
score S.






Table 6.1: Performance of the PLIP Fu-
sion Fingerprint on the Desaphy bench-
mark set in comparison to the author’s
original design[238]. The new PLIP fin-
gerprint performs better (AUROC and
F-measure) compared to the TIFP fin-
gerprint and shows comparable perfor-
mance to the graph-based (Grim) and
shape-based (IShape) approaches by De-
saphy et al. [63]
The novel PLIP fusion fingerprint has been benchmarked using the
same strategy applied on the state-of-the-art structure-invariant inter-
action fingerprint by Desaphy et al. [63].
The PLIP Fusion fingerprint was tested on the Desaphy bench-
mark set 1, which contains equally-sized sets of each 900 similar and
dissimilar protein-ligand complexes each, with a parameter space
of 8,400 combinations. For each test run, the ability to discriminate
between the similar and dissimilar complexes in the set was measured
with the area under the ROC curve (AUROC) and the F-score, which
considers precision and recall equally. The latter measure was chosen
to rank the parameter configurations[238].
The best design showed a AUROC of 0.942 and a F-measure of
0.877 (ROC curve shown in Figure 6.4). Compared to TIFP fingerprint
by Desaphy et al. [63], the PLIP Fusion Fingerprint shows superior
performance in both AUROC and F-measure (Table 6.1). It even
comes close to the graph- and shape-based approaches Grim and
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Figure 6.4: ROC characteristics for dis-
crimination performance of the PLIP Fu-
sion Fingerprint on the Desaphy bench-
mark set (N = 1, 800)[238].
IShape, which also use interaction data but are much more expensive.
CONCLUSIONS
The large data set on small-molecule complexes from the PDB gen-
erated with PLIP allowed a new general insight into small ligands’
binding behaviour. The novel approach of 3D interaction profiling
is presented as a knowledge-based screening workflow based on
the key interaction of a known binder to a protein target of interest.
When compared to other similar techniques, the approach showed
a superior or comparable performance. The latter demonstrates the
power of the presented workflow and, more generally, the potential









From malaria to Cancer
This chapter is based on the publication From malaria to cancer:
Computational drug repositioning of amodiaquine using PLIP inter-
action patterns[239] published in 2017 in Scientific Reports. For
detailed information on author contributions see the chapter
Publications and Contributions.
7.1 Drug resistance in Cancer
Drug resistance remains one of the biggest challenges in cancer ther-
apy. It exists across all types of cancer and all modes of treatment, in-
cluding molecular targeted therapy, immunotherapy, and chemother-
apy. It is well known that the inherent resistance to cytotoxic and
therapeutic agents contributes to the highly aggressive nature of some
types of cancer[124]. In that sense, therapies targeting the essential
pathways for drug resistance are considered to hold great promise for
the improvement of the current cancer treatments.
Figure 7.1: Cancer cells sensitivity to
treatments. Cancer cells have different
molecular features, which may make
them sensitive or resistant to treatments.
Although the treatment may kill the
sensitive cells, the resistant cells will
survive, continue multiplying and con-
tributing to the tumor growth[124].
Tumours are made of diverse cells that may have different genetic,
epigenetic, and metabolic characteristics that have different sensitivi-
ties to treatment. Tumours also consist of immune cells, blood vessels,
fibroblasts, and other cells and components that interact with the
cancer cells. These interactions often promote tumour development,
progression, and response to treatment[78].
Although a drug may kill some cancer cells, others will be resistant
and survive the treatment (Figure 7.1). Cancers often have multiple
mechanisms for surviving and growing, which may change over
time and in response to treatment[124, 78]. That is why combining
treatments that have different mechanisms of action can kill more
cancer cells and reduce the chance that drug resistance will emerge[1].
7.2 The role of HSP27 in chemotherapy resistance
Heat shock proteins (HSPs) are molecules synthesized by cells in
response to heat or chemical stress and highly conserved across
species. HSPs, as chaperone molecules, play crucial roles in the native
folding of proteins, assembly of multiprotein complexes, transport
of proteins into correct subcellular compartments, cell-cycle control,
and protection of cells against apoptosis[177]. Although normal cells
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also express HSPs under stressful conditions, it appears that their
uncontrolled expression in cancer cells has a key role in tumour
progression and drug resistance.
In particular, HSP27 (Heat shock protein beta-1; HSPB1) is known
to be expressed in many cell types and up-regulated across many
cancer types, such as breast, pancreas, colorectal, liver, tongue, blad-
der, lung, and prostate, among others[135, 170, 299, 309, 82, 282, 132,
116, 236]. Moreover, HSP27 protects cells against apoptotic cell death
triggered by a variety of stimuli including hyperthermia, oxidative
stress, staurosporine, Fas ligand and cytotoxic drugs[31].
Many authors have reported over the past years that targeting
HSP27 is a promising anti-cancer strategy. Chauhan et al. reported
that resistance of multiple myeloma cells to dexamethasone could be
overcome by inhibition of HSP27 over expression[41]. For bladder
cancer, Kamada et al. found that HSP27 overexpression is related
to paclitaxel resistance and increased UMUC-3 cell growth[132]. In
pancreatic cancer, Kuramitsu et al. showed that the overexpression of
HSP27 is related to higher rates of Gemcitabine resistance[164]. Zhang
et al. identified up-regulation of HSP27 in the doxorubicin-resistant,
ERp29 over-expressing MDA-MB-231 breast cancer cell line[307].
7.3 Brivudine binds and inhibits the HSP27 target
Brivudine was first introduced in 1980 as a treatment for Herpes
zoster infection. Brivudine is a thymidine analogue composed of a nu-
cleobase ring, a deoxyribose moiety, and a bromovinyl residue. In the
infected cell, brivudine is phosphorylated by a viral thymidine kinase
and then erroneously integrated into the viral genome, terminating
the viruses ability to replicate[239].
In previous work on target identification, Heinrich et al. showed
that the herpes drug Brivudine binds in vitro to the heat shock pro-
tein HSP27 and inhibits the interaction with its binding partners.
Moreover, Brivudine was proved to be a potent drug against chemore-
sistance with experimental evidence in animal models and three
clinical studies with late-stage pancreatic cancer patients[112].
Since there is no three-dimensional structure of HSP27 available
to the date, Heinrich et al. constructed a three-dimensional model of
HSP27 using SAM-T08 web server.1 Moreover, by the use of extensive1 structure prediction program which
generates good quality structures across
all classes of predictions as evaluated in
the CASP8 structure prediction assess-
ment.
molecular dynamics simulations and taking as base the structures
of the original target of Brivudine, the viral thymidine kinase, they
predicted brivudine binding site in HSP27.
Notwithstanding the remarkable finding presented by Heinrich et
al., several reports have reported the life-threatening drug-drug in-
teraction between brivudine and chemotherapeutic agents. Tsifi et al.
remarked the case of a patient experiencing severe effects involving
the concurrent administration of capecitabine, a chemotherapeutic
agent, and brivudine[274]. The patient developed a skin rash, severe
oral mucositis, and severe and prolonged pancytopenia. These side
effects were attributed to a severe capecitabine interaction with brivu-
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dine, resulting in inhibition of dihydropyrimidine dehydrogenase.
Furthermore, Garcia Fernandez et al. reported the death of a patient
after the joint administration of brivudine and the antineoplastic agent
5-fluorouracilo (5-FU), which produces severe toxicity associated with
5-FU as a consequence of the inhibition of its metabolism[90].
In light of this, it is clear that brivudine can not be further pursued
as a repositioned treatment for cancer chemoresistance. Nonetheless,
the novel insights about its binding to HSP27 can be exploited in the
quest for other suitable candidates.
7.4 Structure-based screening and identification of novel
HSP27 inhibitors
Characterization of brivudine’s binding mode
As the starting point of the virtual-screening, the binding mode
of brivudine was characterized with PLIP v1.1.1 and encoded into
a consensus meta-pattern 2. For such purpose, five structures (or 2 A meta-pattern in this context is a su-
perset of all observed characteristic in-
teractions describing the binding mode
of Brivudine to its targets
fourteen PDB complexes when considering the different chains) with
either brivudine (PDB HET ID: BVD) or brivudine monophosphate
(PDB HET ID: BVP) were considered for the analysis, exploring
the observed non-covalent interactions and their spatial orientations
(Table 7.1).
PDB Target name Organism
BVD 1KI8 thymidine kinase Herpes simplex virus type I
2VQS deoxyribonucleoside kinase Drosophila melanogaster
BVP 1OSN thymidine kinase Varicella Zoster
2JAW mitocondrial deoxiribonucleotase Human
2WOS thymidilate kinase Vaccinia virus
Table 7.1: PDB structures of brivudine
and brivudine monophosphate. For the
definition of the metapattern, the inter-
actions of the phosphate moiety were
not considered
An interaction pattern was defined as a single non-covalent inter-
action or an arrangement of up to two of these interactions and their
geometric constraints (observed distance ranges and angles between
atoms or bonds) in the complex ensemble, which was recurrently ob-
served among the brivudine complexes (see Appendix Figure 15.11).
Together, ten patterns are conforming the brivudine meta pattern
(Figure 7.2).
Figure 7.2: Patterns found in complexes
with brivudine(-MP) with the ligand
brivudine (orange) and the interacting
target residues (blue). Letters indicate
the patterns: A Base pattern - aromatic
ring in ligand, B Double π-stacking to
base ring, C Double π-stacking to base
ring on opposite sites, D Parallel dou-
ble π-stacking to base ring, E Double
hydrogen bonds to base ring, F Dou-
ble hydrogen bonds to the same residue,
G Parallel double hydrogen bonds, H
Distal hydrophobic contact, I Distal hy-
drogen bond and J Distal halogen bond.
Brivudine’s binding mode comprises different interaction types,
such as hydrogen bonds, π-stacking, halogen bonds, and hydrophobic
contacts, by using its central nucleobase ring, the deoxyribose moiety,
and the bromovinyl residue. While an aromatic ring in the ligand
served as a base pattern (A), all other patterns were defined in relation
to this anchor (Table 7.2).
The ten interaction patterns (A–J) were derived from five different
PDB structures originating from viruses, human, and fruit fly. Given
the variety of species, it can be expected that not all patterns are
present in all complexes. While all complexes have at least one π-
stacking interaction to the central aromatic ring (base pattern A), the
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double stacking (pattern B) is present in three of the five structures.
Moreover, the sandwich stacking (patterns BCD ) is only visible in the
Varicella zoster thymidine kinase complexes (PDB ID 1OSN). The two
parallel hydrogen bonds to the base aromatic ring in the nucleobase
part (patterns EFG ) are most predominant in the ensemble with
presence in all but one structure (2JAW), and the distal hydrophobic
contact (pattern H), is visible in all complexes.
Table 7.2: Definitions of patterns A-J.
The base pattern A is required in every
complex. For the patterns G to J, ad-
ditional geometric constraints for their
definition were necessary and have been
derived from the observed geometries in
brivudine and brivudine-MP complexes.
Pattern Geometric Constraints
A Base pattern: aromatic ring in ligand
B Double π-stacking to base ring
C Double π-stacking to base ring on opposite sites
D Double π-stacking to base ring in parallel type
E Double hydrogen bonds to base ring
F Double hydrogen bonds to shared residue
G Double hydrogen bonds in parallel angle is 180 ° ± 18 °
H Distal hydrophobic contact dist. to ring 4.0 Å < x < 6.5 Å
I Distal hydrogen bond dist. to ring 5.4 Å < x < 6.1 Å
J Distal halogen bond dist. to ring 7.8 Å < x < 9.2 Å
While a single hydrogen bond in the sugar residue (pattern I )
appears in all complexes of three structures (1KI8, 1OSN, 2W0S), the
distal halogen bond (pattern J ) is predominant in the complexes with
the proteins from D. melanogaster and Vaccinia virus. Overall, the
key interaction patterns within the same crystallographic structure
are mostly consistent.
Virtual screening of PDB compounds with brivudine’s binding mode
After defining the brivudine meta-pattern, a 3D interaction profiling
workflow was designed for the automated detection of the patterns.
The workflow was tested against the original fourteen brivudine com-
plexes, and it was able to recover all previously manually annotated
patterns A - J with 100% accuracy. Consequently, a virtual screening
workflow was designed to screen for the brivudine meta-pattern in
the full set of PDB complexes. A custom script was used to find inter-
action patterns in protein-ligand complexes using PLIP data. For each
complex, the information on the presence of subpatterns was stored
in a simple 10-bin boolean fingerprint, with each bin representing the
presence (1) or absence (0) of a subpattern.
Compounds were ranked by the number of patterns and annotated
whether they were approved for therapy by the FDA. The drug classi-
fication was performed using the classification for compounds from
the Therapeutic Target Database (TTD)[44]. Overall, there are fewer
than 250 compounds with at least six brivudine patterns, and there
is no complex that contains all ten interaction patterns. However,
the compound thymidine, which is the parent scaffold from which
brivudine is derived, is among the two compounds that contain nine
patterns.
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Candidate compounds prioritization
Three criteria were used to prioritize the candidate compounds:
1. Only FDA-approved compounds.
FDA-approved compounds have been extensively researched and
have vast information on safety, pharmacology, dosing, and formu-
lation. Such data can significantly increase the value of potential
repositioning candidates.
Figure 7.3: Brivudine patterns effec-
tively identify repositioning candidates.
There are 247 compounds with six or
more brivudine patterns including 12
approved drugs. One such drug is
amodiaquine, an anti-malaria agent. As
a control, thymidine, a brivudine ana-
logue, satisfies nine brivudine patterns.
From those 250 compounds with at least six brivudine patterns, 58
are categorized as FDA drugs, from which 12 are in the approved
state and 46 in the candidate state (i.e. experimental drugs or drugs
which are currently in clinical trials) (Figure 7.3). The 12 approved
drugs display the brivudine patterns across different disease and
targets (see Appendix Figure 15.13).
2. Compounds with a different scaffold to brivudine.
A chemical grouping of compounds was manually performed
according to the observed scaffolds in the molecules. Compounds
with no explicit group membership were labelled as singletons.
Many of the top-scoring hit compounds were nucleobases, which
is expected since brivudine is a thymidine analogue.
Figure 7.4: Scaffold hopping from
brivudine to amodiaquine. Pairwise
chemical similarity of compounds
(red=similar,yellow=dissimilar) ar-
ranged by chemical scaffold and
clustered by chemical similarity within
each group. The top group shows
brivudine among 40 nucleobases.
Amodiaquine is one of 18 compounds
with a scaffold different from brivudine
In that sense, thymidine is ranked highest with nine matching
patterns and thus serves as a positive control. Similarly, deoxy-
adenosine, -guanosine, and -cytidine contain seven brivudine pat-
terns, and deoxy-uridine has six patterns. Overall, the 58 drugs
with six or more patterns include 40 of the nucleobase type.
The 58 drugs were grouped according to chemical similarity. Struc-
tures of chemicals were downloaded from PubChem in SDF format,
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and the similarity between them calculated using the PubChem
Score Matrix Service. A chemical heatmap was generated with
hierarchical clustering using average linkage (Figure 7.4).
The chemical grouping revealed two large clusters (orange-red
boxes), which comprise pyrimidine and purine scaffolds. The re-
maining groups are much smaller in size and comprise very distant
scaffolds from brivudine. Half of the 12 FDA-approved drugs have
a different scaffold to brivudine, namely the aminopteridones (folic
acid, tetrahydrobiopterin, triamterene), the flavone quercetin as
well as the singletons pyridoxal phosphate and amodiaquine (Table
7.3).
Table 7.3: Approved drugs with a dis-
tant scaffold to brivudine. Listed are the
drugs and their targets as well as their
original indication. They are sorted ac-
cording to the number of brivudine pat-
terns the have.
Drug name Target Disease N Patterns
Folic acid Folate receptor alpha Folate deficiencies 7
Tetrahydrobiopterin Nitric oxide synthase Phenylketonuria(PKU) 7
Amodiaquine Histamine N-methyltransferase Acute malaria attacks 6
Pyridoxal Phosphate D-serine dehydratase Dietary shortage or imbalance 6
Quercetin Xanthine dehydrogenase/oxidase Dicrease capillary fragility 6
Triamterene Pteridine reductase 1 Edema in congestive heart failure 6
3. Compounds binding brivudine’s targets.
To assess whether candidates could bind to the known targets of
brivudine, an in silico docking of the hit candidates was performed
to the relevant binding sites in the viral thymidine kinase and a
homology model of Hsp27. For such purpose, AutoDock software
4.2 with rigid body docking was used.
Surprisingly, the anti-malaria drug amodiaquine ranked better
than brivudine in both cases. When docked to the two targets,
amodiaquine poses to satisfy the π-stacking patterns A-D as well
as the distal hydrophobic contact pattern. However, they do not
fulfil the hydrogen bond patterns E-G. In this respect, amodiaquine
binds the brivudine targets in the same manner as one of its targets,
histamine methyltransferase (Figure 7.5).
Figure 7.5: Amodiaquine in complex
with its original target histamine methyl
transferase (2AOU), with the in silico
docked target thymidine kinase (1OSN)
and Hsp27 model. All contain the pat-
terns A-D and H.
7.5 Amodiaquine as a novel HSP27 inhibitor
The anti-malaria drug amodiaquine
Amodiaquine is a 4-aminoquinoline, similar and the cheap alter-
native to chloroquine, has been used widely to treat and prevent
malaria[213].
Although amodiaquine is on the World Health Organization’s List
of Essential Medicines, 3 adverse reactions have been reported in
3 WHO EML lists the safest and most
effective medicines needed in a health
system.
adults taking it for prophylaxis. Consequently, the manufacturer
(Parke-Davis) modified the labelling and withdrew prophylaxis as an
indication and the WHO has recommended that amodiaquine should
not be used as monotherapy but rather as part of a combination
treatment for uncomplicated falciparum malaria.
The most common combination therapies consider amodiaquine
jointly with the antimalarial drugs artesunate and sulphadoxine-
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pyrimethamine, achieving a faster effect against fever and improve
sustained parasites clearance[191].
Cell resistance assay
Brivudine has its anti-cancer effect by suppressing the cancer cells’
ability to develop resistance to chemotherapy. Heinrich et al. demon-
strated this by treating a multiple myeloma cell line with bortezomib
at increasing doses, which creates a selective pressure for the cells
to develop resistance. Bortezomib is an anti-cancer medication used
to treat multiple myeloma and mantle cell lymphoma. Co-treatment
with bortezomib and brivudine inhibits cell growth effectively and
allows bortezomib to reestablish its cytotoxic effect. Moreover, the au-
thors proved that brivudine achieves such effect only in combination
with bortezomib and has no cytotoxic activity on its own [111].
Similarly, Amodiaquine was tested in the chemoresistance assay
to document its anti-cancer potential (Figure 7.6). The cancer cells
were exposed to increasing doses of bortezomib over three cell culture
passages. At the beginning of the third passage on day 12, 100,000
cells are exposed to the treatment regimes (bortezomib on its own
and bortezomib with amodiaquine). After one week, resistance to
bortezomib is clearly shown as cells continue to grow and have
multiplied eightfold to 800,000. In contrast, the co-treatment with
amodiaquine leads to a significant reduction in cell number to 80,000
(10%).
Figure 7.6: Cell resistance assay. Amodi-
aquine re-establishes chemosensitivity
in resistant cancer cells. Cells are treated
with increasing doses of the cytotoxic
agent bortezomib and amodiaquine over
three passages. There is a clear differ-
ence in growth behaviour between treat-
ment with bortezomib only or with ad-
dition of amodiaquine. In comparison
to the known binder BVDU at 30, amodi-
aquine is more effective at 1/60th of this
dose.
Furthermore, Heinrich et al. devised an assay to show how BVDU
impacts Hsp27’s function as a chaperone. Citrate synthase is used
as a client protein of Hsp27 and misfolds at 43 deg, but in the pres-
ence of Hsp27, misfolding is inhibited. The chaperone activity of
Hsp27 can be measured by the amount of misfolded client protein
determined by capillary electrophoresis of precipitated protein. Thus,
amodiaquine was tested in such Hsp27 chaperone assay, revealing
that it significantly inhibits Hsp27’s chaperone activity and that it was
43 more potent than brivudine (see Appendix Table 15.1).
These findings are supported by Qiao et al.[231], who treated cul-
tured malignant melanoma cells with amodiaquine and found that it
sensitized them to starvation- and chemotherapeutic-induced death.
The authors argued that autophagy and lysosomal degredation play
an essential role in cancer, and since many anti-malarial drugs are
lysosomotropic, they set out to screen anti-malarial agents for their
anti-cancer behaviour.
CONCLUSIONS
Notwithstanding the strong evidence demonstrating amodiaquine
as a feasible Hsp27 inhibitor with a potent anti chemo resistance
effect, further studies are necessary to confirm such effect at a more
significant level. Moreover, previous knowledge in amodiaquine
side-effects should be considered and extensively evaluated before
considering the drug as a potential treatment for cancer patients.
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Nonetheless, taking a look from a more general perspective, this
case study demonstrated the potential of structure-based drug reposi-
tioning with interaction patterns, which was able to identified novel
repositioning candidates for the cancer target Hsp27. Candidates that
are structurally unrelated to the query drug brivudine (scaffold hop-
ping) also showed a desired inhibitory activity on the target protein
Hsp27 and the potential to suppress chemoresistance.
Chapter 8
Ibrutinib to Autoimmune Diseases
This chapter is based on the publication Structure-based drug
repositioning explains ibrutinib as VEGFR2 inhibitor[6] published
in 2020 in PLoS ONE. For detailed information on author
contributions see the chapter Publications and Contributions.
8.1 Autoimmune diseases
The immune system is a complex machinery designed to protect the
body against foreign substances, infectious agents and tumour cells.
The optimal function of the immune system requires a sequential and
regulated interaction between immune cells and cells products while
not responding to self molecules.
The body’s immunologic tolerance breakdown leads to an immune
response against self molecules, causing autoimmune disorders. In
most of cases, the causes triggering the immune response to self
molecules are unknown. However, previous studies suggest associa-
tions with environmental factors, genetic disorders, and certain types
of infectious diseases[261, 147, 173, 57, 284].
Figure 8.1: B cells play a key role in
the autoimmune responses via antibody-
dependent and antibody-independent
pathogenic functions. Secreted auto an-
tibodies specific to receptors or receptor
ligands can activate or inhibit receptor
functions. Moreover, they can bind to
basic structural molecules, interfere with
the synthesis of structural elements, and
facilitate the uptake of antigen. Indepen-
dent of antibody secretion B cells secrete
pro inflammatory cytokines, support the
formation of ectopic GCs, and serve as
antigen presenting cells. Both secreted
auto antibodies and BCR on B cells can
modulate the processing and presenta-
tion of antigen and thereby affect the
nature of presented T-cell determinants.
8.2 The role of B cells in autoimmune diseases
B lymphocytes or B cells are produced continuously throughout life,
and their development and differentiation occur in multiple phases,
requiring the coordinated action of a network of cytokines and crucial
transcription factors. Initially, B cells arise from the foetal liver and
then from hematopoietic stem cells that originate from the bone
marrow and further differentiate into multi-potent progenitor cells
and later into common lymphoid progenitor cells[48, 169].
Although it has become very clear that B cells play an important
role in both the humoral and cellular immune response, such a role
is not yet fully understood. B cells do not only produce antibodies,
but also play important regulatory roles unrelated of their antibody-
producing cells function[103] (Figure 8.1). This is highly relevant in
autoimmunity because autoreactive B cells can activate pathogenic
T cells, produce pro-inflammatory cytokines, and promote the for-
mation of tertiary lymphoid tissue in target organs. Misregulation
of the replication and/or activation of specific B cells subsets can
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lead to certain diseases such as forms of blood cancer (leukaemia,
myeloma and lymphoma) or autoimmune diseases (e.g. systemic
lupus erythematosus and rheumatoid arthritis)[79, 163].
8.3 Cancer and B cells
There are many common elements shared by the B cells based on
pathological conditions. Thus, some therapeutic approaches are also
shared between blood cancers and autoimmune diseases. For in-
stance, rituximab and bortezomib are two agents targeting B cells
with both anti-cancer and immunosuppressive indication. Rituximab
is a recombinant antibody, a CD20 inhibitor used for both rheumatoid
arthritis and B cells non-Hodgkin’s lymphoma [230]. Bortezomib is a
small cytotoxic molecule widely used to treat multiple myeloma and
mantle cell lymphoma. Recently, it was also tested for its autoimmune
potential in lupus [10]. However, both drugs kill B cells rather than
modulating their activity, causing B cells depletion and susceptibility
to other infections.
Other molecules currently used to contrast non-blood forms of
cancer are also gaining attention in the treatment of autoimmunity.
For example, the Vascular Endothelial Growth Factor (VEGFR2) in-
hibitors such as pazopanib, sunitinib, and sorafenib, are commonly
used to block the vessel growth at the cancer site[104] but are not
first-line therapeutic tools against B cells linked blood cancers. How-
ever, VEGFR2 inhibitors, whose first indication is kidney cancer, have
shown a positive effect against the autoimmune condition psoriasis
[99].
Another element that draws connections between B cells neoplasms
and autoimmunity is Bruton’s tyrosine kinase (BTK) inhibitor, ibru-
tinib, is an essential drug for treating leukaemias, lymphomas, and
chronic graft vs host disease. Despite its high specificity against BTK,
recent evidence also showed anti-angiogenic properties for ibrutinib
[228], suggesting a putative polypharmacological action. More studies
are needed to confirm the presence of different targets for ibrutinib
and clarify the link between VEGFR2 inhibitors and autoimmunity.
Figure 8.2: B cells targets selection
While the link from cancer to auto-immune diseases is almost
transparent, the direct link between drugs and targets causing such
effects is not fully understood. Moreover, most of the studied drugs
are nonetheless cytotoxic. In that sense, it seems interesting to com-
plement these drugs with novel small molecules, which inactivate B
cells and which have low toxicity.
8.4 Kinase targets for B cells inactivation
As a first step towards novel B cells modulators, suitable candidate
targets were identified (Figure 8.2). To this end, human kinases were
knocked out one by one and the knock out’s effect on cell survival
and inactivation was measured using the assay introduced in [277].
Nearly all human kinases (501) were present in the RNAi library. Cell
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survival is vital in the recognition of targets, as the main goal is the
modulation of B cells and not their depletion. After knock out, 400
proved to be non-lethal, and 22 inactivate B cells, i.e. the cell surface
markers CD70 and CD80, were down-regulated in expression (Table
8.1).
CD70 CD80
Protein PDB down down % cell
gene structures reg. reg. surv. C CIS AD
1 DAPK1 39 1.21 0.87 100 x x x
2 KDR 36 1.27 0.98 75.6 x x x
3 NEK2 24 1.37 0.79 100 x x
4 CSNK1D 17 0.97 1.28 100 x
5 EPHB4 14 1.95 0.74 100 x
6 CDC7 4 1.88 0.83 100 x
7 ILK 2 1.28 0.95 100 x
8 MST-4 2 2.63 0.73 100 x x
9 MAP2K2 2 1.32 0.67 82.9 x
10 MLK4 1 1.81 0.54 99.7 x
11 PXK 0 1.16 0.54 94.4 x
12 PTK7 0 1.07 0.71 86.2 x x
13 PAK3 0 2.83 0.98 86.8 x
14 BRSK1 0 1.76 0.83 100 x
15 FER 0 1.60 0.95 100 x
16 IRAK-3 0 1.70 1.02 93.3 x x
17 MAP3K10 0 1.65 0.93 87.0 x
18 PRKAG2 0 1.57 0.74 100 x
19 SCYL1 0 1.18 0.68 84.6 x
20 STK33 0 1.43 0.92 100 x
21 TXK 0 1.49 1.06 79.9
22 WNK2 0 1.47 0.86 100 x
Table 8.1: Candidate targets identified
in RNAi B-cell activation screen. The
top ten candidate targets are suitable
for structure-based drug repositioning
screening. For 10 candidate targets (be-
low the line) no structures were avail-
able and thus they could not be used
for the cirtual screening. Silencing
of all listed candidate targets leads to
strong the down regulation of CD70 and
CD80 expressions in the B cell Namalwa
cell line activated by the TLR9 agonist
ODN2006 without causing cell death (%
cell survival). Literature evidence links
nearly all candidate targets to cancer (C)
and some to autoimmune diseases (AD)
or cancer of the immune system (CIS).
Targets are sorted by availability of struc-
tural data.
As hinted in the previous section, drugs targeting B cells are used
in anti-cancer therapy and against autoimmune diseases. Therefore,
the disease relation of the 22 identified candidate targets was charac-
terized, focusing in particular on cancer (C), cancer of the immune
system (CIS), and autoimmunity (AU). A literature review revealed
that nearly all candidate targets are linked to cancer, four to cancer
of the immune system, and five to autoimmunity. Among those five
is the KDR gene that encodes for the VEGFR2 protein, which is a
key cancer target with approved drugs. Clinical trials are ongoing
exploring the inhibition of VEGFR2 as a treatment for psoriasis (pa-
zopanib, phase 1) and systemic scleroderma (nintedanib, phase 3).
The other four candidate targets with a link to autoimmunity are
DAPK1 (inflammatory bowel disease), MST4 (Grave’s disease), PXK
(systemic lupus erythematosus), and IRAK3 (rheumatoid arthritis).
8.5 Known binders of selected targets
The Open Targets Platform [35] covers over 20.000 targets with asso-
ciated information on drugs and clinical trials. Such a platform was
explored to assess the 22 kinases’ potential as drug targets. VEGFR2,
EPHB4, CDC7, MAP2K2, and MAP3K10 resulted in being very estab-
lished targets with many known binding approved drugs.
Furthermore, the 22 targets were explored in BindingDB[95], the
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most extensive collection of drug-target binding affinities. There, 22
drugs were identified as known and confirmed binders of one or
more of the 22 targets (Figure 8.3).
Figure 8.3: Known drugs bind unspecif-
ically. Known drugs binding 22 iden-
tified kinases with Ki, Kd, or IC50 <
50 µm. Drugs are colored by indication:
red for cancer, blue for cancer of im-
mune system, green for immunomod-
ulation, yellow for infection and gray
for other indications. Overall, the ma-
jority of drugs are anti-cancer and bind
unspecifically.
From the 22 targets, 14 of them have at least one inhibitor at a
micromolar range, and all but six drugs are polypharmacological
drugs hitting multiple targets. Fifteen FDA approved drugs inhibit
the same thirteen targets, which documents the polypharmacological
potential of these drugs. However, most of these drugs are chemically
closely related (see Appendix Figure 15.14). For instance, erlotinib,
vandetanib, and gefitinib belong to the same chemical class of quina-
zolines. To find a different compound with a better toxicity profile
and specificity, it is necessary to expand the scaffold space by running
a structure-based drug repositioning screening.
8.6 Structure-based screening and identification of hit
candidates
Virtual screening
A prerequisite for structure-based screening is the availability of struc-
tural templates. In this screening, 10 out of the 22 candidate targets
have structural data available. For these ten candidate targets, there
were a total of 141 complexes. They were compared to over 300,000
ligand-target complexes in the Protein Databank PDB and ranked by
p-value. Based on these data, the structural drug repositioning screen
predicted 157 approved drugs with a high fingerprint similarity score,
meaning they have a similar set of non-covalent interactions than
those in our 141 kinase structural templates, and therefore they are
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predicted to bind the candidate targets.
The 157 predictions are not equally distributed across the ten ki-
nases, but they correlate with the amount of structural data available
for the candidate target, e.g. for VEGFR2 with 36 structures, there are
53 predictions, whereas MLK4 with one structure has three predic-
tions only.
Kinase activity assay to validate the predictions
The predicted drugs (available on the market) were tested at 10 µm
and 1 µm on the panel of the 10 selected kinases (Table 8.2). A 50%
inhibition of the kinase activity was considered as strong and 30% to
50% inhibition as weak.
Compound Target % Enzime act. % Enzime act.
1 µm 10 µm
Hexachlorophene NEK2 84.92 00.02
Ibrutinib VEGFR2 19.52 01.50
Hexachlorophene VEGFR2 109.5 05.14
Suramin VEGFR2 72.67 06.48
Toremifene DAPK1 90.42 14.77
Ibrutinib DAPK1 95.59 23.72
Saquinavir DAPK1 87.09 27.81
Tolcapone CK1d 91.69 35.58
Ritonavir DAPK1 92.58 38.46
Etravirine VEGFR2 108.4 41.08
Thyroxine NEK2 90.16 48.11
Lopinavir DAPK1 90.43 49.89
Adenosine CK1d 87.72 50.22
Diethyldtilbestrol NEK2 97.92 50.73
Proflavine NEK2 104.1 51.57
Triiodothyronine NEK2 111.9 55.67
Adenosine NEK2 96.13 58.99
Triclosan NEK2 99.17 64.62
Triclosan CDC7 70.45 65.43
Propofol EPHB4 66.96 68.44
Prochlorperazine NEK2 70.10 68.73
Estradiol DAPK1 110.6 68.98
Amodiaquine CK1d 107.2 69.07
Niacinamide EPHB4 69.30 69.74
Table 8.2: Experimental kinase activ-
ity assay on predicted compounds. En-
zyme activity was measured at a com-
pound concentration of 1 µm and 10 µm.
Drugs able to lower the enzyme ac-
tivity to less than 50% (above dashed
line) at 10 µm were defined as strong in-
hibitors while drugs that lowered kinase
activity at 10 µm between 50% and 70%
(below dashed line) were classified as
weak inhibitors. Discarding the disinfec-
tant Hexachlorophene because of its low
medical interest, two compounds have
been highlighted for showing inhibition
at both 1 µm and 10µM, ibrutinib and
suramin .
Ibrutinib is the only compound that displays a strong kinase in-
hibition at 10 and 1 µM on VEGFR2. The activity of ibrutinib on
VEGFR2 is also confirmed by other experimental results in the LINCS
kinomescan database [140]. From the tested compounds, 9 show a
strong inhibition at 10 µM only and 10 additional compounds show a
weak inhibition at 10 µM (Table 8.2).
Whereas the majority of known drugs are used in cancer, promiscu-
ously targeting multiple targets, and with a high chemical similarity,
the novel identified drugs cover a more diverse chemical space and
have a less promiscuous tendency (for more details see Appendix
Figure 15.14 and 15.15).
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8.7 Ibrutinib as a micromolar VEGFR2 inhibitor
To further sustain the ibrutinib’s kinase inhibition, a dose-response
curve against VEGFR2 was determined with the KINOMEscan TM by
DisvcoverX, which is a competition binding assay that quantitatively
measures the ability of a compound to compete with an immobilized,
active-site directed ligand.
The assay is measured via quantitative PCR of the DNA tag linked
to the kinase. An 11-point 3-fold serial dilution of each test compound
was prepared in 100% DMSO at 100x of the final test concentration
and subsequently diluted to 1x in the assay (final DMSO concentration
= 1%).
Most Binding constants (Kds) were determined using a compound
top concentration of 30000 nm. If the initial Kd determined was lower
than 0.5 nm (the lowest concentration tested), the measurement was
repeated with a serial dilution starting at a lower full concentration. A
Kd value reported as 40000 nm indicates that the Kd was determined
to be higher than 30000 nm.
Kds were calculated with a standard dose-response curve using
the Hill equation:
Response = Background +
Signal − Background
1 + (KdHillSlope/DoseHillSlope)
with a Hill Slope set to -1.
Curves were fitted using a non-linear least square fit with the
Levenberg-Marquardt algorithm. The curve in Figure 8.4 plots the
drug concentration in nm against amount of bound kinase. The
experiment was carried out in duplicates showing that ibrutinib binds
to VEGFR2 at a Kd of 2 µm
Figure 8.4: Ibrutinib binds VEGFR2 at
micromolar concentrations. The assay
was performed in duplicates (light and
dark blue boxes) and the concentration
measured at nm.
8.8 Binding mode of Ibrutinib to VEGFR2
To better understand how ibrutinib achieve this high affinity against
VEGFR2, we checked its interaction profiles. The prediction of ibru-
tinib was based on ibrutinib’s interaction with CDPK1 (PDB 4ifg),
which is very similar to pazopanib’s interaction with VEGFR2 (PDB
3cjg). This is a remarkable similarity, as CDPK1 is from the para-
site Toxoplasma gondii and human VEGFR2. Despite two targets
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from completely different species, Figure 8.5 shows that both inter-
actions comprise a double hydrogen bond (1) and five hydrophobic
interactions in a similar position (2), (3), (4), (5), and (6).
This case study not only documents scaffold hopping from pa-
zopanib to ibrutinib, but also target hopping from parasitic CDPK1
to human VEGFR2. This jump in target space is large since it crosses
family and species boundaries.
Figure 8.5: Ibrutinib’s binding mode to
VEGFR2 based on its binding mode to
CDKP1. Both structures share similar
interaction patterns (1-6) although the
targets are dissimilar and from different
species.
8.9 Ibrutinib effectively inactivates B cells.
In a final validation step, ibrutinib’s ability to impede B cells’ ac-
tivation was tested. The best scenario is to obtain an inhibition of
activation without cell death and specific to B cells. For such purpose,
a therapeutic index, which relates toxicity to inactivation, was intro-
duced and calculated for both B- and T-cells. From this, the specificity
index as the ratio of B cells to T-cell therapeutic index was calculated
and compared to Tofacitinib, which can be seen as a control, due to
its approval for autoimmune indications.
As a main result, ibrutinib has a very high B cells therapeutic index
of over 40000, confirming ibrutinib’s ability to inactivate B cells at low
toxicity. A selectivity index of over 5000 also means that ibrutinib
interferes only a little with T-cells.
8.10 Ibrutinib as a treatment for autoimmune diseases
Ibrutinib is an approved drug for treating B cell cancers like mantle
cell lymphoma, chronic lymphocytic leukaemia, and Waldenstrom’s
macroglobulinemia. It is also known to permanently bind to the
protein Bruton’s tyrosine kinase (BTK). In this work, ibrutinib was
successfully predicted as a VEGFR2 inhibitor and later positively
validated as a potent B cells inactivator.
Figure 8.6: Chemical structure of ibruti-
nib.
However, a clear connection between both findings can not be made.
Despite the RNAi screen identified VEGFR2 as a novel target driving
B cells inactivation, many other possible factors could influence that
effect. Even if a drug and a target can be linked to a disease, it
still does not necessarily mean that the drug acts through the target.
For example, the RNAi screen suggests that silencing of VEGFR2
leads to B cells inactivation; the inhibition of VEGFR2 with ibrutinib
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confirmed this effect, whereas a further VEGRF2 inhibition study
with the compound suramin did not.
Generally, besides a methodological difference in silencing and in-
hibition, ibrutinib may have a more favourable polypharmacological
profile for B cells inactivation than other candidates. However, as
for many other drugs on the market, Ibtuinib’s intake comes with
related side effects widely reported over the years. The most relevant
one is that the chronic treatment with ibrutinib could impact the b
cell development and activation due to its high and specific affinity
for BTK. However, a study from 2014[24] modelled the pharmaco-
logical impact of BTK inhibition in the immune response of patients
chronically treated with BTK inhibitors such as ibrutinib. The study
successfully revealed that BTK inhibition does not shut down BCR
signalling entirely and preserves an efficient humoral response in
patients.
CONCLUSIONS
Overall, further studies are necessary to confirm a clear connection
between VEGFR2 inhibition and B cells inactivation. Nonetheless,
both finding were enough to prove the efficacy of the presented drug
repositioning approach as it comes to this work.
Chapter 9
Repositioning for Chagas Disease
This chapter is based on the publication Repositioned Drugs for
Chagas Disease Unveiled via Structure-Based Drug Repositioning[3]
published in 2020 in the International Journal of Molecular
Science. For detailed information on author contributions see
the chapter Publications and Contributions.
9.1 A life-threatening disease in South America
Chagas disease, also known as American trypanosomiasis, is a life-
threatening infection caused by the protozoan parasite Trypanosoma
cruzi[40](Figure 9.1). According to the World Health Organization
(WHO), about 7,000,000 people worldwide are afflicted with Chagas
disease. Most cases of Chagas disease occur in South America, mostly
in rural areas, with the infection being endemic in 21 countries [290].
The parasite is often transmitted via Triatomine insects. The infection
occurs when the insect bites and subsequently defecates in the bite,
allowing T. cruzi to enter the bloodstream. Moreover, T. cruzi can
be congenitally transmitted from a pregnant mother to her baby via
blood transfusion, organ transplantation, or even due to laboratory
accidents [40].
Figure 9.1: Trypanosoma cruzi mor-
phological forms. (A) The replicating
epimastigote form. (B) Trypomastig-
ote in a peripheral blood smear. (C)
Nest of amastigotes within a cardiac my-
ocyte in a patient with chronic Chagas
disease.[27]
The acute phase of the disease occurs during the first few months
after infection. T. cruzi propagates in the bloodstream, which produces
mild symptoms, such as a skin lesion at the infection site, headache,
fever, and muscle ache [55]. During the chronic phase of infection, the
parasite lodges itself mainly in digestive and cardiac tissues. During
this phase, about 30% of patients suffer from cardiac issues, and 10%
suffer from digestive or neurological issues, which can be fatal [290].
Fatality is frequently caused by Chronic Chagas Cardiomyopathy,
which weakens the heart muscles due to the parasite invasion.
Currently, there are only two drugs on the market for Chagas
disease: Benznidazole works via inducing reductive stress, whereas
Nifurtimox causes the generation of free radicals. Both drugs cause
the parasite to be vanquished within 60–90 days. However, they are
only effective in the predominantly asymptotic acute phase of the
disease [26]. Once the disease reaches the chronic stage, there is not
much that can be done. Furthermore, both drugs produce severe
side effects in over 40% of patients and are contraindicated for use in
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pregnancy, reducing their applicability. Nifurtimox has severe side
effects related to the nervous system, including depression, anorexia,
neuropathy, insomnia, headache, and vomiting. On the other hand,
Benznidazole has severe toxicities related to skin hypersensitivities,
such as dermatitis and severe symptoms like the depression of bone
marrow, thrombocytopenic purpura, and agranulocytosis [36].
Due to the unspecific mechanism of action, the severe side effects,
and the limited efficacy of the current chemotherapeutic options, there
is a need for improved drugs with targeted action and less severe side
effects.
9.2 Previous repositioning attempts for Chagas disease
Several studies have reported repositioning candidates for Chagas
with promising trypanocidal effects. Examples are Amiodarone,
which is actually used as a Class III anti-arrhythmic agent [212];
Trimetrexate, an antifolate drug used against Pneumocystis carinii
infection in patients with Acquired Immune Deficiency Syndrome
(AIDS) [251]; and, most relevant, Posaconazole and Ravuconazole,
which entered phase II clinical trials. Unfortunately, the latter showed
poor results compared to Benznidazole [196, 273]. Still, combination
therapy could lead to better results[229].
Nowadays, with the exponential growth of structural data, it is pos-
sible to exploit drug repositioning at a structural level and to screen
vast amounts of drug-target interactions to predict polypharmaco-
logical potential and repositioning opportunities [5]. For instance,
Haupt et al. explored shared binding sites between Chagas targets
and other proteins to identify novel drugs for the treatment of Chagas
disease. Using their approach known as Target Hopping, they pre-
dicted that the antiviral Foscarnet would inhibit the target Farnesyl
Pyrophosphate Synthase (FPPS) in T. cruzi [109]. In a more recent
study, a virtual screening approach combining classical docking with
protein-ligand interaction profiling identified drug repositioning can-
didates against T. cruzi infection. Nilotinib, Glipizide, Glyburide, and
Gliquidone were predicted to bind to the Chagas target Dihydrofo-
late Reductase-Thymidylate Synthase (TcDHFR-TS) with high affinity.
They were tested on T. cruzi epimastigotes, where they showed a
growth inhibitory activity in the micromolar range, making them
potential lead compounds in the development of new treatments for
Chagas disease [129].
9.3 Identification of relevant Chagas targets and their
structural data
In the case of Chagas disease, a "good" target is a protein found
in T. cruzi and not in humans and is essential to parasite survival,
or, alternatively, a T. cruzi protein that is different enough from its
human homolog to reduce off-target effects. It is important to consider
that the current chemotherapeutic options for Chagas—nifurtimox
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and benznidazole—do not act through a primary target but kill the
parasite by generating free radicals and inducing reductive stress,
respectively [26]. To find a drug with a more focused mechanism of
action, a list of drugable targets first had to be established.
As the starting point of this work, a set of 20 Chagas targets was
assessed. Structural data was available for 16 targets (see Appendix
Table 15.2). The targets were evaluated based on their dependability
as a Chagas target. The seven targets listed above the bold line have
been thoroughly researched, and there is high confidence that their
modulation will produce the desired effect in T. cruzi, while the nine
targets below the line have at least been researched as T. cruzi targets.
Most of the Chagas targets have at least one structure with a biolog-
ically relevant ligand available in the PDB (see Appendix Table 15.2),
with the exception of cyclic nucleotide specific phosphodiesterase, Di-
hydrolipyl dehydrogenase, Ribose-5-phosphate dehydrogenase, and
Triosephosphate Isomerase. Interestingly, only five structures of dihy-
droorate contained relevant ligands, although there were 58 structures
available. The other complex structures involved cofactors, molecules
from the buffer solution, or molecular fragments.
9.4 Structure-based screening and identification of hit
candidates
We analyzed drug interaction pattern similarities between binding
sites of the query complexes and over 130,000 protein structures.
The identified targets comprised 22 binding sites in complex with
several relevant ligands (see Appendix Table 15.2). Each binding site
accounted for an independent screening. The screening output was a
list of hit complexes with high interaction pattern similarity ranked
by p-value and aggregated by ligand. In total, there were 523 hits
across the 22 screenings, ranging from 0 to 97 hits per screening with
a mean of 23. There was a modest positive correlation between the
number of query structures and the number of hits, as indicated by
a Pearson correlation1 coefficient of 0.6. Several compounds yielded 1 In statistics, the Pearson correlation co-
efficient is a measure of linear correla-
tion between two sets of data.
a hit in multiple screenings, while others were unique to only one
screening. Most frequent hitters were not relevant to Chagas diseases,
such as glutathione, citric acid, and different amino acids. On the
other hand, some screenings produced hit numbers well above the
average, such as the screenings of squalene synthase with 96 hits and
lanosterol demethylase with 69 hits.
To get a first impression of the significance of the screening predic-
tions, we checked the Binding DB [95] for binding evidence. Affinity
data were available for only three drug-target pairs. Of these three,
the binding of Risedronate to the target FPPS was also predicted by
our screening. In contrast, there was binding evidence for Etravirine
and the target Cruzipain as well as Chlorpromazine and Trypanthione
reductase, but these drug target pairs were not a hit in the screenings.
Following several filtering steps, the primary list of 512 compounds
was narrowed down to 38 high-priority predictions (see Appendix
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Table 15.3). These compounds were selected as our top repositioning
candidates for Chagas disease and were further explored under three
main criteria:
• Novelty of Chagas activity
• Interaction pattern similarity between query and hit
• Availability at a low price
Based on the aforesaid features, eight compounds were selected
for further experimental validation.
9.5 Inhibitory effects on T. cruzi
The trypanocidal activity of the eight candidates was assessed in vitro
for the epimastigote stage and ex vivo for the trypomastigote stage
using the T. cruzi strains Ninoa and INC-5.
Table 9.1: Inhibition of proliferation of
Ninoa and INC-5 strains of T. cruzi tr-
pomastigotes, cytotoxicity and selectiv-
ity index of tested FDA-approved drugs
compared to the known treatments with
nifurtimox and benznidazole (positive
controls).
T.cruzi blood trypomastigote Cytotoxicity Selectivity Index
Drug IC50 (µM) CC50 (µM) CC50/IC50
Ninoa INC-5 Ninoa INC-5
Ciprofloxacin 25.7 ± 0.04 21.3 ± 0.09 7.7 × 1023 ± 0.31 3.0 × 1022 3.6 × 1022
Folic Acid 28.1 ± 0.01 21.5 ± 0.03 9.1 × 1017 ± 0.31 3.2 × 1016 4.2 × 1016
Naproxen 58.5 ± 0.07 38.3 ± 0.06 2.5 × 1018 ± 0.16 4.3 × 1016 6.5 × 1016
Celecoxib > 100 ± 0.06 > 100 ± 0.15 1.2 × 1016 ± 0.19 < 1.2 × 1014 < 1.2 × 1014
Glutathione > 100 ± 0.08 > 100 ± 0.05 1.7 × 1018 ± 0.07 < 1.7 × 1014 < 1.7 × 1014
Leucovirin > 100 ± 0.18 > 100 ± 0.05 7.9 × 1023 ± 0.23 < 7.9 × 1021 < 7.9 × 1021
Pentoxyfiline > 100 ± 0.25 > 100 ± 0.12 7.9 × 1017 ± 0.05 < 7.9 × 1015 < 7.9 × 1015
Theophyline > 100 ± 0.18 > 100 ± 0.15 8.3 × 1035 ± 0.14 < 8.3 × 1033 < 8.3 × 1033
Nifurtimox 167.1 ± 0.03 115.2 ± 0.17 164.2 ± 0.25 0.10 1.42
Benznidazole 156.0 ± 0.11 130.6 ± 0.08 133.9 ± 0.06 0.85 1.02
Of the compounds tested, ciprofloxacin, folic acid, and naproxen
showed the greatest inhibitory activity against T. cruzi trypomastigotes
(Table 9.1), with IC50 values of 25.7 µM, 28.1 µM, and 58.5 µM for the
Ninoa strain, and 21.3 µM, 21.5 µM, and 38.3 µM for the INC-5 strain,
respectively. Moreover, the active drugs demonstrated relatively low
cytotoxicity with CC50 (the concentration of the drug that causes the
death of 50% of viable cells in the host) values of 7.7 × 1023 µM for
ciprofloxacin, 2.5 × 1018 µM for naproxen, and 9.1 × 1017 µM for
folic acid. Based on these results, the selectivity indices (CC50/IC50)
were 2.9 × 1022, 4.2 × 1016, and 3.2 × 1016, respectively. While
ciprofloxacin, folic acid, and naproxen had IC50 values in the same
range as the standard Chagas disease medications nifurtimox and
benznidazole, they exhibited lower cytotoxicity and higher selectivity
in comparison.
However, none of the drug repositioning candidates showed try-
panocidal activity in the lower micromolar range against T. cruzi
epimastigotes (see Appendix Table 15.4). This behaviour can be ex-
plained by the morphological differences between the two stages of T.
cruzi and has already been observed in previous studies[39, 139, 137]
During the life-cycle of T. cruzi, the parasite experiences multiple
changes in its morphology (Figure 9.1), metabolism, and gene ex-
pression, going from its epimastigote replicative stage in the insect
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to its pathogenic metacyclic trypomastigote form[97]. After penetra-
tion into the host cell, T. cruzi differentiates into the amastigote form
and initiates the intracellular binary division. Finally, the amastig-
otes transform into trypomastigotes, which break open the host cell
and enter the bloodstream. The trypomastigotes spread through the
bloodstream to penetrate cells of different organs, where the cycle
process is repeated[271, 182].
Over time, it has been assumed that replicating epimastigotes
present in the insect gut is not infectious to the mammalian host
since only the epimastigote stage is susceptible to the innate immune
system of mammals and can be killed by the complement system[210].
Nonetheless, recent studies have remarked the relevance of treatments
that also kill T. cruzi epimastigotes[271, 237, 142].
9.6 In vivo Trypanocidal Activity of the Drug Reposition-
ing Candidates
Since ciprofloxacin, naproxen, and folic acid showed a growth in-
hibitory activity in the micromolar range against T. cruzi, they were
tested for parasitemia inhibition in vivo. Mice were infected with
blood trypomastigotes, and at day 13 post-infection, a single dose
(at 100 mg/kg body weight) of the drugs ciprofloxacin, nifurtimox,
or folic acid was orally administered. Parasitemia was monitored at
2, 4, 6, and 8 h after administration (Figure 9.2).
Figure 9.2: Parasitemia inhibition (%)
of T. cruzi NINOA (A) and INC-5 (B)
strains by the tested FDA-approved
drugs during 8 h after administration.
The plot shows parasitemia inhibition
by the drugs ciprofloxacin (yellow line),
naproxen (blue line), and folic acid (red
line) at 2, 4, 6, and 8 h after admin-
istration. Drugs at a single dose of
100 mg/kg body weight were orally ad-
ministered at day 13 post-infection when
the infected mice reached an average
parasitemia of 5 × 106 parasitemia/mL.
Infected mice treated with nifurtimox
(green line) and infected non-treated
mice (gray line) were used as positive
and negative controls, respectively.
All drugs tested demonstrated inhibition of parasitemia. Eight
hours after administration to the mice infected with the Ninoa strain
of T. cruzi, folic acid, ciprofloxacin, and naproxen showed parasitemia
inhibition of 57.2%, 66.7%, and 85.8%, respectively, while the estab-
lished Chagas treatment nifurtimox exhibited parasitemia inhibition
of 77.8%. Interestingly, the trypanocidal activity of naproxen was
significantly higher than that shown by nifurtimox (p ≤ 0.05). In mice
infected with the T. cruzi strain INC-5, folic acid, ciprofloxacin, and
naproxen showed parasitemia inhibition of 66.7%, 43.8%, and 42.9%,
respectively, eight hours after administration. In comparison, nifur-
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timox exhibited inhibition of 72.3%. It is worth mentioning that folic
acid showed significantly higher activity than nifurtimox against INC-
5 strain at 4 and 6 h after drug administration (p ≤ 0.05), although it
was maintained at 8h, it was lower than the reference drug. Overall,
the drug repositioning candidates achieved parasitemia inhibition of
T. cruzi trypomastigotes in vivo.
9.7 Ciprofloxacin, Naproxen and folic acid as potential
Chagas treatments
Ciprofloxacin
Figure 9.3: Chemical structure of the
bacterial drug ciprofloxacin.
Ciprofloxacin is a broad-spectrum antibiotic of the semisynthetic
fluoroquinolone class (Figure 9.3). Fluoroquinolones are well known
to inhibit the ligase activity of bacterial type II topoisomerases, thereby
blocking bacterial growth. However, several studies have also reported
the relevance of fluoroquinolones as parasitic inhibitors and suggested
inhibition of DNA topoisomerases as the mechanism of action [207,
37, 161, 114].
In the virtual screening, ciprofloxacin was predicted to bind trans-
sialidase, an enzyme that catalyses the transfer of sialic acid from host
glycoconjugates to acceptor molecules on the parasite surface, and
therefore, it is fundamental for T. cruzi survival [205]. The prediction
suggests for the first time that the anti-parasitic effect of quinolones
is rather caused by trans-sialidase inhibition.
Nenortas et al. reported ciprofloxacin activity against Trypanosoma
brucei in vitro with an EC50 of 52 µm [207]. Now it was shown that
ciprofloxacin is also a potent inhibitor of T. cruzi trypomastigotes with
an IC50 of 21 µm (Table 9.1) and blocks T. cruzi growth in vivo.
Generally, ciprofloxacin is considered a relatively safe, well-tolerated,
and widely used drug in clinical practice. As for most other drugs on
the market, several side effects have been reported to cause gastroin-
testinal, central nervous system, skin, cardiovascular, lymphatic, or
nutritional issues. However, most of them are reversible and occur
at a mild or moderate intensity (in about 94% of cases) [245]. The
widespread use of ciprofloxacin has caused a remarkable increase in
bacterial resistance to the drug, making it a less effective antibiotic
[51]. For this reason, it’s repositioning to a parasitic indication would
be sustainable and profitable.
Naproxen
Figure 9.4: Chemical structure of the
NSAID-like drug naproxen.
Naproxen is a bicyclic propionic acid derivative that has analgesic,
anti-inflammatory, and antipyretic effects and is classified as a non-
steroidal anti-inflammatory drug (NSAID)(Figure 9.4).
Like most NSAIDs, naproxen acts via the inhibition of Cyclooxy-
genase (COX) isoforms I and II, which are involved in the synthesis
of prostaglandins, prostacyclin, and thromboxane from arachidonic
acid[16, 294].
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Naproxen was proveed as a potent inhibitor of T. cruzi trypomastig-
ote (Table 9.1). Furthermore, the virtual screening predicted naproxen
to bind the T. cruzi farnesyl pyrophosphate synthase (TcFPPS). Farne-
sylation is a post-translational modification required for membrane
localization of many proteins, such as small GTPases. Therefore, the
inhibition on TcFPPS disrupts various cellular functions [118]. This
makes TcFPPS a well-known Chagas target and could explain the
trypanocidal activity of naproxen.
Although naproxen effectively inhibits T. cruzi proliferation, several
aspects should be considered before its repositioning. The safety of
NSAIDs with regards to cardiovascular events has been evaluated in
a large number of retrospective and prospective clinical studies, all of
which have reported cardiotoxicity[278]. Moreover, Cossentini et al.
demonstrated that the gastric mucosal damage caused by the intake
of Aspirin, a commonly used NSAID, facilitates T. cruzi infection by
the oral route[53]. While this has not been tested particularly for
naproxen, the side effects in the gastrointestinal tract and kidneys
are a well-known disadvantage of NSAIDs[278]. Nonetheless, in a
recent study, Santo et al. tested Aspirin as a combination therapy to
benznidazole during the acute phase of Chagas and discovered that
such treatment prevents cardiovascular dysfunction and decreases
typical cardiac lesions in the chronic phase[243].
Folic acid
Folic acid is the manufactured version of folate. As the human body
cannot produce folate on its own, folic acid is used as a dietary
supplement and food fortification (Figure 9.5).
Figure 9.5: Chemical structure of folic
acid.
Folic acid was predicted to bind the Dihydrofolate Reductase (TcD-
HFR) Chagas target. The repositioning has been proposed between
the same protein among different species (from human to T. cruzi
DHFR), meaning that the targets are expected to have similar bind-
ing sites and thus form similar non-covalent interactions with their
ligands. Although the repositioning itself is not very surprising, the
trypanocidal activity of folic acid was demonstrated in this study for
the first time. However, there is no clear explanation for the trypanoci-
dal activity of folic acid since it is a known substrate of the predicted
target.
Folate plays an essential role in the human body as a signifi-
cant coenzyme in one-carbon metabolism, including DNA synthe-
sis (dTMP) and methylation [46]. Moreover, folate deficiency has
been associated with a risk for several diseases, involving, among
others [312], cancer[308, 96, 147], Alzheimer[59], hypertension[302],
and some pregnancy and birth complications, such as megaloblastic
anemia[113] or neural tube defects (NTDs)[150, 193].
Moreover, it has been shown that cell-mediated immunity is highly
affected by folate deficiency [65]. In fact, the blastogenic response
of T lymphocytes to certain mitogens is decreased in folate-deficient
humans and animals, and the thymus is preferentially altered. In
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light of this, it might be that the trypanocidal effect of Folic acid is
not due to Chagas target inhibition but rather to a beneficial effect of
the compound as a supplementary diet. In that sense, the intake of
Folic acid might help to improve the immune system of the infected
host, indirectly affecting the proliferation of T. cruzi. However, further
studies are necessary to test this hypothesis.
9.8 Binding mode of the predicted drugs
Ciprofloxacin, naproxen, and folic acid were identified as drug reposi-
tioning candidates for Chagas disease based on the Tanimoto similar-
ity score of the interaction fingerprints between the query and the hit
complexes of the screening. In other terms, the screening identified a
high non-covalent interaction pattern similarity between the drugs in
complex with their original targets and the therapeutic Chagas targets
in complex with their original binders.
Ciprofloxacin’s binding mode
The binding mode of ciprofloxacin to porin F is similar to the one of
acetylneuraminic acid to trans-sialidase (sialic acid site). Figure 9.6.
A shows the query complex of the Chagas target trans-sialidase and
its original binder acetylneuraminic acid (PDB ID: 1ms0).
Among the interactions that define the binding mode of the target
template, there is a clear set of interactions (a meta-pattern) that is also
present in the hit complex of ciprofloxacin and its original target outer
membrane porin F (PDB ID: 4kra). The meta-pattern includes a pair
of salt bridges (1), three hydrogen bonds (2), and one hydrophobic
interaction within the same distance and angle.
Naproxen’s binding mode
The same applies to the repositioning of naproxen. As shown in
Figure 9.6.B, there is a common interaction pattern between FPPS
(homoallylic site) with its binder zoledronate (PDB ID: 3iba) and
naproxen with its original target serum albumin (PDB ID: 4ot2). The
meta-pattern includes a pair of salt bridges (1), a pair of water bridges
(2), one hydrogen bond, and a couple of hydrophobic interactions (4),
in both complexes within the same distance and angle thresholds.
Folic acid’s binding mode
In the case of folic acid, there is an explicit interaction pattern that is
present in both the complex of TcDHFR with its binder methotrexate
(PDB ID: 3cl9) and in the complex of folic acid with human DHFR
(PDB ID: 1drf) (Figure 9.6.C). The meta-pattern includes two salt
bridges (1) and (2), several hydrogen bonds (3), a couple of hydropho-
bic interactions (4) in both complexes within the same distance and
angle thresholds. However, it should be noted that the protein targets
repositioning for chagas disease 85
are homologous, and the residues that define the binding pocket are
very similar.
Figure 9.6: Non-covalent interaction
patterns accounting for the reposition-
ing predictions of ciprofloxacin (A),
naproxen (B), and folic acid (C). The
repositioning is based on the similarity
of the non-covalent interactions (a meta-
pattern) defining the binding mode of
inhibitors (orange) to their targets (blue)
between target template (left) and drug
template (right) complexes.
CONCLUSIONS
This study has demonstrated the potential of structure-based drug
repositioning to produce a high rate of true positive hits, which trans-
lates into reduced cost and time compared to a conventional drug
discovery process. Moreover, the screening predicted drugs with
no prior evidence of an association with Chagas disease and novel
chemical scaffolds, indicating the potential of the approach to reveal
promising drug repositioning candidates. As over the counter drugs,
they are perfect for further validation in models and humans and
could eventually lead to more efficient and better-tolerated treatment
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of Chagas disease. Overall, the approach represents a promising op-
tion for all rare and neglected diseases for which no reliable treatment
has yet been found.
Part IV





Limitations of the approach
This chapter is partially based on the publication Structure-
based drug repositioning: Potential and limits[5] published in 2020
in Seminars in Cancer Biology. For detailed information on
author contributions see the chapter Publications and Contri-
butions.
10.1 Limitations of structure-based repositioning
There are many reasons why a drug could be a cure for two diseases.
The diseases might be closely related, the drug’s target may play a
role in two different diseases, or the drug has two targets, each linked
to a different disease[5]. Consequently, there is an inherent necessity
of available public data to construct the biological links underlying
the repositioning stories. However, as with many other computational
techniques, data availability is one of the main limitations of the ap-
proach. In particular, there is an important need for more data along
two major axes: identifying therapeutic targets with their concrete
link to the different indications and the structural characterization of
compounds and targets.
Identification of therapeutically relevant targets
The ultimate objective of biomedical research is to connect human
diseases with the genes that underlie them and drugs that treat them.
Rapid advances in genomics, protein structures, proteomics, and
molecular mechanisms of diseases enable the search for new targets
and facilitate the study of existing targets for finding clues to new
target identification and probing the molecular mechanisms of drug
actions[310, 73]. Such efforts have resulted in a number of proteins
and nucleic acids accurately labelled as therapeutic targets.
Drug repositioning relies on the biological network defining the
relationships between the biological entities. Therefore, a strong link
between targets and therapeutic indications is a fundamental part of
the process.
There are many platforms available to infer new connections be-
tween molecular entities and therapeutic indications. The Therapeutic
Target Database (TTD)[44], provides information about the known
therapeutic protein and nucleic acid targets described in the litera-
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ture, the targeted disease conditions, the pathway information and
the corresponding drugs/ligands directed at each of these targets.
Open targets, as a more recently introduced platform, provides the
integration and visualization of collected association evidence of
known/potential drug targets with diseases[156]. In a less direct
way, some platforms offer proposed linking between entities via the
integration of several resources, such as High-throughput screening,
pathways, biological actions, and gene expresions[293, 134, 128, 167],
among others.
However, despite they contain multiple links between targets and
indications based on literature and experimental evidence, many
times, those links are only correlations or associations instead of
causal evidence with a well-understood mode of action. Thus, there is
a need for data and databases, which curate detailed mode-of-action
and causal models disease implication of a target.
The availability of structural data
The revolution in sequencing technologies has resulted in an enor-
mous growing number of gene sequences over the last decade. At
the same time, the number of experimentally determined protein
structures has increasingly diminished behind due to the inherently
slower, more resource-intensive, and less-predictable nature of this
kind of experiments[143].
A protein’s shape is closely linked with its function, and the ability
to predict this structure unlocks a greater understanding of what it
does and how it works. Many of the world’s greatest challenges, like
developing treatments for diseases or finding enzymes that break
down industrial waste, are fundamentally tied to proteins and the
role they play.
The Protein Data Bank (PDB) is universally regarded as a core
data resource essential for understanding the functional roles that
macromolecules play in biology and medicine. The PDB was es-
tablished in 1971 as the first open-access molecular data resource
in biology. More than 47 years later, the PDB continues to serve
as the single global repository for atomic-level, 3D structure data,
with experimentally-determined structures of proteins, DNA, and
RNA, and their complexes with metal ions, drugs, and other small
molecules freely available without restrictions on use[298].
Figure 10.1: PDB growth over the years.
The dark blue bar represents the struc-
tures released annually since 1976 and
the light blue bar, the total aggregated
structures.
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Currently, with more than 170,000 structures (Figure 10.1), PDB is
estimated to cover the vast majority of the known drug targets (about
92%)[215], with more than 52,000 different protein sequences, and
most of the structures (more than 60%) in complex with biologically
relevant ligands[303].
Notwithstanding the great amount of structural data available
and despite many years of continuous effort, not all therapeuti-
cally relevant protein families are equally represented in structural
databases. In fact, according to Khafizov et al., by 2013 a 60% of
known protein families in the Pfam database still lacked structural
characterization[143]. For instance, with over 20,000 entries, enzymes
are the structurally most populated family by far, while only a handful
has been resolved for GPCRs.
10.2 Novel techniques towards the expansion of struc-
tural data
With a calculated growth rate of 170% (last ten years), it is predicted
that in ten years ahead, the number of available structures in PDB
could double the current one, or even triple if one considers the fast
progress in novel techniques to obtain high-resolution structures[5].
The most commonly used technique is the X-ray diffraction. Indeed,
the structure collection has been almost exclusively borne by X-ray
crystallography, as highlighted by the fact that more than 88% of all
entries in the Protein Data Bank are crystal structures (Figure 10.2).
Despite the massive success of crystallography, many supra-molecular
edifices, self-assembling systems, membrane proteins, and proteins
with extended dynamic domains are difficult to crystallize, or the
crystals simply do not diffract to high resolution[91]. Accordingly,
huge efforts are being put into practice to overcome these limitations,
mainly exploring novel techniques as alternatives to X-ray crystallog-
raphy.
Figure 10.2: PDB structures percentage
according to the experimental method
used for the structure characterization,
i.e. x-ray diffraction, NMR, Cryo-em,
and others.
Nuclear Magnetic Resonance (NMR) spectroscopy
NMR spectroscopy is a technique to observe local magnetic fields
around atomic nuclei. The sample is placed in a magnetic field, and
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the NMR signal is produced by excitation of the nuclei sample with
radio waves into nuclear magnetic resonance, which is detected with
sensitive radio receivers[2]. In recent years, NMR has become an
essential tool in the field of intrinsically disordered proteins that
are unlikely to crystallize[188, 9]. Furthermore, solid-state NMR
is specifically efficient when determining the conformations of pro-
teins, nucleic acids and other biomacromolecules in solutions or
biomembranes[187]. The major limitation of NMR remains the size
of the proteins, although proteins up to 1 MDa have been partially
studied[188]. In terms of the number of proteins studied (Figure
10.2), NMR spectroscopy cannot compete with other high-throughput
methods in the proteomics area but provides an alternate view on
many systems of biological interest.
Cryo-Electron Microscopy (Cryo-EM)
The recently introduced Cryo-EM technique is rapidly catching up
with the conventional X-ray crystallization, as it can now resolve
features at the atomic level of up to 1.2Å across, becoming more
sensitive and widely available for solving protein structures [34].
Structures of large macromolecules can now be obtained at near-
atomic resolution by averaging thousands of electron microscope
images recorded before radiation damage accumulates[159].
Figure 10.3: The large subunit of the
yeast mitochondrial ribosome at 3.2 Åre-
ported by Amunts et al.[13]
To the date, PDB holds about 4% of structures obtained with this
technique (Figure 10.2). For instance, Amunts et al.[13] reported the
structure of the large subunit of the mitochondrial ribosome at 3.2
Å resolution by cryo-EM (Figure 10.3). Only a few years ago, this
achievement would have been considered almost impossible, but now
heralds the beginning of a new era in molecular biology.
Cryo-EM and NMR hybrid approach
Cryo-EM and NMR spectroscopy both provide structural information,
but currently, cryo-EM does not routinely give access to atomic-level
structural data, and, generally, NMR structure determination is re-
stricted to small (<30 kDa) proteins. Gauto et al. introduced an
integrated structure determination approach that simultaneously uses
NMR and EM data to overcome the limits of each of these methods[91].
The approach enables structure determination of the 468kDa large
dodecameric aminopeptidase TET2 to a precision and accuracy below
1Å by combining secondary-structure information obtained from near-
complete magic-angle-spinning NMR assignments of the 39 kDa-large
subunits, distance restraints from backbone amides and ILV methyl
groups, and a 4.1Å resolution EM map[91]. The resulting structure
exceeded current NMR and EM structure determination standards in
terms of molecular weight and precision.
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Homology models
In the absence of an experimentally determined structure, compar-
ative or homology modelling can sometimes provide a useful 3D
model for a protein that is related to at least one known protein
structure[226, 80, 189]. Comparative modelling predicts the 3D struc-
ture of a given protein sequence (target) based primarily on its align-
ment to one or more proteins of known structure (templates). The pre-
diction process consists of fold assignment, target-template alignment,
model building, and model evaluation[80]. The number of protein
sequences that can be modeled and the accuracy of the predictions
is increasing steadily because of the growth in the number of known
protein structures and because of the improvements in the modelling
software[189]. Different databases of high-quality 3D protein models
such as SWISS-MODEL Repository (SMR)[146] are already available
to support structure-based drug repositioning pipelines. In fact, the
repositioning of BVDU from herpes to cancer built on a model of the
heat shock protein Hsp27[112]. Similarly, Kinnings et al. used a rat
model of the human target COMT[149].
Artificial intelligence-based approaches
In recent years, modelling techniques and other methods for structure-
prediction have been gaining benefit from novel breakthroughs in
artificial intelligence (AI)[250, 186, 287]. In a major scientific advance,
the latest version of the AI based system AlphaFold[250] has been
recognised as a solution to this grand challenge by the organisers
of the biennial Critical Assessment of protein Structure Prediction
(CASP)1. According to the 14th CASP assessment results, the latest Al- 1 CASP is a community-worldwide ex-
periment for protein structure predic-
tion taking place every two years since
1994, which provides research groups
with an opportunity to objectively test
their structure prediction methods.
phaFold system achieves a median score of 92.4 GDT2 overall across
2 GDT is the measure of similarity
between two protein structures with
known amino acid correspondences.
all targets. This means that its predictions have an average error
(RMSD3) of approximately 1.6 Angstroms, which is comparable to
3 Root-mean-square deviation of atomic
positions
the width of an atom (or 0.1 of a nanometer). Even for the very most
complex protein targets, those in the most challenging free-modelling
category, AlphaFold achieved a median score of 87.0 GDT (details in
CASP14). This breakthrough demonstrates the impact AI can have
on scientific discovery and its potential to dramatically accelerate
progress in some of the most fundamental fields that explain and
shape our world.
CONCLUSIONS
The novel technologies have made protein crystallisation more cost-
effective and robust. Still, many cases require both high-level expertise
and many years of effort[311]. Thus, it will take some time before the
achievements in structure prediction finally expose their full potential.
Consequently, it is necessary to find momentary solutions to the data




The Concept of Building Blocks
The pharmaceutical industry has seen a major change in the way
in which lead molecules are identified. An effective combination of
automation, high throughput screening, and combinatorial chemistry
now allows the screening of libraries of vast numbers of compounds
against prospective biological targets. Moreover, researchers are de-
vising new ways to identify chemical leads for specific protein targets
by using as starting point chemical structures that reflect the physical
properties of successful oral drug molecules. Such chemical structures
are commonly known as fragments.
11.1 Molecular fragments as building blocks
Jencks was the first author to explore the idea of chemical fragments
and the concepts that underpin the chemical fragments [125], who
showed that a drug-like molecule could be regarded as the combina-
tion of two or more individual binding fragments (chemical blocks)
which confer the relevant properties to the drug.
Fragments are usually small molecules, typically with a molecular
weight in the range of 40 ≤ MW ≤ 300Da or 8-18 non-hydrogen
atoms. They are chemical blocks with less functionality than drug-
like molecules and are correspondingly weaker than most hits from
high-throughput screening (HTS)1, with typical binding affinities in 1 HTS is currently the established ap-
proach for hit identification within the
pharmaceutical industry
the range nm–30 µm[233].
Figure 11.1: Fragments building blocks
in FBDD. (A)Fragment F1 has an opti-
mal binding to the left site of the protein
binding pocket. (B) In a similar manner,
Fragment F2 has the optimal binding to
the right site. (C)Fragments are joined
together by a linking group that allows
the lead molecule to span both sites and
making good contact with the upper sur-
face of the protein pocket.
Fragment-based drug design (FBDD) is a well-established method
to find new drug candidates by optimizing small chemical fragments
into larger molecules[233, 72]. Figure 11.1, shows the example use of
fragments as building blocks for lead optimization. The two fragments
F1 and F2 have been identified to bind in separate binding sites of the
same protein pocket, and they are close enough to each other to be
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chemically linked by the addition of another linking group.
Fragment-based approaches have been widely studied and ex-
ploited because they offer a number of attractive features compared
with HTS[178, 194, 29, 203, 120, 202]. For instance, fragments have in
principle a high proportion of functional groups involved in protein
binding, and many of them precisely fit the target sub pockets. A high
proportion of the atoms in a fragment hit are directly involved in the
desired protein-binding interaction, so fragments can be described as
efficient binders. Moreover, due to their reduced size and complexity,
fragments allow an efficient exploration of protein binding sites[74].
11.2 Identification of privileged molecular Fragments
Several techniques have been developed to systematically identify
structural motifs/fragments common to molecules which interact
with specific biological targets or target classes[151, 174, 62, 285, 84,
93].
RECAP: Retrosynthetic Combinatorial Analysis Procedure
Figure 11.2: Predefined bond cleav-
age types in RECAP algorithm. The
bond types are derived from common
chemical reactions and each molecule is
cleaved into fragments if it contains any
of the 11 bond types.
One of the most popular fragmentation methods is the retrosynthetic
combinatorial analysis procedure (RECAP) developed in GSK[174].
The technique identifies common motifs/fragments in biologically
active molecules based on fragmenting molecules around bonds that
are formed by common chemical reactions. By fragmenting real drug-
like molecules into fragments, RECAP can identify fragments that
are likely to be responsible for biological activities. In the process
of fragmentation, RECAP considers 11 predefined bond cleavage
types (Figure 11.2) derived from common chemical reactions, all of
which are amenable to combinatorial chemistry. Furthermore, the
knowledge of the chemical environments of the fragments is retained
by assigning them “isotopic labels” to represent the classes of bonds
in the pre fragmented molecules.
BRICS: Retrosynthetically Interesting Chemical Substructures
In an attempt to improve existing approaches for the automatic decom-
position of molecules into fragments, Degen et al. compiled fragment
spaces by specifying a RECAP complementary set of rules for the
recombination of the corresponding chemical motifs[62]. The BRICS
model consists of 16 chemical environments indicated by link atoms
of different types and the corresponding cleavage options. BRICS put
all its effort into compiling a set of fragments that are meant to serve
as the basis for molecular design objectives and techniques. Its design
is based on elaborate medicinal chemistry concepts, and includes for
instance, explicit isosteric replacements for cyclic and acyclic cases
and further distinguished activated from inactivated heterocyclic ring
systems.
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molBLOCKS: decomposing small molecule sets and uncovering en-
riched fragments
In order to identify statistically enriched fragments that might explain
the common activity of small molecules sharing properties, Ghersi
and Singh implemented the molBLOCKS suite[93]. The software con-
sists of two command-line programs: fragment and analyze. Together
they allow users to break down small molecules into chemically mean-
ingful fragments (by integrating RECAP, BRICS, and CCQ2 rules) and 2 Cleaving a bond between two carbon
atoms of which at least one is connected
to a heteroatom.
analyze the resulting fragment distribution with enrichment analysis
at the level of either fragments or clusters. In a recent study, Heikamp
et al. presented the optimized version of molBLOCKS by expanding
the RECAP rules and allowing the generation of larger fragments by
merging others. This leads to a more diverse fragments set than those
obtained by standard fragmentation programmes.
Although the latter tools offer several improvements to the original
RECAP algorithm, such as increasing the fragment space and the
customized options for delimiting the size and design of the motifs,
it should be kept in mind that they are mostly oriented to obtain
fragments from biologically active compounds and vendor catalogue
sources.
11.3 Fragments binding mode
Similarly, as for drug-like molecules, the binding mode of fragment
molecules is determined by covalent and non-covalent contacts that
influence the binding energetic forces. FBDD approaches usually rely
on the assumption that the binding mode of a fragment is unique and
that the binding mode of a fragment and its drug-like counterpart
will be conserved[157]. Thus, it is assumed that the orientation of
fragments in their respective binding pockets will remain the same
whether they bind on their own or as a moiety of a larger ligand.
The hypothesis has been rigorously tested in a number of studies by
deconstructing larger ligands into their component fragments and
characterizing how these fragments bind.
Figure 11.3: Fragment and fragment
superstructure with a conserved bind-
ing conformation to the detected tar-
get hot spot. (A)Phenylmalonate 5
and (B)Phenylmalonate-based inhibitor
4 binding at the main hot spot of
pp60 Src SH2. Molecules are shown
in stick representations and the gray
pocket shows the main hot spot in the
target[157]
Kozakov et al. showed that fragments coinciding with low-energy
hot spots tend to have conserved binding modes (Figure 11.3)[157].
The detection of protein hot spot has been proposed to assist fragment
selection and elaboration by prioritizing protein subpockets.
In 2018, Drwal et al. explored the binding mode of fragments
in PDB[75]. Overall, they observed that PDB fragments tend to
exhibit the same position and orientation when crystallized multiple
times within the same pocket and their binding mode is generally
conserved (in about 74.3% of cases). Furthermore, they showed
that PDB fragments tend to make the same interactions within a
protein pocket when alone and when included in a larger drug-
like superstructure ligand. The finding supports the idea that small
chemical changes in the fragment are tolerated without alteration of
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the fragment binding mode. Nonetheless, it should be noted that
such conservation is weaker in multi-target fragments[74].
In a more recent study, Bolz et al.[30] evaluated the binding mode
conservation of PAINS-defining substructures (PAINS-ds) 3. Although3 Pan-assay interference compounds
(PAINS) are promiscuous compounds
that produce false positive hits in high-
throughput screening. A PAINS-ds
is chemical substructure found in all
PAINS belonging to the same PAINS
class.
the definition of PAINS-ds is not exactly the same as fragments, they
both are regarded as small molecular entities that are substructure of
larger compounds. The findings described by Bolz et al. in regard to
binding mode conservation fit close to the work done by Drwal et al.
Versatile non covalent binding modes of PAINS-ds allow PAINS com-
pounds to engage dissimilar targets, thereby representing a possible
mechanism of PAINS activity and of promiscuous binding in general.
CONCLUSIONS
Given the highlighted relevance of molecular fragments in the drug
discovery process, it seems interesting to explore their molecular
properties and binding mode conservation from a structural perspec-
tive. However, most of the aforesaid studies have been conducted
in a relatively limited space. For instance, Drwal et al. work was
constrained to fragments that were crystallized as small molecule
ligands in PDB structure, meaning the narrowed set is biased towards
crystallographers’ research interests. In that sense, it is necessary to
further explore the molecular fragments from a structural perspective
and evaluate their potential in drug repositioning approaches.
Chapter 12
Molecular Fragments in PDB
Given the recent breakthroughs of molecular fragments as building
blocks in drug discovery, fragments in PDB were explored from a
structural perspective to evaluate their potential in drug repositioning
approaches.
12.1 PDB compounds fragmentation
In order to expand the previous analysis carried out by Drwal et
al.[75], fragments and their structural features were this time directly
extracted from all molecules in PDB. For this purpose, 138,546 curated
PDB structures (to date 07.10.2020) were processed and analyzed with
OpenBabel v3.0.0[211] for the detection of small molecule compounds
and their atom coordinates. The code behind this approach is in
Appendix Section 15.1).
RECAP vs BRICS
RECAP[174] and BRICS[62] algorithms were used to fragment the
detected compounds SMILES1 and explore their fragment space. Both 1 The Simplified Molecular-Input Line-
Entry System (SMILES) is a specification
in the form of a line notation for describ-
ing the structure of chemical species us-
ing short ASCII strings.
algorithms are implemented and distributed by the open-source RD-
Kit v2019.09.12 which makes them easy to access and offers two
2 RDKit is an open-source chemoinfor-
matics software.
fragmentation option: full hierarchical three of fragments and the tree
leaves only. The latter ignores the option to construct fragments by
merging smaller ones, leading to a reduced set of fragments avoid-
ing redundancy of data. Table 12.1 summarizes the results from the
fragmentation process.
Algorithm Structures Ligands Fragments Total time Mean time
RECAP tree 99,962 37,182 151,744 93,955.18 0.68
BRICS tree 98,945 36,146 530,317 113,091.69 0.82
RECAP leaves 100,880 38,385 54,068 83,267.07 0.60
BRICS leaves 104,491 43,260 52,504 57,055.66 0.41
Table 12.1: Fragmentation algorithms
applied to PDB ligands. Both algo-
rithms were tested with the full tree
and the leaves only options. On each
case, the number of unique PDB struc-
ture, unique ligands and unique frag-
ments were accounted for the generated
data set. The fragmentation processing
time was measured in seconds for the
full PDB data set fragmentation as well
as for each independent PDB structure
with a calculated mean.
Despite the fact that in general there is no considerable difference
in the number of successfully analyzed structures and ligands frag-
mented between RECAP and BRICS, a consistent rise in the number
of generated fragments is observed by the BRICS tree mode. RECAP
tree constructed a total of 151,744 unique fragments, whereas BRICS
tree obtained 530,317 fragments leading to an elevated processing
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time. This is a clear result of the extended and relaxed rules defined
for BRICS algorithm on its ultimate goal of expanding the fragments
space for catalogue vendors.
Considering that this work aims to explore the fragments space
and their binding mode conservation in a general and clean perspec-
tive, the RECAP leaves mode offers the ideal fragmentation to avoid
redundant fragments as substructures of others.
PDB fragments with RECAP leaves algorithm
With the application of the RECAP leaves, 100,880 PDB structures
and 38,385 ligands were successfully fragmented into 54,068 molec-
ular fragments. Figure 12.1 illustrates the construction of the PDB
fragments data set.
Figure 12.1: PDB fragments data set con-
struction. From the top starting point of
the curated structures in PDB until the
final resulting fragments, passing over
the the three layers representing the ex-
traction data levels: structures, ligands,
and fragments. The lost of data is ac-
counted and explained for each layer in
the pyramid.
Since one PDB structure can contain multiple ligands (compounds),
which may contain multiple fragments, the data space is represented
as a pyramid. Within each layer of the pyramid, the figure depicts
the loss of data due to different reasons. For instance, the great-
est loss at the structure level is due to more than 30,000 structures
without a binding ligand. Similarly, about 17,000 compounds have
none of the RECAP cleavage rules. Therefore no fragments could be
obtained from them. Most of such compounds can not be fragmented
because they are already fragments that were crystallized as ligands
(as studied in Drwal et al. analysis[75]).
Nonetheless, to keep the uniformity of the data, they were excluded
from this analysis. Finally, the unique loss of data at the fragment
layer is due to no possible atom mapping between the original PDB
file and the generated fragment molecule. Without such mapping, it
is impossible to track back the structural information from the PDB
and therefore, the aforesaid cases can not be further analyzed.
PDB fragments space
There is a number of "large" fragments mostly derived from steroids,
porphyrins, and staurosporin analogues, among others. Moreover,
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there is a significant number of aromatic fragments such as amino
acids, nucleotide analogues, or sugars. For the latter, specifically
amino sugars which are usually very soluble, have a number of
groups capable of interacting with the target protein in a usually well
defined 3D structure. In a less frequent level, but still significant,
there is a number of organic fragments with hetero atoms capable of
interacting with the target proteins, specifically with kinases.
Overall, the number of fragments per ligand obtained after frag-
mentation varies from ligand to ligand (Figure 12.2.A).
Figure 12.2: Fragmentation of PDB com-
pounds. (A)The bar plot shows the
amount of PDB compounds by the num-
ber of fragments obtained after fragmen-
tation. Most of the compounds are frag-
mented from 2 to 10 fragments. (B) The
bar plot shows the frequency of frag-
ments among the compounds. Most of
them are unique for one compound, but
others are highly frequent.
Most of the compounds were fragmented from 2 to 10 fragments.
Only 26 compounds are conformed by one unique fragment, whereas
more than 6000 compounds lead to more than ten fragments. This last
reflects the complex chemical design of some compounds. In general,
it is expected that the number of fragments in a compound is directly
influenced by the size of the same. Meaning, larger compounds are
expected to have more fragments and vice versa. However, a Pearson
correlation of 0.4 and a p-value of 0.0 shows a significant but weak
correlation between both features.
Figure 12.3: Examples of rare and fre-
quent fragments. Fragment I is part of
one unique compound, which is mainly
attrbutted to it chemical design. Frag-
ment II is a substructure found in 65
different compounds, binding to 69 dif-
ferent targets. As a pyrimidine deriva-
tive, this fragment is frequently found
in nature, as well as, part of many artifi-
cially created compounds.
At the same time, Figure 12.2.B shows that PDB fragments tend
to be unique among the PDB compounds and are present in one
compound only, which is explained by the complex diversity of struc-
tures in the chemical space but also by the reduced chemical space in
PDB. Nonetheless still, more than 10,000 fragments are present in at
least two different compounds. Examples of both cases are illustrated
in 12.3. Fragment I is part of just one compound binding to one
unique target, whereas Fragment II is a substructure of 65 different
compounds binding to 69 different targets. The uncommon essence
of Fragment I could be attributed to its chemical structure. Despite
that the phosphate group is a frequent functional group among the
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chemical compounds, the rest of the fragment’s chemical structure is
relatively rare. On the other hand, the recurrent appearance of Frag-
ment II is due to its properties as a pyrimidine derivative compound.
It is well known that the pyrimidine ring system has wide occurrence
in nature[166] and therefore, the same applies for all its derivatives.
Computational complexity
The fragmentation uses Rdkit for the internal representation of the
molecular structures. After reading the input PDB structure, the
complete molecule is loaded into memory for the subsequent analyses,
resulting in constant memory usage.
In terms of computation time, the fragmentation approach reaches
its maximum from the calculation of interactions fingerprints at the
fragment atoms level. First, there is a detection of all ligands l in
the structure. Then for each ligand, the fragmentation algorithm is
applied and all fragments f are extracted. Finally, for each fragment
the PLIP interactions i are obtained from the PLIP binding site profile
and encoded into the fingerprint. In that sense, the worst case is
given when the structure has multiple ligands, from which multi-
ple fragments are extracted, and each fragment atom has multiple
PLIP interactions. This makes it necessary to consider a cubic time
complexity with O(l × f × i).
12.2 Binding mode conservation of PDB fragments
In a similar manner, as performed in the analysis by Drwal et al., the
binding mode conservation of PDB fragments was further explored.
The code behind this approach is in Appendix Section 15.1).
Fragments binding mode profiling
The non-covalent interactions of all PDB compounds were calculated
using the Protein Ligand Interaction Profiler (PLIP)[241] with stan-
dard settings. As shown in Figure 12.1 the PDB structures without
a PLIP profile and compounds without PLIP data (no interactions
detected) were removed from the data set.
Figure 12.4: Fragments binding mode
encoding. (A)Fragments are obtained
from the PDB compounds. (B)The frag-
ments atom are processed with the PLIP
tool for the detection of non-covalent
interactions and the generation of an
interactions profile. (C)For each interac-
tion detected in the binding mode of a
fragment, three features were combined:
(1)the interaction type, (2)the interacting
functional group in the fragment, and
(3)the interacting residue of the protein
target. Each of these features combina-
tion is hashed (between 1 and 500) and
encoded in a fingerprint of 500 bits.
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Additionally, the PLIP non-covalent interactions for the PDB frag-
ments were encoded into a binary fingerprint, which was constructed
considering only the interactions mediated by the fragment atoms.
The interactions were encoded similarly as previously discussed in
Chapter 6. However, this time the interaction patterns definition was
simplified by totally ignoring the geometrical features of the interac-
tions and instead focusing on the types of interaction in the involved
functional groups and in the interacting residues (Figure 12.4). Finally,
the constructed fingerprint has a total of 500 bins.
It might be expected that the size of the fragments relates to the
number of observed non-covalent interactions, thus influencing its
binding mode. However, a Pearson correlation of 0.4 and a p-value of
0.0 shows a significant but very weak correlation between the size of
the fragments and the number of interactions displayed in the binding
mode.
Binding mode conservation subset
It is well known that the PDB data is unbalanced and usually biased
towards biologically relevant proteins or over-represented compound
scaffolds resulting from lead optimization. To make a fair estimation
of binding mode conservation, the PDB fragments data must be
adequately filtered and homogenized, considering certain criteria.
RECAP algorithm considers fragments as small as one atom, e.
g. the oxygen molecule. However, according to the definition of
fragments (Chapter 11), fragments are within the range of 40 ≤ MW
≤ 300. Moreover, as shown in Figure 12.2.B, many fragments are a
substructure of just one unique compound or only a few different
targets. In such cases, the binding mode conservation can not be
properly estimated. Overall, the PDB fragments data set has a mean
of 7.8 in respect to the different compounds of which a fragment is
part of, and 12.1 for the number of different protein targets they bind
to.
Considering the above mentioned, a fragments subset has been
defined with fragments at a molecular weight in the range of 40 ≤
MW ≤ 300, being a substructure of at least five different compounds,
and binding to at least ten different proteins. In addition, to deal
with the over-representation of some fragments compared to others,
a maximum of 500 PDB complexes per fragment have been selected.
If there are more than 500 complexes available in the data set for
a given fragment, then its complexes are grouped by unique pairs
of protein Uniprot ID and compound InChIkey3 and only one is 3 The IUPAC International Chemical
Identifier (InChI key). It is a textual iden-
tifier for chemical substances, designed
to provide a standard way to encode
molecular information and facilitate the
search for such information in databases
and on the web.
randomly selected as the representative complex of the pair.
Binding mode similarity calculation
As mentioned before, one unique fragment can be a substructure of
multiple different compounds, which could be in multiple different
PDB structures (or complexes). In order to estimate how conserved
is the binding mode for a given fragment, all the PDB complexes
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containing such fragment must be compared in terms of interactions
fingerprints.
The binding mode similarity of fragments is measured by calculat-
ing a pairwise Tanimoto Interaction Similarities (TIS) of fragments
interaction fingerprints. In other words, for two protein-ligand com-
plexes (C1 and C2) having the same fragment as substructure, the
TIS is calculated as follow:
TISC1,C2 =
C1bins ∩ C2bins
C1bins + C2bins− C1bins ∩ C2bins (12.1)
C1bins refers to the number of activated bins in the interactions
fingerprint of C1, C2bins the activated bins in C2, and C1bins ∩
C2bins is the number of bins activated in both C1 and C2. Finally, the
mean of all TIS (mTIS), obtained from the pairwise similarities of a
given fragment, was calculated as the score for evaluating the binding
mode conservation.
Figure 12.5: Binding mode conservation
of PDB fragments. For each fragment
a mean Tanimoto Interaction Similarity
(mTIS) was calculated and plotted as
frequency under three different scenar-
ios: fragments in different compounds
binding different targets (gray), in differ-
ent compounds binding the same target
(blue), and in the same compound bind-
ing to different targets (green). The red
line represents the proposed threshold
for binding mode conservation.
Figure 12.5 shows the mTIS of PDB fragments evaluated under
three criteria in the context of targets and compounds: the same
fragment in all different compounds superstructures binding all kinds
of targets (grey curve), the same fragment in the same compound
superstructure binding to different targets (green curve), and the
same fragment as part of different compounds binding always to the
same target pocket (blue curve).
The red line is the proposed threshold at mTIS=0.6 to define bind-
ing mode conservation, which is based on literature[75]. Thus, frag-
ments on the right of the red line are considered to have a conserved
binding mode. Whereas fragments on the left, the opposite. Overall,
PDB fragments display a non-conserved binding mode when are
they compared without considering the ligand superstructure and
the target they bind to (grey curve). Nonetheless, when the fragments
binding mode is compared within the same compound or binding
to the same target (curves green and blue respectively), it shows
a conserved tendency, which agrees with the previous analysis by
Drwal et al.[75].
Fragment I in Figure 12.6 is part of 18 different compounds binding
to the same target (O26232), and it has a relatively conserved binding
mode with an mTIS of 0.66. The interactions displayed (dashed
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Figure 12.6: Examples of conserved frag-
ments in a 2D representation. Fragment
I (left side) has a relatively conserved
binding mode, defined by a set of fre-
quent non-covalent interactions, with
a mTIS=0.66. Fragment II displays a
highly conserved binding mode, with
an unique pair of hydrogen bonds and
a mTIS=0.89.
coloured lines) are highly conserved among the different structures,
with variations only in the target residues (letters). Similarly, fragment
II is part of 5 different compounds binding to the same target (O14965)
and it has a highly conserved binding mode (mTIS of 0.89) with two
hydrogen bonds to the target residues Glutamate (E) and Leucine
(L). Since the fingerprints are dependent on the binding site residues,
minor variations among the different targets might affect the final
mTIS scores.
Computational complexity
The conservation analysis is divided into two steps: the independent
fragment’s subset generation and the pairwise similarity calculation
of all fragments’ fingerprints. The first step generates intermediate
output files for each fragment’s subset to avoid memory overload and
facilitate parallelization of the conservation analysis.
In terms of time complexity, the first step has linear complex-
ity with O( f ), where f is the number of fragments to be analyzed.
However, the conservation approach reaches its maximum from the
pairwise distance calculation between the fragment’s fingerprints.
This makes it necessary to consider a complexity of O( f p2) where f p
is the number of fragment’s fingerprints to compare.
CONCLUSIONS
Given the conserved nature of the fragments binding mode, they can
be used to extend the limits of structure-based drug repositioning
by offering a different perspective to explore the binding mode of
drugs. The overall concept seeks to take one step down (deconstruct
a compound) to learn from available data and then later transfer
that knowledge back up again to other compounds. Chapter 13 will




The concept of molecular fragments and their conserved binding
modes have been further exploited to overcome the limitations on
data availability. Overall, the reconstruction of drugs’ binding mode
seeks to transfer the structural knowledge from molecular fragments
to full molecules. The code behind this approach is in Appendix
Section 15.1)
13.1 Overview on the reconstruction approach
The recent literature evidence supports the idea that molecular frag-
ments tend to behave in a conserved manner and that chemical
changes in the surrounding area of the fragment are tolerated without
alteration of the fragment binding mode. Given that non-covalent in-
teractions usually determine a compound’s binding mode, it could be
assumed that fragments tend to have a conserved set of non-covalent
interactions.
Figure 13.1: Binding mode reconstruc-
tion approach. (A)The compound with-
out structural data is fragmented into
molecular fragments. (B)The binding
mode (interaction patterns) of all molec-
ular fragments in PDB are character-
ized using PLIP and for each fragment a
representative binding mode is chosen.
(C)The binding mode of full compounds
is reconstructed using fragments struc-
tural data.
Figure 13.1 illustrates the reconstruction approach. Based on the
concept of fragments as building blocks, the proposed approach
suggests that fragments non-covalent interactions profiles could be
exploited to reconstruct the profile of full molecules. In other words, it
would be possible to determine the non-covalent interaction patterns
of full drugs based on their fragments structural profiles, and thereby
expand the scope of structure-based drug repositioning by interaction
patterns to drugs that are not in PDB.
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13.2 Fragments subset used for reconstruction
Given the conservation result discussed in Chapter 12, the PDB frag-
ments’ binding mode conservation could be exploited under two
criteria: different compounds - same target (blue curve) or same compound
- different targets (green curve) (Figure 12.5). However, considering
that the approach’s main goal is to reconstruct the binding mode of
different drugs using the fragments structural data, a target-based
reconstruction pipeline has been developed based on the category
different compounds - same target. In other words, the binding mode
of a compound can be reconstructed only for a given target, and the
reconstruction considers only the structural data of fragments binding
to that specific target.
In order to achieve a quality reconstruction of the binding modes,
only fragments with a conserved binding mode were selected for this
purpose. Since the binding mode conservation of PDB fragments was
evaluated under different conditions than the state of the art study,
the subset of fragments was selected with a slightly more permissive
threshold at mTIS=0.5 than the proposed in the literature, leading to
a total number of 26,840 fragments-targets pairs.
13.3 Reconstruction pipeline
The fragments subset is used to reconstruct the compounds according
to the following target-based pipeline:
A. Compound fragmentation
Given a set that contains compounds binding to specific targets, each
of those compounds is fragmented with the RECAP leaves algorithm
using the compounds’ SMILES and default settings (Figure 13.2.A).
The fragments resulting from the fragmentation are further scanned
within the PDB fragments subset. Given the target-based nature of the
approach, only the structural data of fragments binding to the specific
target will be further considered. If at least one of the fragments has
available data in the PDB fragments subset, the approach continues.
Otherwise, it is impossible to reconstruct the compound.
B. Compound’s proportion
In a perfect scenario, all the compound’s fragments would be repre-
sented in the PDB fragments subset. However, given that the PDB
chemical space covers only a limited part of the ChEMBL chemical
space, it is expected that many fragments have no structural data nor
binding mode defined. Therefore, an optional threshold (Compound
proportion) has been introduced at this step of the reconstruction (Fig-
ure 13.2.B), to define the minimum amount of fragments considered
enough to emulate the binding mode of the full compound. For
instance, for the compound in Figure 13.2.A, a compound proportion
> 0.5 would require that at least 2 of the 3 fragments are in the PDB
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fragments subset. If the proportion is lower than the cutoff, then the
reconstruction is not possible.
Figure 13.2: Compounds binding mode
reconstruction with PDB fragments. The
PDB fragments binding mode are char-
acterized with PLIP and represented as
binary interactions fingerprints. (A)A
compound without structural data is
fragmented and its fragments bind-
ing mode are extracted from the PDB
fragments data set. (B)The fragments
must cover the minimum compound
proportion and (C)they must meet the
minimum binding mode conservation.
(D)Only then, a representative interac-
tions fingerprint is calculated for each
independent fragment to later (E)be all
merged into one interactions fingerprint
representing the binding mode of the
full compound.
C. Binding mode conservation
In another aspect, the fragments subset has been constructed with
fragments having binding mode conservation (BM conservation) above
0.5 mTIS. However, stricter thresholds may lead to better/different re-
sults depending on the fragments of independent cases. Consequently,
an additional threshold (BM conservation) has been introduced in the
reconstruction pipeline as an option to restrict this feature even more
when needed (Figure 13.2.C). Therefore, only fragments meeting
the specified threshold will be used for the following compound’s
reconstruction.
D. Representative fragment’s fingerprint
As previously discussed, one unique fragment can be a substructure
of multiple different compounds, which could be in multiple different
PDB structures (or complexes). However, for reconstruction purposes
it is necessary to define a consensus binding mode (interactions
fingerprint) for a specific fragment.
The most intuitive way to achieve such consensus is by merging
all the interactions fingerprints found for a given fragment into a
representative one (Figure 13.2.D). A simple union of activated bins
between the fingerprints would lead to a representative fingerprint
loaded with many false negatives. On the contrary, a representative
fingerprint constructed with the frequency of the activated bins offers
a fair representation of all possible interaction patterns with their
weighted appearance, i.e. interaction patterns that frequently appear
among the different fingerprint, will get a higher score than those
which do not. For instance, the fragment in Figure 13.3 is part of
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three different compounds. When constructing its representative
binding mode, the fingerprints defining such binding mode, as part
of each independent compound, are merged into one by considering
the frequency of the activated bins. It should be noted that the
constructed representative fingerprint is not any more of the binary
type but rather float due to the frequency score.
Figure 13.3: Representative fragment’s
fingerprint. The fragments is part of
three different compounds binding to
the same target of interest. For each
compound, there is a fingerprint (FP)
with activated bins (blue boxes) for the
interaction patterns defining the binding
mode to the target. The representative
fingerprint is defined by the frequency
of each activated bin among the finger-
prints.
E. Reconstructed compound’s fingerprint
Finally, all the representative fingerprints describing the binding mode
of each of the compound’s fragments are merged into one unique com-
pound fingerprint (Figure 13.2.E). The merging of fingerprints is done
by accounting for the union of all activated bins and calculating the
mean between frequencies. The reconstructed fingerprint represents
the binding mode of the compound to the target in question.
13.4 Performance of the approach
Validation of the reconstruction
The performance of the approach was evaluated in a PDB subset of
compound-target pairs. Since the compounds in the PDB subset have
available structures and, thus, an actual PLIP fingerprint describing
the binding mode, it is possible to check how similar the reconstructed
fingerprints are compared to the real ones.
The PDB subset includes all compound-target complexes found
up to the second level (Ligand level) of the pyramid in Figure 12.1,
along with the non-fragmentable compounds that were excluded at
the fragmentation stage.
The reconstruction pipeline was applied to the PDB subset, trying
different combination of the modifiable thresholds, i.e. the com-
pound’s proportion and the fragments binding mode conservation.
To avoid bias in the validation, the binding mode (fingerprint) of a
compound-target complex is reconstructed without using the struc-
tural data from the complex itself. Meaning, the construction of repre-
sentative binding mode of fragments does not take into consideration
the fingerprint of the compound-target complex to be reconstructed.
Furthermore, the quality of reconstruction was evaluated for each
thresholds combination. To this purpose, a Reconstruction Similarity
Score (RSS) was defined as the mean of all the reconstructed-original
fingerprint pairs similarities, which was calculated using the simple
Tanimoto Similarity approach.







Where, P is the total of reconstructed-original fingerprint pairs,
Onbins is the activated bins in the original fingerprint, and Rnbins the
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activated bins in the the reconstructed fingerprint.
Table 13.1 summarizes the validation results, with the number
of compound-target pairs that were reconstructed for each given
thresholds combination.
Compound proportion








on 0.5 6325 2,806 1,513 1,175 1,023 1,023
0.6 4,493 1,581 762 589 527 527
0.7 2,625 866 310 210 148 148
0.8 1,662 494 162 102 66 66
0.9 1,174 368 128 58 22 22
1.0 1,134 368 128 58 22 22
Table 13.1: Reconstruction of PDB
compound-target binding mode at dif-
ferent thresholds. The numbers refer to
the amount of compound-target binding
mode reconstructed at each threshold
combination. The color gradient indi-
cates the quality of the reconstruction in
terms of RSS calculated. Overall, there
is trade off between amount of data and
quality of the reconstruction.
Moreover, the gradient colour represents the quality of the recon-
struction given by the mean RSS previously calculated. The table
reflects a clear trade-off between the amount of data and the quality
of the reconstruction. The more restrictive the thresholds are, the less
data is obtained from the reconstruction pipeline. For instance, con-
sidering the extreme case at which all the fragments of a compound
have structural data (full proportion of 1.0) and only fragments with a
full conserved binding mode (BM conservation of 1.0) are used, only
22 PDB compound-target pairs were reconstructed.
Figure 13.4 shows an example of the validation set at the thresholds
Compound proportion = 0.6 and BM conservation = 0.6, with a RSS = 0.66
when comparing the original binding mode and the reconstructed
one. In the example, brivudine binds to one of its targets, the de-
oxynucleoside kinase, with a specific set of non-covalent interactions
(left). Brivudine compound can be usually fragmented into three
molecular fragments: Cc1c[nH]c(=O)[nH]c1=O, OCC1OCCC1O, and
Br. However, since Br has not enough structural data to character-
ize its binding mode conservation (less than five compounds), it is
not part of the selected fragments subset and thus, not considered
in the reconstruction. Nonetheless, the remaining fragments have
a relatively high binding mode conservation with an mTIS of 0.88
and 0.63 (BM conservation > 0.6) which ultimately leads to a com-
pound proportion of 2/3=0.66 (Compound proportion > 0.6). The
binding mode of Fragment I to the deoxynucleoside kinase target
was constructed using structural data of 5 different compounds in 30
different structures. The fragment exhibits a highly conserved set of
non-covalent interactions, i.e. two hydrogen bonds, one hydrophobic
contact, and one π-stack, which are frequent among the different
structures and are always in contact with the same target residues.
However, there is also a less frequent water bridge displayed in a few
112
structures making contact with arginine (R), and it is the reason for
the mTIS=0.88.
Figure 13.4: An example of binding
mode reconstruction. The binding mode
of the compound brivudine binding
to the target deoxynucleoside kinase
was reconstructed with an RSS=0.66.
On the left, it is represented the orig-
inal binding mode of the complex
(2VQS:BVD:C:1210) and on the right the
reconstructed binding mode based on
the fragments. Both fragments have a
relatively high binding mode conserva-
tion with an mTIS of 0.88 and 0.63. The
interactions look almost alike in both
cases, except for the water bridge in
Fragment I and the salt bridge and the
hydrogen bond in Fragment II.
On the other hand, Fragment II was constructed using structural
data of 6 different compounds in 32 different structures. It has two
highly frequent interactions among the structures: a hydrogen bond
always in contact with arginine or glutamic acid and a hydrophobic
contact to phenylalanine or isoleucine. However, it also has another
hydrogen bond, and a salt bridge displayed only in a few structures,
which confers it its mTIS=0.66, defining a more variable binding mode
than fragment I.
Even though none of the fragments has a perfectly conserved bind-
ing mode (mTIS=1.0), the reconstruction turned out to be successful
as it fairly represents the relevant interactions defining the binding
mode of brivudine to deoxynucleoside kinase.
Overall, the validation results evidence the complexity behind
the process. Although, in general, fragments tend to have a highly
conserved binding mode, most of them never reach the perfect con-
servation of 1.0 mTIS, which comes hand to hand with the binding
mode variability under special binding environments. On the other
hand, the compound proportion limitation reflects the still unmet
necessity of a representative structural space covering a diverse set of
molecular fragments.
Nevertheless, the approach in overall was able to reconstruct mul-
tiple compound-target pairs at optimal thresholds and with high
similarity (RSS) to the real fingerprints.
Computational complexity
The reconstruction uses Rdkit for the internal representation of the
molecular structures. The approach works for independent com-
pounds, which are in the first place fragmented. Then, for each
fragment, a representative interaction fingerprint is constructed from
all the fragment’s fingerprints in the PDB fragments data set. Fi-
nally, the representatives are merged into one unique compound
fingerprint.
Regarding time complexity, the reconstruction approach reaches its
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maximum in the construction of fragments’ representative fingerprint.
This makes it necessary to consider the complexity of O( f × f p)
where f is the number of fragments extracted from the compound,
and f p is the number of interaction fingerprints found for a given
fragment.
13.5 Binding mode reconstruction on ChEMBL data set
ChEMBL compound-target subset
ChEMBL is a manually curated database of bioactive molecules with
drug-like properties[192]. The aim of ChEMBL is to collect chemi-
cal, bioactivity and genomics data to aid the translation of genomic
information into effective new drugs. To the date, the database con-
tains about 2.1 million compounds, 14K biological targets, and more
than 17.2 million compound-target activity assays. The large chemi-
cal space available in ChEMBL, makes it the best option to explore
compounds so far not crystallized (not found in PDB) to which the
proposed approach could be applied.
Figure 13.5: ChEMBL data base filtering
steps.
For this purpose, ChEMBL database in SQLite format (v26 released
on March 2020) was locally downloaded. Subsequently, the data
retrieved was filtered (Figure 13.5) according to the following crite-
ria: compounds under the category of small molecules, compounds
having SMILES descriptor and UNIPROT ids, compounds having
activity data (type IC50, EC50, Kd, and KI in nm), compounds that
are not in PDB, compounds binding and having activity data to PDB
targets, and compounds with molecular weight ≤ 600Da. Finally, the
application of the filtering steps yielded a ChEMBL subset with a
total of 264,033 compound-targets pairs.
Reconstruction results
The reconstruction pipeline was applied to the ChEMBL subset trying
different combination of the modifiable thresholds. Table 13.2 summa-
rizes the results, with the number of compound-target pairs that were
successfully reconstructed with each given thresholds combination.
Compound proportion








on 0.5 7686 1737 202 48 34 34
0.6 5344 991 83 11 10 10
0.7 3844 651 49 7 6 6
0.8 2531 353 24 2 1 1
0.9 2100 279 20 1 0 0
1.0 2028 271 19 1 0 0
Table 13.2: Reconstruction of ChEMBL
compound-target pairs at different
thresholds. The numbers refer to the
amount of compound-target pairs suc-
cessfully reconstructed at each threshold
combination. Overall, there is trade off
between amount of data and quality of
the reconstruction.
The numbers in the table show a similar trade-off between the
amount of data and the quality of the reconstruction. The stricter
the thresholds are, the less data is obtained from the reconstruction
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pipeline. For instance, considering the extreme case at which all the
fragments of a compound have structural data (full proportion of
1.0), and only fragments with a full conserved binding mode (BM
conservation of 1.0) are used, no compound-target pair in ChEMBL
was reconstructed. However, as the thresholds are relaxed, more and
more reconstructions are possible.
In general, so far the reconstruction using PDB fragments is able to
cover a small proportion of ChEMBL compounds, which demonstrates
the little overlap between the PDB chemical space and giant chemical
libraries such as ChEMBL.
As previously mentioned, some fragments are over represented in
PDB, whereas other barely appeared in one PDB compound. Recap
and the many other tools developed under the same basis, have exten-
sively tested the fragmentation process in multiple chemical libraries
such as ChEMBL. The fact that certain fragments are found just in
one PDB compound, does not directly mean that such fragments are
not common among the large chemical libraries, but rather implies
that there is not enough data in PDB to cover the real chemical space.
The above clearly limits the reconstruction process, as the approach
only uses fragments with a conserved binding mode. Therefore, if a
fragment appears in less than 5 different PDB compounds, no binding
conservation score can be calculated. Thus, the fragment can not be
used in the reconstruction.
As an ultimately solution, the reconstruction constrictions could
be slightly relaxed in order to avoid the aforesaid issue, however, the
results should be analysed under a more permissive perspective and
several uncertainties should be taken into consideration.
CONCLUSIONS
Given the conserved nature of the fragments binding mode, they
have proved to be helpful to extend the limits of structure-based
drug repositioning by offering a different perspective to explore the
binding mode of drugs. The reconstruction turned out to be relatively
successful as it fairly represents the relevant non-covalent interactions
defining the binding mode of the reconstructed drugs.
Although fragments tend to have a highly conserved binding mode,
most of them never reach the perfect conservation, which comes hand
to hand with the binding mode variability under particular binding
environments. On the other hand, the compound proportion limi-
tation reflects the still unmet necessity of a representative structural
space covering a diverse set of molecular fragments. Nevertheless, in
general, the approach was able to reconstruct multiple compound-
target pairs at optimal thresholds and high similarity to the actual
fingerprints, which calls for an optimistic future on the approach’s
potential.
The reconstructions are of great value and benefit to the structure-
base drug repositioning since they automatically enlarge the tech-
nique’s scope and allow to explore the so far "unexplored compounds"
from a structural perspective. Additionally, novel machine learning
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techniques could improve the conventional pattern matching screen-









This thesis introduced the novel approach of structure-based drug
repositioning by interaction patterns, exploiting the binding mode
similarity of drugs. Below, the individual contributions will be revis-
ited with an outlook towards future research challenges.
Framework for comprehensive repositioning
Due to the increasing costs and high failure rates in drug discovery,
systematic repositioning approaches have become highly important
as an alternative solution to the problem. Notwithstanding the numer-
ous in silico approaches designed to exploit the existing biological data
to predict novel drug-target links, data on protein-ligand interactions
remained largely unexplored. This thesis makes a substantial con-
tribution to structure- based repositioning approaches by providing
comprehensive algorithms and workflows to understand the complex
3D interaction patterns between proteins and ligands.
Analysis of PLIP interaction patterns reveals the mechanism at
the heart of molecular recognition. These intermolecular contacts are
the most detailed data source available to identify compounds with
desired binding behaviour and enable high-confidence predictions
for binding.
The concept of interaction profiling and comparison was explored
with the PLIP Fusion Fingerprint as a flexible solution for high-
throughput screening. Here, a performance improvement on the
current state-of-the-art fingerprint was achieved with a new structure-
invariant design. Furthermore, the approach attained results beyond
the scope of structurally or functionally related proteins and with
divergent drugs when compared to the existing treatments.
Overall, interaction patterns can be applied to any query with
a small ensemble of complexes available for pattern definition and
effectively detect compounds with similar binding behaviour.
Successful applications of the approach
The case studies covered in this thesis serve as a crucial validation
to the developed repositioning approach. Among the most remark-
able findings, there is a novel use for the Amodiaquine drug as a
chemoresistant treatment, the prediction and validation of ibrutinib
as a VEGFR2 inhibitor and its positive validation as a potent B cells
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inactivator, and finally, the discovery of ciprofloxacin, naproxen, and
folic acid as novel treatments for T. cruzi proliferation inhibition.
All these studies have demonstrated the potential of structure-
based drug repositioning to produce a high rate of true positive hits,
which translates into reduced cost and accelerated time compared
to a conventional drug discovery process. Moreover, the screening
predicted drugs with no prior evidence of an association with the
corresponding disease and novel chemical scaffolds, indicating the
potential of the approach to reveal promising drug repositioning
candidates. Overall, the approach represents a promising alternative
to drug discovery and a reliable hope for all rare and neglected
diseases for which no reliable treatment has yet been found.
The expansion of the repositioning approach using frag-
ments data
The novel technologies have made protein crystallization more cost-
effective and robust. Still, many cases require high-level expertise
and many years of effort. Thus, it will take some time before the
achievements in structure prediction finally expose their full potential.
Given the conserved nature of the fragments binding mode, they
have proved to be useful to extend the limits of structure-based drug
repositioning by offering a different perspective to explore the binding
mode of drugs. The reconstruction turned out to be successful as it
fairly represents the relevant non-covalent interactions defining the
binding mode of the reconstructed drugs.
Although, in general, fragments tend to have a highly conserved
binding mode, most of them never reach the perfect conservation,
which comes hand to hand with the binding mode variability under
special binding environments. On the other hand, the compound
proportion limitation reflects the still unmet necessity of a represen-
tative structural space covering a diverse set of molecular fragments.
Nevertheless, in general, the approach could reconstruct multiple
compound-target pairs at optimal thresholds and with high similarity
to the real fingerprints. The reconstructions are of great value and
benefit to the structure-base drug repositioning since they automat-
ically enlarge the technique’s scope and allow to explore the so far
"unexplored compounds" from a structural perspective.
Chapter 15
Outlook and future work
The appropriate definition of biological concepts
The unclear and non-uniform definition of certain biological concepts
does not make drug repositioning an easy task. Therefore, there
is an urgent need to unify such biological concepts to make drug
repositioning approaches reliable and comparable.
For instance, the previously mentioned drug promiscuity is com-
monly known as one drug binding to more than one target. How-
ever, when exactly are two targets considered different?. Although
the concept of "target" seems to be clearly defined, it is yet not
clear at which level should two targets be regarded as equals or
not. Some articles refer to equal targets if they share identical
sequence[98, 206, 179], whereas some others take into consideration
the structural classification[257, 14], e.g. superfamily for targets that
diverged from a common ancestor.
Similarly, there is no clear definition for identical small-molecule
compounds. Some comparisons are rigorous, focusing on the chemi-
cal similarity of the molecular entities[291], whereas others rely on
the chemical scaffold as the central core of the chemical structure[254].
Even more recent definitions suggest a biological similarity by func-
tionally characterizing small molecules, e.g. molecules with similar
cell-sensitivity profiles tend to share the mechanism of action[224].
Additionally, the analysis of biological activity data of the small-
molecule compounds of interests plays a critical role in drug discovery
pipelines. However, such data is often scattered in the scientific lit-
erature and difficult to be utilized. In the past decade or so, various
public-domain data resources have been developed to collect and nor-
malize the bioactivities into a uniform set. Still, many inconsistencies
in experiments protocols, measurements, and labels are found.
Artificial Intelligence in drug discovery
Advancements in computational science have allowed a wide use
of Artificial intelligence (AI) in drug discovery and development.
Machine learning (ML), an essential component in AI, has been used
to discover drug efficacy, ensure safety biomarkers, optimize the
bioactivity of molecules, and in high relevance to this work, predict
drug-protein interactions[144, 276, 185, 232, 220].
In a similar manner as state of the art, ML models could be trained
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to learn from the non-covalent interaction patterns defining the bind-
ing mode of drugs, identify the relevant synergistic contributions to
the binding, and provide an automated and fast prediction of drug-
target interactions. In this respect, the whole purpose of a ML model
design is to improve the screening by replacing a ranked similarity
metric-based search with a trained model to identify the direct links
between proteins and drugs. The analysis of interactions between
proteins and ligands with the help of ML comes closest to under-
standing molecular recognition of drugs at a larger scale. With the
presented algorithms and workflows, reliable hypotheses for drug
repositioning can be generated within a short time frame, and their
compatibility to existing approaches and an explanatory component
may help translate hidden repositioning opportunities into working
drugs.
Data availability and quality are key ingredients for the success
of ML methods. To achieve good results, a ML model requires a
diverse, representative, and big enough data set to be trained with.
Despite the great amount of structural data available, not all of the
therapeutically relevant protein families nor all the existing molecular
entities are equally represented in structural databases. Therefore, the
binding mode reconstruction approach plays a key role to tackle such
a problem by transferring structural data to other molecular entities
not present in structural databases.
A major challenge is the real biological interpretation of the ML
results, especially in matrix factorization and some deep learning
methods performing a dimension reduction[246]. The learned fea-
tures often hardly make sense biologically speaking, which prevents
easy interpretation of the results and sanity checks[232].
It has been a common belief that simple models provide higher
interpretability than complex ones. Linear models or basic decision
trees still dominate in many applications for this reason. This belief
is however, challenged by recent work, in which carefully designed
interpretation techniques have shed light on some of the most complex
and deepest machine learning models[195].
Notwithstanding the many difficulties associated with designing
a proper ML model for predicting drug-target binding, the current
evidence remarking the positive results obtained with such technique
positions AI as a promising novel approach for drug repositioning
via interaction patterns and for drug discovery in general.
Take to home message
Overall, drug discovery success requires immense resources, highly
sophisticated technologies, the best scientific minds, and complex
project management. It also takes persistence and, sometimes, a bit
of luck. Ultimately, though, the process of drug discovery has an





15.1 Most relevant coding
Due to data protection and code availability restrictions by the current
owner of PLIP fusion fingerprints (PharmAI), the full code behind
the fragmentation approach can not be fully shared. Nonetheless, the
most relevant classes and methods of the approach are included in
this section.
Fragmentation of PDB compounds
The following scripts underline the main fragmentation process for
the PDB compounds. There are three main classes defining the levels
of molecular entities among the fragmentation steps: PDB, Ligand,
and Fragment.
1 from supple import * #imports all required packages and used methods
2
3 class PDB():
4 """Defines a PDB file object and detect the binding ligands"""
5 def __init__(self, filename, pdbid):
6 self.pdbparser = PDBParser(filename) #read the PDB file
7 self.pdbid = pdbid
8 self.ligands = self.pdbparser.ligands #all the PDB ligands
9 self.has_ligands = True if len(self.ligands)>0 else False
Figure 15.1: The PDB class defines a
PDB object with all the atoms and bind-
ing information extracted from the file.
The class PDBParser is called to to read
and parse the PDB file, in order to ob-
tain all the elements of the binding sites
and ligands.
1 class Ligand():
2 """Define a ligand class to extract the molecule data"""
3 def __init__(self, lig, plipxml, pdbid, ftype):
4 self.ftype = ftype #set the fragmentation approach (RECAP/BRICS)
5 self.pdbid = pdbid
6 self.mol = lig.mol
7 self.hetid = lig.hetid
8 self.chain = lig.chain
9 self.pos = lig.position
10 self.bsid = ":".join([self.hetid, self.chain, str(self.pos)])
11 self.lig_smiles = lig.cansmiles #Smile representation of the ligand
12 self.inchikey = lig.inchikey
13 self.can_to_type = self.get_atom_type(readmolfromsmile(self.lig_smiles))
14 self.can_to_pdb = into_dict(lig.can_to_pdb)
15 self.atomorder = lig.atomorder
16 self.has_cantopdb_mapping = True if len(lig.can_to_pdb)>0 else False
17 self.has_plip_data = True
18 if self.bsid in plipxml.bsites:
19 self.bsite = plipxml.bsites[self.bsid]
20 self.fragment_smiles = self.get_fragment_smiles(self.lig_smiles, self.
ftype)
21 self.fragments = self.get_fragments(self.fragment_smiles)
22 if self.fragment_smiles else None
23 self.fp = Fingerprints(self.bsite)
24 self.fingerprint = self.fp.plipfusion()
25 self.fingerprint_sf = self.fp.simplefusion()
26 else:
27 self.has_plip_data = False
Figure 15.2: The Ligand class defines
a ligand and all its elements extracted
from the PDB. Moreover, defines the
PLIP analysis for the characterization
of the binding site and the encoded in-
teraction fingerprints for the ligand.
126
Figure 15.2: (Cont.) Within the methods
of the Ligand class are defined the four
optional fragmentation approaches to
obtain the fragments smiles, that will be
later used generate the instances of the
Fragment class.
29 def get_atom_type(self, mol):
30 """Return the atom types for the ligand"""
31 can_to_type = {}
32 for atom in mol.atoms:
33 can_to_type[atom.idx-1] = atom.type
34 return can_to_type
35
36 def get_fragment_RECAP_leaves(self, smile):
37 """Fragmentation with RECAP algorithm leaves of the tree"""
38 #Return a list of fragments for a given ligand smiles
39 fragsmiles = None
40 mol = Chem.MolFromSmiles(smile) #Get the ligand as rdkit mol
41 if mol:
42 hierarch = Recap.RecapDecompose(mol) #RECAP fragmentation
43 recap_fragments = hierarch.GetLeaves() #last leaves in tree
44 if len(list(recap_fragments.keys()))>0: #If at least one fragment
45 fragsmiles = list(recap_fragments.keys())
46 return fragsmiles
47
48 def get_fragment_RECAP_tree(self, smile):
49 """Fragmentation with RECAP algorithm full tree"""
50 #Return a list of fragments for a given ligand smiles
51 fragsmiles = None
52 mol = Chem.MolFromSmiles(smile)
53 if mol:
54 hierarch = Recap.RecapDecompose(mol)
55 recap_fragments = hierarch.GetAllChildren() #full tree
56 if len(list(recap_fragments.keys()))>0: #If at least one fragment
57 fragsmiles = list(recap_fragments.keys())
58 return fragsmiles
59
60 def get_fragment_BRICS_leaves(self, smile):
61 """Fragmentation with BRICS algorithm leaves of the tree"""
62 #Return a list of fragments for a given ligand smiles
63 fragsmiles = None
64 mol = Chem.MolFromSmiles(smile)
65 if mol:
66 if len(list(BRICS.BRICSDecompose(mol,keepNonLeafNodes=False)))>0:
67 fragsmiles = list(BRICS.BRICSDecompose(mol, keepNonLeafNodes=False))
68 return fragsmiles
69
70 def get_fragment_BRICS_tree(self, smile):
71 """Fragmentation with BRICS algorithm full tree"""
72 #Return a list of fragments for a given ligand smiles
73 fragsmiles = None
74 mol = Chem.MolFromSmiles(smile)
75 if mol:
76 if len(list(BRICS.BRICSDecompose(mol,keepNonLeafNodes=True)))>0:
77 fragsmiles = list(BRICS.BRICSDecompose(mol, keepNonLeafNodes=True))
78 return fragsmiles
79
80 def get_fragment_smiles(self, smile, ftype):
81 """Fragmentation selected as parameter by the user"""
82 if ftype == "FRL":
83 fragment_smiles = self.get_fragment_RECAP_leaves(smile)
84 elif ftype == "FRT":
85 fragment_smiles = self.get_fragment_RECAP_tree(smile)
86 elif ftype =="FRBL":
87 fragment_smiles = self.get_fragment_BRICS_leaves(smile)
88 elif ftype =="FRBT":
89 fragment_smiles = self.get_fragment_BRICS_tree(smile)
90 return fragment_smiles
91
92 def get_fragments(self, fragment_smiles):
93 """For each fragment smile generates a Fragment object"""
94 #Return a list of objects of the Fragment class"""
95 fragments = {}
96 for fragsmile in fragment_smiles:
97 fragment = Fragment(fragsmile, name, self.lig_smiles, self.pdbid, self.
bsid, self.bsite, self.can_to_pdb)




2 """Defines a Fragment object"""
3 def __init__(self, fragsmile, name, ligsmile, pdbid, bsid, bsite_original,
can_to_pdb):
4 self.pdbid = pdbid
5 self.fragsmile = fragsmile #Smiles coming from rdkit fragmentation
6 self.name = name
7 self.ligsmile = ligsmile #Smiles of ligand
8 self.bsid = bsid
9 self.bsite = copy.deepcopy(bsite_original)
10 self.can_to_pdb = can_to_pdb
11 self.fragsmile = remove_dummy_atom(self.fragsmile) #rdkit mol removing [*]
12 self.pybel_frag_mol = pybel.readstring(’can’, self.fragsmile) #gets pybel mol
13 self.pybel_frag_mol.removeh()
14 self.inchikey = inchikey(self.pybel_frag_mol)
15 self.lig_mapping = self.mapping_to_ligand()
16 self.pdb_atoms = self.get_pdb_atoms()
17 if self.pdb_atoms:
18 self.reduce_bsite(bsite_original) #gets only interactions by the fragment
19 fingerprint = Fingerprints(self.bsite) #Generate a fingerprint object
20 self.fingerprint = fingerprint.plipfusion() #get PLIP fusion fp
21 self.fingerprint_sf = fingerprint.simplefusion() #get PLIP simple fp
22 else:
23 self.fingerprint = None
24 self.fingerprint_sf = None
Figure 15.3: Class defining a fragment
object with all its elements extracted
from the PDB and transferred via lig-
and class.
26 def mapping_to_ligand(self):
27 """Gets the mapping of fragment atoms to the ligand atoms"""
28 isomorphs = []
29 pybel_lig_mol = pybel.readstring(’can’, self.ligsmile) #gets pybel ligand mol
from smile
30 pybel_lig_mol.removeh()
31 iso = isomorphism(self.pybel_frag_mol, pybel_lig_mol)
32 iso.findIso(findall=False)
33 isomorphs = iso.isomorphs
34 if isomorphs:






41 """Gets the pdb original atoms for the fragment via ligand mapping"""
42 pdb_atoms = []
43 if self.lig_mapping:
44 for mapp in self.lig_mapping:
45 can_id = mapp[1]+1 #can_to_pdb indexes start with 1 instead of 0
46 if can_id in self.can_to_pdb:










57 """Keeps only the binding site interactions done by the specific fragment by
comparing fragment pdb atoms and replacing data with new updated list"""
58 #Hydrophobic interactions in fragment
59 self.bsite.hydrophobics = [hydroph for hydroph in bsiteo.hydrophobics if
hydroph.ligcarbonidx in self.pdb_atoms]
60 #Hydrogen bonds in fragment
61 self.bsite.hbonds = [hbond for hbond in bsiteo.hbonds if hbond.donoridx in
self.pdb_atoms or hbond.acceptoridx in self.pdb_atoms]
62 #Water bridges interactions in fragment
63 self.bsite.wbridges = [wbridge for wbridge in bsiteo.wbridges if wbridge.
donor_idx in self.pdb_atoms or wbridge.acceptor_idx in self.pdb_atoms]
64 #Halogen interactions in fragment
65 self.bsite.halogens = [halogen for halogen in bsiteo.halogens if halogen.
don_idx in self.pdb_atoms or halogen.acc_idx in self.pdb_atoms]
66 #Salt bridges interactions in fragment
67 self.bsite.sbridges = [sbridge for sbridge in bsiteo.sbridges if
check_ele_in_list(sbridge.lig_idx_list, self.pdb_atoms)]
Figure 15.3: (Cont.) In the methods of
the Fragment class is defined the extrac-
tion of atoms type and number from
PDB to fragments, via ligand mapping
with isomorphism search.
128
Figure 15.3: (Cont.) Furthermore, two
methods are included for the exporta-
tion of the fragments as molecules in sdf
file or 2d structures in png file.
68 #Pi-stacking interactions in fragment
69 self.bsite.pi_stacks = [pi_stack for pi_stack in bsiteo.pi_stacks if
check_ele_in_list(pi_stack.lig_idx_list, self.pdb_atoms)]
70 #Pi-cation interactions in fragment
71 self.bsite.pi_cations = [pi_cation for pi_cation in bsiteo.pi_cations if
check_ele_in_list(pi_cation.lig_idx_list, self.pdb_atoms)]
72 #Metal complexes in fragment
73 self.bsite.metal_complexes = [metal for metal in bsiteo.metal_complexes if
metal.target_idx in self.pdb_atoms and metal.location == "ligand"]
74
75 def write_sdf(self):
76 """Writes the fragment’s molecule in SDF format file"""
77 mymol = get_rdkit_mol(self.fragsmile)
78 AllChem.Compute2DCoords(mymol)
79 w = Chem.SDWriter(self.fragsmile+".sdf")
80 w.write(mymol)
81
82 def draw_png(self, outpath):
83 """Draw the fragment’s chemical 2D structure in PNG format file"""
84 mymol = get_rdkit_mol(self.fragsmile)
85 Chem.Draw.MolToFile(mymol, outpath+"/"+self.fragsmile+".png")
Binding mode conservation of PDB compounds
The following scripts underline the main analysis on the evaluation
of binding mode conservation of PDB fragments. In a first step, the
subset files are generated considering the initial filtering thresholds
and the fragments subsets at the three possible conservation levels.
Then a parallel pairwise comparison for the interactions fingerprints
is carried out, to finalize with a global conservation score calculation.
Figure 15.4: Main script to generate the
conservation subsets according to the
initial filters and the different levels of
conservation: fragments in all ligands
binding all targets, fragments binding
the same target, and fragments bind-
ing the same ligand. Independent files
are generated after each step for further
analysis and easy track back of data gen-
eration.
1 ### Parameters to filter the dataset ###
2 MWmin = 40 #Less than 40 are very small fragments
3 MWmax = 300 #According to definition of fragments
4 ligs = 4 #According to scatter plot and mean
5 unireps = 9 #According to scatter plot and mean
6
7 def write_subset(dataset, subset_path, MWmin, MWmax, ligs, unireps):
8 """Read fragments data and generates a subset according to the filter"""
9 #parameters: fragmentation report, output folder, min molsize, max molsize, Nr
ligs, Nr targets
10 #Reads the fragmentation report
11 report = pd.read_csv(dataset, sep = ’\t’, index_col=None, dtype=None)
12 #Filters the data according to type of data and cutoff of MW
13 reportf1 = report[(report[’TYPE’]==’FR’) & (report[’MW’]>=MWmin) & (report[’MW’
]<=MWmax)]
14 #Group the data by fragments and gets count of unique ligands and unique proteins
15 groups = reportf1.groupby(’FRAGINCHI’)[’LIGINCHI’,’UNIREP’].nunique(dropna=False)
.reset_index()
16 #Gets the subset of fragments according to cutoff of ligands and proteins
17 fragments = groups[(groups[’LIGINCHI’]>ligs) & (groups[’UNIREP’]>unireps)]
18 #Subsets the original report by fraginchis in fragments subset
19 fil_subset = reportf1[reportf1[’FRAGINCHI’].isin(fragments[’FRAGINCHI’])]
20 #writes the subset into a file
21 fil_subset.to_csv(subset_path, sep=’\t’, index=False)
22
23
24 def generate_frag_files(subset_path, frags_subsets_path):
25 """Reads the filtered subset and for each fragment gets a new subset"""
26 #parameters: the path to the filtered subset and the path to folder that will
contain the independent fragments subsets
27 fil_subset = pd.read_csv(subset_path, sep = ’\t’, index_col=None, dtype = str)
28 #Gets a list of unique fragments among the filtered subset
29 fragments = fil_subset["FRAGINCHI"].unique().tolist()
30 for frag in fragments:
31 #for a given fragment inchikey gets the full subset
32 frag_subset = fil_subset[fil_subset["FRAGINCHI"] == frag]
33 #writes the fragments subset into an independent file
34 frag_subset.to_csv(frags_subsets_path+frag+".csv", sep=’\t’, index=False)
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36 def generate_same_tar_files(subset_path, frag-tar_subsets_path):
37 """Reads the filtered subset and for each fragment and target combinations
generates a new subset"""
38 #parameters: the path to the filtered subset and the path to folder that will
contain the independent fragments-targets subsets
39 fil_subset = pd.read_csv(subset_path, sep = ’\t’, index_col=None, dtype = str)
40 setcode = []
41 for index, row in fil_subset.iterrows():
42 #for each fragment-target combination generates a code
43 frag = str(row["FRAGINCHI"])
44 tar = str(row["UNIREP"])
45 #appends the code to a list
46 setcode.append(’~’.join((frag,tar)))
47 #Adds the combination code list as new column into the subset
48 fil_subset["SETCODE"] = setcode
49 #obtains the unique codes as a list
50 setcodes = fil_subset["SETCODE"].unique().tolist()
51 for setcode in setcodes:
52 #for each combination code, extract the subset of complexes
53 set_subset = fil_subset[fil_subset["SETCODE"] == setcode]
54 #write the combination code subset into an independent file
55 set_subset.to_csv(frag-tar_subsets_path+setcode+".csv", sep=’\t’, index=False
)
56
57 def generate_same_lig_files(subset_path, frag-lig_subsets_path):
58 """Reads the filtered subset and for each fragment and ligand combinations
generates a new subset"""
59 #parameters: the path to the filtered subset and the path to folder that will
contain the independent fragments-ligands subsets
60 fil_subset = pd.read_csv(subset_path, sep = ’\t’, index_col=None, dtype = str)
61 setcode = []
62 for index, row in fil_subset.iterrows():
63 #for each fragment-ligand combination generates a code
64 frag = str(row["FRAGINCHI"])
65 lig = str(row["LIGINCHI"])
66 #appends the code to a list
67 setcode.append(’~’.join((frag,lig)))
68 #Adds the combination code list as new column into the subset
69 fil_subset["SETCODE"] = setcode
70 #obtains the unique codes as a list
71 setcodes = fil_subset["SETCODE"].unique().tolist()
72 for setcode in setcodes:
73 #for each combination code, extract the subset of complexes
74 set_subset = fil_subset[fil_subset["SETCODE"] == setcode]
75 #write the combination code subset into an independent file
76 set_subset.to_csv(frag-lig_subsets_path+setcode+".csv", sep=’\t’, index=False
)
Figure 15.4: (Cont.) Main script to gen-
erate the conservation subsets according
to the initial filters and the different lev-
els of conservation
1 class Combis():
2 """Defines a Combis object containing the pairwise comparisons of a fragment
subset"""
3 def __init__(self, path_combis, path_FPs, frag_subset, frag):
4 #parameters: output path for combis, output path for the fingerprints, the
input fragment subset, the fragment inchikey
5 self.path_combis = path_combis
6 self.path_FPs = path_FPs
7 self.subset = pd.read_csv(frag_subset, sep = ’\t’, index_col=None, dtype =
str)
8 self.frag = frag
9 self.frag_uids = defaultdict(list)
10 self.uid_combis = defaultdict(list)
11
12 def write_uid_FP_csv(self):
13 """Read subset dataframe and writes csv file with the fingerprint data for
fusion and simple"""
14 subset_fpf = self.subset[[’UID’,’FPFUSION’]]
15 subset_fps = self.subset[[’UID’,’FPSIMPLE’]]
16 subset_fpf.to_csv(self.fol_FPs+self.frag+"_fpf.csv", sep=’\t’, index=False) #
Only FPfusion data
17 subset_fps.to_csv(self.fol_FPs+self.frag+"_fps.csv", sep=’\t’, index=False) #
Only FPsimple data
Figure 15.5: The class Combis takes
care of the pairwise comparisons. Col-
lects the fingerpints by UIDs and writes
down all possible pairs of them.
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Figure 15.5: (Cont.) In order to achieve
a fair comparison of binding modes, the
number of UIDs by fragment subset was
limited to 500. The multiple UIDs hav-
ing the same ligand and target were re-
duced to one representative and only
500 samples were chosen.
19 def get_rep_complex(self):
20 """For a given fragment, subset the dataset and group by uniprot-liginchi
combinations.
21 Then selects only one uid as representative complex of the group and return
the full list of uids"""
22 groups = self.subset.groupby([’UNIREP’,’LIGINCHI’])[’UID’].apply(list).
to_frame() #group by uniprot-liginchi and get list of uids
23 uids = [uid_list[0] for uid_list in groups[’UID’]] #Select the first complex
in group and add to list
24 if len(uids) > 500:




29 """Creates a dictionary with FRAGINCHI as key and as value a list of all UIDs
with such fragment.
30 If the fragment has > 500 uids, the set of UIDs will be reduced"""
31 self.frag_uids = self.subset["UID"].tolist()
32 if len(self.frag_uids) > 500:
33 uids = self.get_rep_complex()
34 self.frag_uids = uids
35
36 def write_uid_combis(self):
37 """Writes a file containing the list of all uid combinations for each
fragment and another file containing each uid combination"""
38 uids = self.frag_uids
39 if len(uids) > 1:
40 rep = open(self.fol_combis+self.frag+".csv", "w")
41 rep.write(’UID1\tUID2\tFRAGINCHI\n’)
42 for combi in itertools.combinations(uids,2):
43 rep.write(’{0}\t{1}\t{2}\n’.format(combi[0], combi[1], self.frag))
44 rep.close()
Figure 15.6: The class FPSimCalculator
defines the calculation of the (cosine or
tanimoto) similarities between pairwise
fingerprints.
1 class FPSimCalculator():
2 def __init__(self, uid_pairs, fpfusion, fpsimple):
3 self.uid_pairs = pd.read_csv(uid_pairs, sep = ’\t’, index_col=None, dtype =
str)
4 self.FPfusion_dic = self.get_data_dict(fpfusion, ’UID’, ’FPFUSION’)
5 self.FPsimple_dic = self.get_data_dict(fpsimple, ’UID’, ’FPSIMPLE’)
6
7 def get_data_dict(self, datafile, key1, key2):
8 """Reads a file as dataframe and constructs a dictionary with column (key1)
as dict key and column (key2) as value"""
9 data_dic = {}
10 data = pd.read_csv(datafile, sep = ’\t’, index_col=None, dtype = str)
11 for index, row in data.iterrows():




16 """Takes two fingerprint vectors va and vb and calculates the cosine
similarity."""
17 va = list(map(int, va))
18 vb = list(map(int, vb))
19 csim = 1.0-distance.cosine(va, vb)
20 if np.isnan(csim):
21 csim = -1.0
22 return csim
23
24 def get_tanimoto_sim(self, va, vb):
25 """Takes two fingerprint vectors va and vb and calculates the cosine tanimoto
coefficient metric"""
26 #common = [a for a, b in zip(va, vb) if a == b]
27 #return float((len(common))/(len(va) + len(vb) - len(common)))
28 common = [a for a, b in zip(va, vb) if a == b and a==’1’]
29 binsva = [a for a in va if a==’1’]
30 binsvb = [b for b in vb if b==’1’]
31 nom = len(common)
32 denom = len(binsva)+len(binsvb)-len(common)





38 def get_fp_sim(self,fp_dic, id1,id2):
39 """Checks if the tuple of ids is different, then calculates the FP similarity
. If not, then sim is automatically 1"""
40 if id1 != id2:
41 id1_fp = fp_dic[id1]
42 id2_fp = fp_dic[id2]
43 fp_sim = self.get_tanimoto_sim(list(id1_fp), list(id2_fp))
44 else:




49 """Iterates over the ID pairs, calls the function to calculates similarity
and write a new report with both types of similarities"""
50 report = open(output, ’w’)
51 report.write(’UID1\tUID2\tFPFUSION_SIM\tFPSIMPLE_SIM\tGROUP\n’)
52 for index, row in self.uid_pairs.iterrows():
53 id1 = row[’UID1’]
54 id2 = row[’UID2’]
55 group = row[’FRAGINCHI’] #In Desaphy analysis is GROUP
56 fpfusion_sim = self.get_fp_sim(self.FPfusion_dic, id1,id2)




Figure 15.6: (Cont.) For each UID pair,
it calculates the fingerprints similarity
and writes it down to a file.
1 class DataAnalyzer():
2 def __init__(self, sim_data_path, frag):
3 self.sim_data = pd.read_csv(sim_data_path, sep = ’\t’, index_col=None, dtype
= str)
4 self.frag = frag
5 self.sim_fpf = self.sim_data[’FPFUSION_SIM’].tolist()
6 self.sim_fps = self.sim_data[’FPSIMPLE_SIM’].tolist()
7 self.len_uids_dict = {}
8 self.sim_min_fp_dict = {}
9 self.sim_max_fp_dict = {}
10 self.fpfsim = None
11
12 def write_fp_sim(self, output):
13 """Writes the MIN/MAX values of fingerprints into a report file"""
14 report = open(output, ’w’)
15 report.write("FRAGMENT\tFPFMIN\tFPSMIN\tFPFMAX\tFPSMAX\tFPFAVG\tFPSAVG\n")
16 minfpf = min(self.sim_fpf)
17 minfps = min(self.sim_fps)
18 maxfpf = max(self.sim_fpf)
19 maxfps = max(self.sim_fps)
20 fpf = list(map(float, self.sim_fpf))
21 fps = list(map(float, self.sim_fps))
22 avgfpf = sum(fpf)/len(self.sim_fpf)
23 avgfps = sum(fps)/len(self.sim_fps)
24 report.write(’{0}\t{1}\t{2}\t{3}\t{4}\t{5:.2f}\t{6:.2f}\n’.format(self.frag,
minfpf, minfps, maxfpf, maxfps, avgfpf, avgfps))
25 report.close()
Figure 15.7: The class DataAnalyzer pro-
vides the final report with the global
binding mode conservation (similarities)
for each fragments subset or group.
Binding mode reconstruction
The following scripts underline the main approach for the binding
mode reconstruction of full compounds using PDB fragments with
conserved binding modes.
A given compound is fragmented using Recap leaves algorithm
with standard settings. Then for each fragment, a representative
fingerprint is defined from all existing complexes, either with the
union or the frequency approach.
Finally all representative fingerprint are merged into one recon-
structed fingerprint that will represent the binding mode of the full
compound.
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Figure 15.8: The class FPrepre gener-
ates the representative fingerprint of a
fragment for a given set of fingerprints
coming from different complexes. The
representative can be genrated under
three approaches: the union of activated
bins in all binary fingerprints or the fre-
quency of activated bin in all binary fin-
gerprints.
1 class FPrepre():
2 """The class generates the representative fingerprint for a fragment with the
given set of fingerprints coming from different complexes"""
3 def __init__(self, liginchi, inchi, unirep, report):
4 self.liginchi = liginchi
5 self.inchi = inchi
6 self.report = report
7 self.FPs = self.get_fps(self.inchi, unirep=unirep)
8 if self.FPs:
9 self.FP_union = self.get_fp_union(self.FPs)
10 self.FP_freq = self.get_fp_freq(self.FPs)
11 self.FP_freq_bin = self.get_fp_freq_binary(self.FPs)
12 else:
13 self.FP_union = None
14 self.FP_freq = None
15 self.FP_freq_bin = None
16
17 def get_fps(self, inchi, unirep=None):
18 """Given a fragment inchikey and a possible uniprot representative, obtains
all fingerprints of fragment complexes from the report"""
19 if unirep: #If unirep provided, then the subsetting is based in fraginchi and
uniprot rep. If not, then just in fraginchi
20 complexes = self.report[(self.report["FRAGINCHI"] == inchi) & (self.
report[’UNIREP’] == unirep)]
21 else:
22 complexes = self.report[(self.report["FRAGINCHI"] == inchi)]
23 complexes = complexes[complexes.LIGINCHI != self.liginchi] #Remove the
complex with the drug to reconstruct, to avoid overfitting
24 fps = complexes.FPSIMPLE.tolist()
25 if len(fps) == 0: #If no complexes for given fragment then set to None
26 fps = None
27 return fps
28
29 def get_fp_union(self, fps, string=False):
30 """Given a list of fingerprints it constructs a representative one of the
union: for a given position, if at least in one fp the bin is on, then in the
representative it is on"""
31 if len(fps) == 1: #If only one, then that one becomes the representative
32 rep_FP = fps[0]
33 else:
34 all_FPs = zip(*fps)#Generates a tuple of bins in the same index but
coming from different FPs lists:
35 rep_FP = [1 if sum(map(int,item))>0 else 0 for item in all_FPs]#Iterates
over all tuples. Transform each tuple into integers and sums each tuple. If the
sum is bigger than 0 then adds a 1 into the consensus FP, otherwise a 0.
36 return rep_FP
37
38 def get_fp_freq(self,fps, string=False):
39 """Givel a list of fingerprints it constructs a representative one of the
frequency"""
40 lenth = len(fps)
41 if lenth == 1: #If only one, then that one becomes the representative
42 rep_FP = fps[0]
43 else:
44 all_FPs = zip(*fps) # Generates a tuple of bins in the same index but
coming from different FPs lists:
45 rep_FP = [sum(map(int,item))/lenth for item in all_FPs] #Iterates over
all tuples. Transform each tuple into integers and sums the numbers in tuple.
Round the result to one decimal
46 return rep_FP
47
48 def get_fp_freq_binary(self, fps, string=False):
49 """Givel a list of fingerprints it constructs a representative one of the
frequency. According to cutoff (>=30%=1) converts the fp into a binary"""
50 lenth = len(fps)
51 if lenth == 1: #If only one, then that one becomes the representative
52 rep_FP = fps[0]
53 return rep_FP
54 else:
55 all_FPs = zip(*fps)#Generates a tuple of bins in the same index
56 freq_FP = [round(sum(map(int,item))/lenth,1) for item in all_FPs] #
Iterates over all tuples. Transform each tuple into integers and sums the
numbers in tuple. Round the result to one decimal
57 freq_FP_bin = [1 if per >= 0.3 else 0 for per in freq_FP] #If the





2 """The class generates the reconstructed fingerprint for a given compound smile.
"""
3 def __init__(self, smile, unirep, report, recontype, confrag, threshold):
4 self.smile = smile
5 self.unirep = unirep
6 self.report = report
7 self.recontype = recontype
8 self.inchi = self.get_inchikey(self.smile)
9 self.confrag = confrag
10 self.threshold = threshold # Proportion of ligand fragments that have an
interaction fingerprint.
11 self.inchi = self.get_inchikey(self.smile)
12 self.fragsmiles = self.get_fragments(self.smile, app=’recap’)
13 self.used_fragments = []
14 if self.fragsmiles:
15 self.fraginchis = [self.get_inchikey(smile) for smile in self.fragsmiles]
16 self. rec_fp = self.get_rec_fp()
17 else:
18 self.fraginchis = None
19 self.fr_fp_union = None
20 self.fr_fp_freq = None
21 self.fr_fp_freqbin = None
22 self.rec_fp = None
23
24 def get_inchikey(self, smile):
25 """Given a ligand or fragment smiles, generates the pybel molecule and then
obtains the inchikey """
26 try:
27 smile = remove_dummy_atom(smile) #from supple functions on top
28 pybel_frag_mol = pybel.readstring(’can’, smile) #gets pybel query mol of
fragment coming from fragsmiles
29 pybel_frag_mol.removeh()
30 inchi = inchikey(pybel_frag_mol) #from supple functions on top
31 except:
32 inchi = None
33 return inchi
34
35 def get_fragments(self,smile, app): # Add option for BRICKS
36 """Given a ligand smiles, returns a list of canonical SMILES fragments using
RECAP algorithm. If not possible it returns None"""
37 fragsmiles = None
38 mol = Chem.MolFromSmiles(smile)
39 if mol:
40 hierarch = Recap.RecapDecompose(mol)
41 recap_fragments = hierarch.GetLeaves() # Gets the last childs in
hierarch (the ligand splitted simply and without redundant data)
42 if len(list(recap_fragments.keys())) > 0: # If RECAP generated at least
one fragment




47 """For each fragment in the ligand generates an instance of the FPmerge class
and obtains the representative fingerprint. Then merge them all into one
reconstructed fingerprint"""
48 self.fr_fp_union = [] # Initialized as list
49 self.fr_fp_freq = []
50 self.fr_fp_freqbin = []
51 rec_fp = None # Initialized as none
52 # For each fragment smile generates an instance of FPrepre class to get the
representative fingerprint
53 for fragsmile in self.fragsmiles:
54 fraginchi = self.get_inchikey(fragsmile)
55 if not "{}~{}".format(fraginchi, self.unirep) in self.confrag:
56 continue
57 self.used_fragments.append(fragsmile) # Here in case the threshold is
modified and allows to reconstruct drugs with not all fragments
58 fprep = FPrepre(self.inchi, fraginchi, self.unirep, self.report)
59 if fprep.FP_union: # If fragment had FPs and generated the






65 # For each type of representative fragments a different reconstruction of the
full FP for ligand is needed
66 if self.recontype == ’union’:
67 if self.fr_fp_union and (len(self.fr_fp_union)/len(self.fragsmiles)) >=
self.threshold:
68 rec_fp = self.fr_fp_union[0] # By default set to the first fragment
fp in the list
Figure 15.9: The class Reconstructor gen-
erates the reconstructed fingerprint for
a given ligand smile by using its frag-
ments data. The methods first obtain
the fragments of the ligand using Recap
leaves algorithm with default settings.
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Figure 15.9: (Cont.) For each fragment
an instance of FPrepre is called to ob-
tain its representative fingerprint un-
der the union, freq, or freq binary way.
Finally all representatives fingerprints
are merged to reconstruct the full com-
pound’s binding mode.
69 if len(self.fr_fp_union) > 1: # If there is more than just one FP,
then takes the union of them
70 zipped_fps = zip(*self.fr_fp_union)
71 rec_fp = [1 if sum(list(map(int, item))) > 0 else 0 for item in
zipped_fps]
72 if self.recontype == ’freq’:
73 if self.fr_fp_freq and (len(self.fr_fp_freq)/len(self.fragsmiles)) >=
self.threshold:
74 rec_fp = [round(float(bin), 1) for bin in self.fr_fp_union[0]] # By
default set to the first fragment fp in the list
75 if len(self.fr_fp_freq) > 1: # If there is more than just one FP,
then takes the union of them
76 zipped_fps = zip(*self.fr_fp_freq)
77 rec_fp = [round(np.mean(list(map(float, item))), 1) for item in
zipped_fps] # If two fragments have the same bin acticated, the chances
increase
78 if self.recontype == ’freqbin’:
79 if self.fr_fp_freqbin and (len(self.fr_fp_freqbin)/len(self.fragsmiles))
>= self.threshold:
80 rec_fp = self.fr_fp_freqbin[0] # By default set to the first
fragment fp in the list
81 if len(self.fr_fp_freqbin) > 1: # If there is more than just one FP,
then takes the union of them
82 zipped_fps = zip(*self.fr_fp_freqbin)
83 rec_fp = [1 if sum(list(map(int, item))) > 0 else 0 for item in




All the required packages, libraries, and modules for the code above
are imported and defined in the external script called supple.
Figure 15.10: The main libraries and
modules are imported in supple script,
which is later imported in all indepen-
dent scripts.
1 import pybel
2 from openbabel import *
3 from rdkit import Chem
4 from rdkit.Chem import Recap, BRICS, Draw, AllChem
5 #from rdkit.Chem.inchi import InchiToInchiKey
6
7 import pickle
8 import pandas as pd
9




14 import sys, os
15
16 def invert_dict(dicti):
17 """Invert the key and values in a dictionary"""
18 inverted = {}
19 for key in dicti:
20 value = dicti[key]




25 """read a csv file and returns it"""




30 """Transform a given list of tuples into a dictionary"""
31 dicti = {}
32 for tup in tup_list:




37 """read a pickle file and returns it"""
38 pickle_file = open(path,"rb")
39 data = pickle.load(pickle_file)
40 return data
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42 def check_ele_in_list(element, lis):
43 """Check if an element (tuple, list, string, int, etc) is in a given list"""
44 if type(element) is tuple:
45 sublist = list(element)
46 isin = set(sublist).issubset(lis)
47 elif type(element) is list:
48 isin = set(element).issubset(lis)
49 else:




54 """Obtain the Pybel molecule from the smiles"""
55 obc = pybel.ob.OBConversion()
56 obc.SetInFormat(’smi’)
57 mol = pybel.ob.OBMol()
58 obc.ReadString(mol, smile)
59 ##### TEST






66 """Clean the fragment mol removing the * atoms"""
67 if ’*’ in fragsmile:
68 mol = Chem.MolFromSmiles(fragsmile, sanitize=False) #rdkit mol from fragment
smiles
69 #print (Chem.MolToSmiles(mol))
70 duatom = Chem.MolFromSmiles(’*’) #dummy atom saved as molecule
71 mol = AllChem.ReplaceSubstructs(mol,duatom,Chem.MolFromSmiles(’[H]’),True)[0]
#replace * by H)
72 #print (Chem.MolToSmiles(mol))
73 mol = Chem.RemoveHs(mol) #delete Hydrogens
74 #print (Chem.MolToSmiles(mol))




79 """Generate an rdkit molecules from a given smiles.
80 If the default mode does not work, then it creates the mol without strict
sanitization """
81 try:
82 mol = Chem.MolFromSmiles(smile)
83 if mol is None:








91 def inchikey(pybelmolecule, ignoreStereo=True, stripH=False, use_rdkit=True):
92 """Returns the InChI key of a molecule without stereo info. Hydrogens are
stripped upon request."""
93 if not use_rdkit:
94 return obconvert(pybelmolecule, outputformat=’inchikey’, ignoreStereo=
ignoreStereo, stripH=stripH)
95 else:
96 smiles = obconvert(pybelmolecule, outputformat=’can’, ignoreStereo=
ignoreStereo, stripH=stripH)
97 m = Chem.MolFromSmiles(smiles, sanitize=False)
98 try:
99 inchikey = Chem.inchi.InchiToInchiKey(Chem.MolToInchi(m))




104 def mapper(mapold, proteinmap):
105 """Map to the right numerations of atoms obtained on parse_pdb"""
106 mapfixed = {}
107 for nid_key in mapold:
108 old_id = mapold[nid_key]
109 mapfixed[nid_key] = proteinmap[old_id]
110 return mapfixed
Figure 15.10: (Cont.) The supple module
defined multiple methods that support
the main scripts with functionalities that
are frequently used.
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Figure 15.10: (Cont.) The methods pro-
vide functionalities to obtain the canoni-
cal smile of molecules, obtain matching
indices between molecules, and properly
map atom IDs from PDB to compounds
and fragments with the Mapper class.
1 def obconvert(pybelmolecule, outputformat=’can’, ignoreStereo=True, stripH=False):
2 """Returns the canonical SMILES of a molecule without stereo info. Hydrogens are
stripped upon request."""
3 obc = pybel.ob.OBConversion()
4 obc.SetOutFormat(outputformat)
5 if ignoreStereo:




10 obc.AddOption(’n’) # don’t write the name to the output SMILES
11 return obc.WriteString(pybelmolecule.OBMol).strip()
12
13 def cansmi(pybelmolecule, ignoreStereo=True, stripH=False, use_rdkit=True):
14 """Returns the canonical SMILES of a molecule without stereo info. Hydrogens are
stripped upon request."""
15 if not use_rdkit:
16 return obconvert(pybelmolecule, outputformat=’can’, ignoreStereo=ignoreStereo
, stripH=stripH)
17 else:
18 smiles = obconvert(pybelmolecule, outputformat=’can’, ignoreStereo=
ignoreStereo, stripH=stripH)
19 m = rdkit.Chem.MolFromSmiles(smiles, sanitize=False)
20 return rdkit.Chem.MolToSmiles(m)
21
22 def get_match_bond_indices(query, mol, match_atom_indices):
23 """Given a query mol (rdkit mol) as substructure of another mol (rdkit mol) and
the atom indices describing the substructure match,
24 the function extracts the bonds between the given atoms"""
25 bond_indices = []
26 for query_bond in query.GetBonds():
27 atom_index1 = match_atom_indices[query_bond.GetBeginAtomIdx()]






34 """Provides an mapper object with methods to map atom IDs in the correct way"""
35 def __init__(self):
36 self.proteinmap = None # Map internal atom IDs of protein residues to
original PDB Atom IDs
37 self.ligandmaps = {} # Map IDs of new ligand molecules to internal IDs
38 self.original_structure = None
39
40 def mapid(self, idx, mtype, bsid=None, to=’original’): # Mapping to original IDs
is standard for ligands
41 if mtype == ’reversed’: # Needed to map internal ID back to original protein
42 return self.reversed_proteinmap[idx]
43 if mtype == ’protein’:
44 return self.proteinmap[idx]
45 elif mtype == ’ligand’:
46 if to == ’internal’:
47 return self.ligandmaps[bsid][idx]
48 elif to == ’original’:
49 return self.proteinmap[self.ligandmaps[bsid][idx]]
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15.2 Figures and Tables
Figure 15.11: Brivudine interactions pat-
terns from five target proteins. Ten pat-
terns relating to π-stacking (A–D), paral-
lel hydrogen bonds (E–G), hydrophobic
contacts (H), hydrogen bond (I) and a
halogen bond (J) and their presence in
five targets from five species
Figure 15.12: Docking results for can-
didate compounds to viral thymidine
kinase (top) and the Hsp27 model (bot-
tom). Predicted binding energies are
shown on the ordinate in kcal/mol.
Compounds are listed on the abscissa
with their PubChem CIDs. BVDU was
used as a reference compound and its
data points are indicated with dotted
lines.
138
Figure 15.13: Approved drugs with six
or more patterns. Twelve FDA-approved
drugs across very different diseases and
targets (panel A). Six are nucleobases
like brivudine, but six are novel scaf-
folds. The patterns for π-stacking (A–D)
and double hydrogen bond (E–G) are
present in the majority of these com-
pounds.
Figure 15.14: Pairwise chemical similar-
ity of known and predicted inhibitors.
Known inhibitors labeled with orange
tag on bottom line and predicted ones
with a green tag on bottom line. Dark
blue boxes represent high chemical sim-
ilarity of inhibitors (see Methods). Bars
on the left are therapeutic indication
(red = cancer, blue = cancer of the im-
mune system, green = autoimmune dis-
ease, yellow = infection, and gray =
other) and gray bars on the right repre-
sent the number of known targets (size
of bar). The top left quadrant are mostly
known inhibitors, which are chemically
similar to each other and are mostly
linked to cancer. The bottom right
quadrant are new, predicted inhibitors,
which have different scaffolds and are
hence not derived from the known in-
hibitors. Consequently, these inhibitors
have other therapeutic indications.
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Figure 15.15: Drug-target-disease net-
work. Inner circle (14 targets), mid circle
(known and predicted inhibitors), outer
circle (diseases). There is a tight network
of cancer drugs and targets while there
is only one known autoimmune com-
pound, which binds, however, many of
the cancer targets. VEGR2, the promis-
ing autoimmune target, we identified,
is inhibited by cancer and anti-infection
drugs.
Figure 15.16: Chemical space of the hit
candidates. The heat map shows the
pairwise similarity of the chemical struc-
tures of the hits. The similarity scores
range from 0 (low) to 1 (high) with a
color scheme from white to blue, respec-
tively. The color tags on the right in-
dicate the novelty of the drug with re-
gard to the trypanocidal activity: direct
evidence (green), indirect evidence (or-
ange), and no previous evidence (red).
Some clusters of drugs with a relatively
high chemical similarity are marked: (A)
nucleic acid analogs, (B) adamantane
analogs, and (C) folate analogs
140
Approach Compound Dosage Rel. CS precip. Rel. Inhibition
PLIP Amodiaquine 10 µm 0.57 43x
Heinrich et al[112]
CAS 0-53-3 10 µm 1.06 80x
CAS 50-53-3 10 µm 1.06 80x
CAS 61-00-7 10 µm 0.99 74x
CAS 104715-80-2 10 µm0.92 69x
CAS 1222781-87-4 10 µm 0.81 61x
CAS 161363-17-3 10 µm 0.71 53x
CAS 1222812-38-5 10 µm 0.65 49x
CAS 53-86-1 — — —
Control brivudine 750 µm 1 1x
Table 15.1: Hsp27 chaperone assay for
amodiaquine and lead compounds from
the study by Heinrich et al[112] in com-
parison to the control BVDU. Listed are
the dosage used in the experiment, the
relative precipitation of the client pro-
tein citrate synthase, and the relative in-
hibition after correcting for the dosage.
Amodiaquine is substantially better than
BVDU in inhibition of Hsp27 chaperone
activity and within the activity range of
compounds identified by Heinrich et al.
Target Binding Site Enzyme Class PDB ID Ligand Name Nr. Hits





TS site Transferase 3CL9 DUMP 7
2 Cruzipain [266] unspecified Transferase 2OZ2 K11777 15
3LXS WRR483




homoallylic site Transferase 1YHM Isopentyl Pyrophosphate 8
3ICK Isopentyl Pyrophosphate
3IBA Isopentyl Pyrophosphate
4 GAPDH [100] active site Oxidoeductase 1QXS 1,3-bisphospho-d-glyceric acid 18
1K3T Chalepin
covalent site Oxidoeductase 3IDS Iodoacetamide 24








6 trans-sialidase [32] acceptor site Hydrolase 1MS9 Beta-lactose 20
1MS0 Beta-lactose
sialic acid site Hydrolase 1MS0 DANA 12
1S0J Methylumbelliferyl Sialic Acid
1S0I Lactose Sialic Acid
7 Trypanothione Reductase [145] unspecified Oxidoeductase 1GXF Quinacrine Mustard 13
1BZL Trypanothione
8 B Cell Mitogen [32] unspecified Isomerase 1W61 Pyrrole-2-Carboxylic acid 10





10 Glucose 6-phosphate dehydrogenase [121] unspecified Oxidoeductase 6D24 Beta-Glucose-6 Phosphate 2
5AQ1 Beta-Glucose-6 Phosphate
11 HGPRT [77] PRPP site Transferase 1TC2 PRPP 0
purine site Transferase 1TC2 7HPP 42
1P19 Inosinic Acid
1TC1 Formycin B
12 Old Yellow Enzyme [201] unspecified Oxidoeductase 3ATZ Hydroxybenzaldehyde 34
13 Pteridine Reductase [247] unspecified Oxidoeductase 1MXF Methotrexate 26
1MXH Dihydrofolic Acid
14 Spermidine Synthase [12] dcSAM site Transferase 5B1S dcSAM 6
4YUW dcSAM
putrescine site Transferase 5B1S 2-(2-fluorophenyl)ethanamine 30
4YUW trans-4-methylcyclohexanamine






16 UDP-galactapyranose mutase [214] unspecified Isomerase 4DSH UDP 11
4DSG UDP
Table 15.2: T. cruzi targets used as input
for the computational screening. The
targets above the bold line have been
thoroughly researched and the ones
below the line have been at least re-
searched for being involved in T. cruzi’s
survival. For each target, the target
name, the specific binding site (in case
of a multi-binding site target), the en-
zyme class, the PDB ID of the available
structures, and the binding ligand are in-
dicated. An independent screening was
conducted for each target binding site.
The last column on the right indicates
the number of hit complexes predicted
for each screening.
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Drug Predicted Target P-value Current Indication VI TA Reference
1 Glutathione Dihydroorate 3.80×10-6 Antioxidant X ?
2 Naproxen FPPS Homoallylic 6.46×10-6 Anti-inflammatory X ?
3 Amphetamine Spermidine Synthase Putrescine 1.14×10-5 Attention deficit/Hyperactivity X ?
4 Folic acid DHFR 2.66×10-5 Megaloblastic Anemia X ?
5 Sapropterin Pteridine Reductase 2.66×10-5 Phenylketonuria X ?
6 Clioquinol Trypanothione Reductase 2.66×10-5 antifungal X ?
7 Celecoxib DHFR 3.04×10-5 Anti-inflammatory X ?
8 Leucovorin DHFR 4.18×10-5 Toxicity of Pyrimethamine X ?
9 Theophylline HGPRT purine 7.22×10-5 Asthma X ?
10 Fosfomycin FPPS allylic 1.52×10-4 Antibiotic X ?
11 Ticagrelor Pteridine Reductase 1.90×10-4 Platelet aggregation inhibitor X ?
12 Fludarabine HGPT purine 4.18×10-4 Cancer X ?
13 Varenicline Spermidine Synthase Putrescine 4.45×10-4 Nicotine Addiction X ?
14 Progesterone Old Yellow 3.80×10-6 Hormone X + Schuster et al.[249]
15 Pemetrexed Pteridine Reductase 3.80×10-6 Cancer X + Sienkiewicz et al.[256]
16 Ciprofloxacin trans-sialidase sailic 9.51×10-5 Antibiotic X + Hiltensperger et al.[114]
17 Aunomycin Trypanothione Reductase 1.29×10-4 Cancer X + Andrews et al.[15]
18 Pentoxifylline Trypanothione Reductase 2.24×10-4 Muscle Pain Reliever X + Villa-Pereira et al.[281]
19 Pyrimethamine DHFR 3.80×10-6 Toxoplasmosis X ++ Gilbert et al.[94]
20 Trimethoprim DHFR 3.80×10-6 Antibiotic X ++ Gilbert et al.[94]
21 Risedronate FPPS Allylic 3.80×10-6 Osteoporosis X ++ Huang et al. [118]
22 Triamterene Pteridine Reductase 3.80×10-6 Diuretic X ++ Planer et al.[229]
23 Tioguanine Pteridine Reductase 7.61×10-6 Cancer X ++ fernandes et al.[83]
24 Nicotinamide Spermidine Synthase Putrescine 7.61×10-6 Pellagra X ++ Soares et al. [262]
25 Zidovudine Squalene Synthase 1.14×10-5 HIV X ++ Nakajima-Shimada et al.[204]
26 Zanamivir Transsialidase 1.14×10-5 Antiviral X ++ Kashif et al.[138]
27 Rimantadine DHFR 1.54×10-5 Anti-viral X ++ Kelly et al.[141]
28 Quinine DHFR 1.90×10-5 Malaria X ++ Ceole et al.[38]
29 Benzoic acid Galactopyranose Mutase 1.90×10-5 Antifungal ++ Neres et al.[209]
30 Imatinib Cruzipain 6.84×10-5 Cancer X ++ Simoes-Silva et al.[258]
31 Isotretinoin DHFR 7.22×10-5 Acne X ++ Reigada et al.[234]
32 Foscarnet FPPS allylic 7.61×10-5 Antiviral X ++ Haupt et al.[109]
33 Paclitaxel Trans-sailidase Acceptor 8.75×10-5 Cancer ++ Baum et al.[22]
34 Citalopram Squalene Synthase 9.13×10-5 Antidepressant X ++ Jones et al.[126]
35 Thioridazine Squalene Synthase 1.48×10-4 Antipsychotic X ++ Lo Presti et al.[181]
36 Memantine Squalene Synthase 2.51×10-4 Alzheimer’s X ++ Damasceno et al.[58]
37 Saquinavir Spermidine Synthase dcSAM 2.70×10-4 HIV X ++ Sangenito et al.[242]
38 Minocycline Spermidine Synthase Putrescine 3.65×10-4 Antibiotic X ++ Planer et al.[229]
Table 15.3: Computational screening hits
predicted to bind Chagas targets. Top
38 hits from the screening sorted by nov-
elty with regard to trypanocidal activity
(TA), where ? indicates unknown activ-
ity, + indicates indirect evidence of ac-
tivity, and ++ indicates direct evidence
of activity. Within each of the previ-
ous classifications, the hits are sorted
by screening p-value and the original
indication is shown. The Xrepresents
positive visual inspection (VI), meaning
high interaction pattern similarity be-
tween query and hit.
T.cruzi epimastigote Cytotoxicity Selectivity Index
IC50 (µM) CC50 (µM) CC50/IC50
Ninoa INC-5 Ninoa INC-5
Ciprofloxacin > 400 ± 0.17 > 400 ± 0.17 7.7 × 1023 ± 0.31 < 1.9 × 1021 < 1.9 × 1021
Folic Acid > 400 ± 0.03 > 400 ± 0.01 9.1 × 1017 ± 0.14 < 2.3 × 1015 < 2.3 × 1015
Naproxen > 400 ± 0.10 > 400 ± 0.04 2.5 × 1018 ± 0.08 < 6.3 × 1015 < 6.3 × 1015
Celecoxib > 400 ± 0.13 > 400 ± 0.02 1.2 × 1016 ± 0.32 < 3.1 × 1015 < 3.1 × 1015
Glutathione > 400 ± 0.10 > 400 ± 0.17 1.7 × 1018 ± 0.42 < 4.3 × 1015 < 4.3 × 1015
Leucovirin > 400 ± 0.12 > 400 ± 0.08 7.9 × 1023 ± 0.17 < 2.0 × 1021 < 2.0 × 1021
Pentoxyfiline > 400 ± 0.14 > 400 ± 0.16 7.9 × 1017 ± 0.02 < 2.0 × 1015 < 2.0 × 1015
Theophyline > 400 ± 0.21 > 400 ± 0.03 8.3 × 1035 ± 0.08 < 2.1 × 1033 < 2.1 × 1033
Nifurtimox 7.09 ± 0.12 6.47 ± 0.42 164.2 ± 0.08 23.2 25.4
Benznidazole 30.3 ± 0.03 19.9 ± 0.23 133.9 ± 0.71 4.42 6.74
Table 15.4: Inhibition of proliferation
of Ninoa and INC-5 strains of T. cruzi
epimastigotes, cytotoxicity and selectiv-
ity index of tested FDA-approved drugs
compared to the known treatments with
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